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Abstract 
The overall survival of patients with malignant gliomas remains dismal despite 
multimodality treatments. Computed tomography (CT) perfusion is a functional imaging tool 
for assessing tumour hemodynamics. The goals of this thesis are to 1) improve measurements 
of various CT perfusion parameters and 2) assess treatment outcomes in a rat glioma model 
and in patients with malignant gliomas.  
Chapter 2 addressed the effect of scan duration on the measurements of blood flow 
(BF), blood volume (BV), and permeability-surface area product (PS). Measurement errors 
of these parameters increased with shorter scan duration. A minimum scan duration of 90 s is 
recommended.  
Chapter 3 evaluated the improvement in the measurements of these parameters by 
filtering the CT perfusion images with principal component analysis (PCA). From computer 
simulation, measurement errors of BF, BV, and PS were found to be reduced. Experiments 
showed that CT perfusion image contrast-to-noise ratio was improved. 
Chapter 4 investigated the efficacy of CT perfusion as a potential early imaging 
biomarker of response to stereotactic radiosurgery (SRS). Using the C6 glioma model, we 
showed that responders to SRS (surviving > 15 days) had lower relative BV and PS on day 7 
post-SRS when compared to controls and non-responders (P < 0.05). Relative BV and PS on 
day 7 post-SRS were predictive of survival with 92% accuracy. 
 Chapter 5 examined the use of multiparametric imaging with CT perfusion and 18F-
Fluorodeoxyglucose positron emission tomography (FDG-PET) to identify tumour sites that 
are likely to correlate with the eventual location of tumour progression. We developed a 
method to generate probability maps of tumour progression based on these imaging data.  
Chapter 6 investigated serial changes in tumour volumetric and CT perfusion 
parameters and their predictive ability in stratifying patients by overall survival. Pre-surgery 
BF in the non-enhancing lesion and BV in the contrast-enhancing lesion three months after 
radiotherapy had the highest combination of sensitivities and specificities of ≥ 80% in 
predicting 24 months overall survival. 
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Optimization and standardization of CT perfusion scans were proposed. This thesis 
also provided corroborating evidence to support the use of CT perfusion as a biomarker of 
outcomes in patients with malignant gliomas.  
 
Keywords 
Blood flow, blood volume, brain tumour, permeability-surface area product, dynamic 
contrast-enhanced computed tomography, CT perfusion, image noise, principal component 
analysis, radiotherapy, stereotactic radiosurgery 
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Chapter 1  
1 Introduction 
 
1.1 Overview 
Until recently, clinical imaging of brain tumours has been limited largely to 
magnetic resonance (MR) and computed tomography (CT). MR is used routinely for 
diagnosis, surgical and radiotherapy guidance, and assessment of treatment response. CT 
is the workhorse for radiotherapy planning. Both imaging modalities are used for 
depicting the anatomy, size, and location of brain tumours. However, they have limited 
capabilities in providing functional information that relate to tumour pathophysiology. 
There is mounting evidence that functional imaging techniques, such as tumour perfusion 
imaging, are promising tools in this regard. Perfusion imaging, using CT or MR, can 
evaluate brain tumour hemodynamics. At present, perfusion imaging is not incorporated 
into the routine clinical care of patients because the uncertainties in the acquisition and 
analysis of these images make optimization and standardization difficult. Moreover, 
perfusion changes in response to different treatments are complex and not yet well 
understood. These problems make clinical interpretation of perfusion imaging 
information difficult. Optimization and standardization of image acquisition and analysis 
can help facilitate the implementation of perfusion imaging in clinical practice. Serial 
imaging of perfusion changes can improve the interpretation of the perfusion imaging 
data for evaluating response and prognosis in patients. This thesis focuses on optimizing 
the use and interpretation of CT perfusion imaging data based on computer simulation, 
pre-clinical experiments, and clinical studies. This introductory chapter provides an 
overview of the basic biology and treatment of malignant glioma, angiogenesis, a review 
of clinical perfusion imaging studies, and an outline of this thesis.  
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1.2 Malignant Glioma 
More than 22,200 North Americans are diagnosed with cancers of the brain and 
central nervous system each year (1,2). Glial cells are non-neuronal cells that maintain 
homeostasis, and support and protect neurons in the central nervous system. Gliomas are 
brain tumours derived from glial cells with astrocytomas being the most common type of 
glioma. The World Health Organization (WHO) classifies astrocytomas into four grades 
based on histological features (3). Both pilocytic (WHO grade I) and diffuse (WHO grade 
II) gliomas are considered low-grade gliomas and typically behave in an indolent fashion. 
WHO grade III and IV gliomas are high-grade or malignant gliomas, and they account 
for approximately 70% of all malignant brain tumours (1,4). Anaplastic astrocytomas 
(WHO grade III) are diffusely infiltrating, demonstrate a high degree of anaplasia, and 
tend to progress to glioblastoma multiformes (GBMs). Nuclear atypia and mitotic activity 
are the criteria for diagnosing anaplastic astrocytomas. GBM (WHO grade IV) is the 
most malignant form of astrocytoma. It is composed of differentiated neoplastic 
astrocytes. It shows increased mitotic activity, proliferation of microvasculature, and 
necrosis. Neovascularization and necrosis are histologic hallmarks of GBM reflecting the 
dysregulated blood supply of these tumours. Despite aggressive treatment with 
combinations of surgery, radiation and chemotherapy, the median survival of patients 
with GBM is approximately 12 to 15 months, while it is two to five years for those with 
anaplastic gliomas (4). 
 
1.3 Current Treatment Strategy for Malignant Glioma 
The standard of care for patients with malignant gliomas involves maximal 
surgical resection when feasible, followed by radiotherapy and concurrent and adjuvant 
Temozolomide chemotherapy (4,5). Patients usually undergo at least a biopsy to 
determine tumour grade and often undergo surgical resection to debulk the tumour mass 
to palliate symptoms and improve function. Within six weeks after surgery, patients will 
receive 40 to 60 Gy of external beam radiotherapy. The target for radiotherapy is defined 
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using MR and CT. The gross tumour volume includes the contrast-enhancing lesion 
(CEL) depicted on pre-surgical MR/CT. The clinical target volume includes a margin (2 
– 3 cm) to encompass microscopic spread of cancer (6). The planning target volume is 
created by an additional 0.3 cm margin to encompass treatment uncertainties (6). External 
beam radiotherapy is delivered in 2 Gy per fraction, given once daily for five days a week 
over a period of four to six weeks. Patients also receive concurrent Temozolomide at a 
dose of 75 mg/m2 per day, given 7 days per week until the last day of radiotherapy. Six 
cycles of adjuvant Temozolomide start at four weeks after the end of radiotherapy based 
on a five day schedule every 28 days (5).  
 
1.4 Prognostic Factors and Recurrence Patterns 
Advanced age (≥ 50 years old), WHO grade IV, poor Karnofsky performance 
status, and unresectable tumours are the most important pretreatment prognostic factors 
that predict poor survival (7). The extent of resection, radiation dose, and O6-
methylguanine-DNA methyltransferase (MGMT) promoter status are predictors of 
survival and recurrence patterns after treatment of GBM.  
Malignant gliomas often cannot be completely resected due to its infiltrative 
nature and its proximity to adjacent brain tissues that serve important neurologic 
functions. In a retrospective study that involved 1215 patients with malignant gliomas, 
the median survival times after gross-total resection, near-total resection, and subtotal 
resection were 13, 11, and 8 months, respectively. Survival benefits were significant for 
gross-total resection versus near-total resection (P < 0.05), and near-total resection versus 
subtotal resection (P < 0.05) (8). Therefore, maximal surgical resection is favorable 
because survival is influenced by the extent of resection (8–10). 
Radiotherapy plays an important role in prolonging the survival of these patients. 
It has long been established that a dose-survival relationship exist below 60 Gy (11). 
However, radiotherapy does not eliminate the risk of recurrence, and most patients will 
recur despite adjuvant radiotherapy. Over 80% of recurrence occurs within 2 cm of the 
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irradiated volume (12–17). For this reason, treatment volume is limited to the nearby 
surrounding region of the brain in order to reduce the toxicity associated with large field 
radiotherapy. The adoption of partial brain radiotherapy and new radiation technologies 
including three-dimensional conformal radiotherapy (18–20), intensity-modulated 
radiotherapy (21–23), stereotactic radiosurgery (SRS) (24–29), and interstitial 
brachytherapy have attempted to escalate the dose to beyond 60 Gy (30–34). Despite the 
use of high dose radiotherapy (90-120 Gy), dose escalation alone has not resulted in 
survival benefit. The target for dose escalation in these studies was typically defined as 
the CEL on CT or MR after contrast injection, but a few reports showed such procedure 
may not represent the entire tumour. Using 123I-α-methyl-tyrosine single-photon emission 
computed tomography (SPECT) and 11C-methionine positron emission tomography 
(PET) studies have detected areas of increased metabolic activity that were not visible on 
contrast-enhanced CT or MR (35–38). In a group of patients with recurrent malignant 
gliomas, reirradiation of gross tumour volumes based on PET/SPECT + CT/MRI resulted 
in improved survival compared to reirradiation of gross tumour volumes based on 
CT/MR alone (9 vs. 5 months, log-rank P = 0.03) (35). This result suggests that 
functional imaging can provide complimentary information to that of CT/MR, and may 
define a biologic target for dose escalation that is distinct from that delineated by typical 
contrast-enhanced imaging.  
Gliomas are known to be infiltrative neoplasms with the ability to migrate large 
distances in the brain. It is postulated that as treatment of the local tumour improves, 
distant failures beyond the typical 2 cm boundary around the irradiated brain volume may 
become more common.  As of yet, however, even in the most favorable instances 
(completely resected tumours + receiving adjuvant radiotherapy and chemotherapy), the 
majority of failures are still in close proximity to the original tumour. The O(6)-
methylguanine-DNA methyltransferase (MGMT) promoter methylation is a prognostic 
factor of survival and recurrence patterns after radiotherapy and Temozolomide 
chemotherapy. One mechanism of DNA injury induced by Temozolomide is the 
methylation of DNA (39). The DNA-repair protein O6-alkylguanine-DNA-
alkyltransferase is encoded by the gene MGMT, which repairs Temozolomide-induced 
DNA damage by removing the alkylating lesions at the O6 position of guanine. The 
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MGMT gene promoter is often methylated in malignant gliomas leading to the silencing 
of the MGMT gene and rendering tumour cells unable to repair Temozolomide-induced 
DNA damage (40). Patients with methylated MGMT promoter (i.e. silenced) had 
significantly longer survival than patients with unmethylated MGMT promoter (21.7 vs. 
12.7 months, respectively; log-rank P < 0001) (41). MGMT promoter gene status is also 
associated with different patterns of recurrence. Recurrences within or at the margin of 
the irradiated volume were more frequent amongst patients with unmethylated MGMT 
status than those with methylated MGMT status (P = 0.01) although local recurrences 
still predominated (42).  
 
1.5 The Blood Brain Barrier and Tumour Angiogenesis 
 A solid tumour cannot grow beyond 1 to 2 mm3 unless new vasculatures are 
formed to supply oxygen and nutrients to the growing tumour (43–45). Blood flow and 
the exchange of materials between the brain and systemic circulation are tightly regulated 
by the blood brain barrier (BBB). The BBB has important implications in tumour 
development and the growth of new blood vessels.  
Brain vasculature is highly specialized and is unlike those found in other organs. 
The passage of molecules between the systemic circulation and the cerebral parenchyma 
is regulated physically (via tight junctions) and metabolically (via enzymes and transport 
systems) by the BBB. It maintains a constant supply of oxygen, glucose and other 
nutrients for neurons, and excludes exogenous molecules from entering the brain. This 
regulation is primarily established by three types of cells: endothelial cells, pericytes, and 
astrocytes (Figure 1-1). Endothelial cells form the lumen of blood vessels, which is the 
interface for material exchange between the blood and the brain. Pericytes are 
undifferentiated perivascular cells that envelope the outer surface of arterioles, venules, 
and capillaries (46). They play important roles in regulating blood flow (47) and 
maintaining the integrity of the BBB (48). Astrocytes are glial cells that cover more than 
99% of the BBB endothelium (46). 
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Figure 1-1: Schematic diagram of a brain capillary. The capillary lumen is 
surrounded by an endothelial cell, which is connected at both ends by tight 
junctions. Pericytes are attached to the outer surface of the endothelial cell. 
The endothelial cell and pericyte are ensheathed by a layer of basal lamina. 
This capillary is then enveloped by astrocytes. Figure adapted from 
Hawkins and Davis. Pharmacol Rev. 2005;57(2):173-185. Reprinted with 
permission. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tight junctions between adjacent endothelial cells are responsible for the unique 
impermeability of the BBB. They are regions where adjacent endothelial cell membranes 
are tightly associated with each other through the interactions of various tight junction 
proteins (46). This arrangement is continuous and lacks fenestration. The outer leaflets of 
adjacent endothelial cell membranes appear to be fused. The BBB physically prevents 
plasma proteins and hydrophilic molecules (> 500 kDa) from passively diffusing into the 
brain parenchyma (49). For exogenous molecules that can cross the BBB, there are 
several active, receptor-mediated transport proteins that function to export these 
molecules from the brain back into the systemic circulation (50,51). The brain is 
considered a “sanctuary” site for cancer cells because the BBB contributes to drug-
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resistance by excluding many exogenous molecules (e.g. drugs) from entering the brain 
(49).  
1.5.1 The Blood Brain Barrier in Brain Tumours 
The integrity of the blood brain barrier is compromised in malignant brain 
tumours. The expressions of tight junction proteins are decreased or completely lost in 
primary and metastatic brain tumours (52–54). This leads to increased vascular 
permeability and may clinically manifest as vasogenic edema. The reduced number of 
pericytes (55) and astrocytes (56,57) in an aggressive brain tumour further contributes to 
a dysfunctional BBB. Tumour cells further increase BBB permeability by secreting a 
variety of factors that down regulate the expression of tight junction proteins (58,59). 
One such factor is the vascular endothelial growth factor (VEGF), which was originally 
discovered as the vascular permeability factor (49,58). VEGF is also a driver of tumour 
vessel formation. The resulting vessels are structurally and functionally compromised and 
lack the BBB of normal vasculature.  
 
1.5.2 Tumour Hypoxia  
Mammalian cells are usually located within 100 to 200 μm of nearby blood 
vessels, which is the oxygen diffusion limit (60,61). The partial pressure of oxygen (PO2) 
in normal tissue ranges between 10 to 80 mm Hg, but PO2 within certain tumour regions 
are often less than 5 mm Hg (62). Hypoxia occurs when the tumour grows beyond the 
oxygen diffusion limit because the vascular supply cannot meet its metabolic demand. 
This type of hypoxia is called chronic hypoxia, which can lead to tumour necrosis. 
Cycling hypoxia, sometimes known as acute or intermittent hypoxia, occurs in tumour 
regions that are poorly perfused due to chaotic and sluggish tumour vasculature (63). 
Hypoxia is associated with treatment resistance (64,65) and promotes the formation of 
new tumour blood vessels (66,67). The growth of a solid tumour is dependent on the 
growth of new blood vessels (44). There are four mechanisms for brain tumours to form 
new blood vessels, they are co-option, angiogenesis, vasculogenesis, and intussusception. 
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1.5.3 Formation of Tumour Blood Vessels 
1.5.3.1 Co-option 
Initial brain tumour vessel formation (< 1 mm in diameter) is believed to occur by the co-
option of pre-existing blood vessels (68,69). Early reports demonstrated that pre-existing 
vessels that were co-opted by tumour cells were not influenced by the tumour as these 
vessels were not leaky (68,70). This also suggests that this type of vessel formation might 
not be detected by contrast-enhanced CT or MR since these imaging techniques detect 
tumour based on the extravasation of contrast agents (68). 
 
1.5.3.2 Angiogenesis 
Angiogenesis is a common mechanism for gliomas to grow and progress. Tumour 
angiogenesis in the brain involves three major steps: 1) regression of pre-existing blood 
vessels, 2) breakdown of the basement membrane and extracellular matrix, and 3) the 
migration of endothelial cells to form new blood vessels. The initiation of angiogenesis is 
known as the angiogenic switch. This switch is turned on when the pro-angiogenic 
factors in a tumour outweigh the anti-angiogenic factors. The secretion of pro-angiogenic 
factors are triggered by microenvironmental conditions including hypoxia and acidosis 
(71), and by genetic factors such as alterations in oncogene (e.g. ras) or tumour 
suppressor gene (e.g. p53) functions (72,73). The hypoxia-inducible factor 1 (HIF-1) 
pathway is a well-characterized signaling pathway by which hypoxic tumours initiate and 
orchestrate cellular responses to hypoxia. HIF-1 activates the transcription of more than 
100 genes that help tumour cells “cope” with low oxygen conditions (74). The expression 
of VEGF, one of the most potent pro-angiogenic factors, is activated by this pathway 
(71,73).  
The initial response to VEGF overexpression includes increased vascular 
permeability (75–77) and diameter (49). In a normal brain, angiopoietin (Ang-1) binds to 
its receptor Tie-2 to facilitate a close association between endothelial cells and pericytes 
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(48,78). Under hypoxic conditions, Ang-2, an antagonist of Tie-2, is upregulated and is 
suggested to be involved in the detachment of pericytes from endothelial cells and leads 
to the regression of blood vessels (79–81). Increased Ang-2 and hypoxia then lead to the 
expression of matrix-metalloproteinase molecules that mediate the breakdown of the 
basement membrane and the extracellular matrix (82). At the same time, molecules 
including VEGF, Ang-1, and Ang-2 stimulate endothelial cell proliferation and migration 
towards the cancer cells (49,79). The end product of angiogenesis is an abnormal, highly 
tortuous, sluggish, and leaky vascular network (49,63).  
 
1.5.3.3 Vasculogenesis 
Angiogenesis forms new blood vessels from pre-existing ones, whereas 
vasculogenesis forms blood vessels without pre-existing endothelial cells. It is a process 
by which bone marrow-derived cells (83–85), such as circulating progenitor cells (86,87), 
are recruited to the tumour to form new blood vessels. This process is also initiated by 
hypoxia through the HIF-1 pathway (88,89). It has been shown that blocking 
vasculogenesis can prevent or delay local recurrence of GBM after irradiation (88). This 
suggests circulating cells outside the radiation field colonize and stabilize tumour 
vasculature and support the remaining viable tumour cells after irradiation.  
 
1.5.3.4 Intussusception  
Intussusception refers to the remodeling and expansion of pre-existing blood 
vessels by inserting transluminal pillars into vessel lumens that result in partitioning of 
vessel lumens (79,90). Intussusception occurs faster than angiogenesis; it does not 
primarily depend on the proliferation of endothelial cells, degradation of basement 
membrane, and invasion of connective tissue (90,91). It appears to increase the 
complexity and density of tumour vascular networks established by angiogenesis (90).  
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1.6 Conventional Imaging of Malignant Gliomas 
Visualization of brain tumours on contrast-enhanced MR and CT is made possible 
because the compromised BBB in brain tumours allow imaging contrast to extravasate 
into the brain parenchyma after contrast injection. The standard MR protocol for imaging 
brain tumours usually involves a T2-weighted or a fluid attenuated inversion recovery 
(FLAIR) MR and a gadolinium-enhanced T1-weighted MR (Figure 1-2) (92). 
Gadolinium-enhanced T1-weighted MR provides excellent soft tissue contrast, and 
depicts the contrast-enhancing component of the tumour. However, malignant gliomas 
are infiltrative tumours with microscopic processes that extend beyond regions of 
contrast-enhancement. Vasogenic edema, which may be induced by infiltrating tumour 
cells, is a major clinical feature of the non-enhancing portions of these tumours and can 
be visualized on T2-weighted or FLAIR MR.  
 
Figure 1-2: Contrast-enhanced T1-weighted magnetic resonance (MR) and T2-
weighted MR of a patient with glioblastoma multiforme (GBM). 
 
1.7 Criteria for Assessing Treatment Response 
Radiographic response assessment of brain tumours is primarily based on changes 
in the size of the contrast-enhancing part of the tumour. The Macdonald criteria were 
introduced in 1990 for assessing response in gliomas (93). Tumour size is measured using 
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the product of the maximal perpendicular diameters of the enhancing tumour depicted on 
gadolinium-enhanced T1-weighted MR or iodinated contrast-enhanced CT. The use of 
corticosteroid and clinical status are also taken into account. Response can be categorized 
into four categories; they are complete response, partial response, stable disease, and 
progression (Table 1-1).  
 
Table 1-1: The Macdonald criteria for assessing treatment response of malignant 
gliomas.* 
Response Criteria 
Complete 
Response 
Requires all of the following: complete disappearance of all enhancing 
measurable and non-measurable diseases sustained for at least 4 
weeks; no new lesions; no corticosteroid; and stable or improved 
clinically  
Partial Response Requires all of the following: ≥ 50% decrease compared with baseline in 
the sum of products of perpendicular diameters of all measurable 
enhancing lesions sustained for at least 4 weeks; no new lesions; stable 
or reduced corticosteroid dose; and stable or improved clinically  
Stable Disease Requires all of the following: does not qualify for complete response, 
partial response, or progression; and stable clinically  
Progression Defined by any of the following: ≥ 25% increase in the sum of products 
of perpendicular diameters of enhancing lesions; any new lesion; or 
clinical deterioration  
*Reprinted with permission. © (2010) American Society of Clinical Oncology. All rights 
reserved. Table adapted from Wen PY, Macdonald DR, Reardon DA, et al. J Clin Oncol. 
2010;28(11):1963-1972. 
 
The Macdonald criteria have a few limitations. A two dimensional measurement 
of tumour size can be influenced by a number of factors (94–96). Measurement is 
difficult with an irregularly shaped tumour, multifocal tumour, and enhancing wall of a 
surgical cavity. It is also prone to interobserver variability (97). Contrast-enhanced MR or 
CT is a snapshot of tissue contrast-enhancement after contrast injection, so it reflects the 
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extravasation of materials across a disrupted BBB regardless of the cause of disruption. 
Changes in corticosteroid dose, inflammation, post-surgical changes, pseudoprogression 
due to treatment effects, radiation-induced necrosis, and pseudoresponse due to anti-
angiogenic therapies are all factors that can influence contrast-enhancement (98–102). In 
addition, the Macdonald criteria do not take into account the non-enhancing component 
of the tumour. 
Recently, the Macdonald criteria were updated. In 2010, The Response 
Assessment in Neuro-Oncology (RANO) Working Group developed new standardized 
criteria for assessing response in patients with malignant gliomas (92). Size measurement 
of the non-enhancing component of the tumour using T2-weighted or FLAIR MR is 
incorporated into the assessment criteria. It also recognized early changes in contrast-
enhancement could be treatment related (e.g. pseudoprogression and pseudoresponse), 
which could confound the diagnosis of tumour progression or response. To address this 
issue, a time period has been defined for which pseudoprogression can be excluded from 
true progression. For instance, true progression can only be determined within the first 12 
weeks of completion of radiotherapy if the majority of new contrast-enhancement is 
outside the radiation field (80% isodose line) or if there is pathologic confirmation of 
tumour progression (92). 
 The RANO working group recognized that there are still unsolved problems 
associated with these criteria. Better imaging techniques are needed to predict tumour 
response, differentiate treatment-induced changes from tumour progression, and 
differentiate non-enhancing tumours from other etiologies of increased T2-weighted or 
FLAIR signals. The group also recognized that functional imaging, particularly the 
imaging of tumour perfusion and permeability, are promising tools to address these 
challenges.  
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1.8 Perfusion Imaging of Malignant Gliomas 
A growing number of studies demonstrated that perfusion imaging can provide 
physiologic information about tumour aggressiveness and disease prognosis. Dynamic 
susceptibility-contrast MR (DSC-MR), dynamic contrast-enhanced MR (DCE-MR), and 
DCE-CT are commonly used perfusion imaging techniques for evaluating tumour 
hemodynamics and vessel permeability surface area (PS) product in the research setting. 
In this thesis, DCE-CT and CT perfusion are used interchangeably.  
Perfusion imaging refers to imaging techniques that characterize tissue 
hemodynamics by tracking the passage of a bolus of contrast agent as it traverses through 
human tissue. Following injection, contrast passes through the microvasculature of brain 
tissue and produces a change in image signal intensity. DCE-MR and DSC-MR measure 
gadolinium contrast concentration via its effect on surrounding water molecules, while 
DCE-CT measures iodinated contrast concentration via its attenuation of x-rays. 
Quantitative evaluation of hemodynamics and PS from tracer kinetic analysis (103) 
consists of three main steps: 
1. Image signal intensity is converted to contrast concentration to obtain the 
time-concentration curve Ct(t) of brain (tumour) tissue.  
2. Image signal intensity in pixels corresponding to an input artery to the brain is 
similarly converted to the arterial input function Ca(t). It is the time-
concentration curve of contrast that enters the tissue of interest via the selected 
input artery.  
3. Based on the tracer kinetic model adopted, hemodynamic parameters such as 
blood flow (BF) and PS can be estimated. Definitions of the different tracer 
kinetic parameters that can be derived are listed in Table 1-2. The tissue time-
concentration curve Ct(t) is equal to blood flow (BF) multiplying the 
convolution of the arterial input function Ca(t) and an impulse residue 
function R(t). This relationship can be mathematically expressed as: 
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𝐶𝑡(𝑡) = 𝐵𝐹 ⋅ 𝐶𝑎(𝑡)⨂𝑅(𝑡) = 𝐶𝑎(𝑡) ⊗ 𝐵𝐹 ⋅ 𝑅(𝑡) 
𝐶𝑡(𝑡) = ∫ 𝐶𝑎(𝜏) ∙ [𝐵𝐹 ∙ 𝑅(𝑡 − 𝜏)]𝑑𝜏
𝑡
0
 … Equation 1-1 
The impulse residue function R(t) describes the tissue time-concentration curve when the 
arterial input function is 
1
𝐵𝐹
𝛿(𝑡) or when an unit amount of contrast is introduced into the 
arterial input of the tissue instantaneously. Empirically, it is the fraction of contrast that 
remains in the tissue as a function of time after instantaneous contrast injection at the 
arterial input. In practice, contrast is injected intravenously over a period of time (15-25 
s) such that the arterial input function Ca(t) is dispersed in time instead of a delta function 
𝛿(𝑡). Provided the image signal varies linearly with concentration and BF is stationary 
(constant within the period of measurement), the tissue time-concentration curve Ct(t) is 
by the convolution between the arterial input function Ca(t) and the impulse residue 
function R(t) using the principle of linear superposition.  
Below we discuss the technical aspects of DSC-MR, DCE-MR, and DCE-CT.  
 
Table 1-2: Glossary of perfusion imaging parameters. 
Terms Definitions (units) 
Blood flow (BF) Flow rate of blood per unit mass or volume of tissue 
(ml∙min∙100g-1 or ml∙min∙100ml-1). 
Blood volume (BV) Volume of ‘flowing’ blood within the vasculature per unit 
mass or volume of tissue (ml∙100g-1 or ml∙100ml-1). 
Extraction fraction (E) Fraction of contrast that extravasates from the intravascular 
space into the EES in the first pass through the vasculature 
Initial Area Under the 
Curve (iAUC) 
A semi-quantitative measure of contrast enhancement used 
in DCE-MR. It is related to the dose of contrast injected, the 
blood volume, and permeability surface product of the BBB. 
mAUCRH The ratio between the iAUC and the final AUC from a DCE-
MR scan gives the AUCR. The histogram of AUCR of a 
region is bimodal or skewed, the mean for the higher peak of 
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this distribution is calculated to give the mAUCRH.  
Mean transit time 
(MTT) 
Average time (s) for blood to traverse from the arterial to the 
venous end of the vasculature. 
Normalized BV (nBV) BV of a region-of-interest normalized to the contralateral 
normal brain. The normal appearing white matter is used for 
normalization. 
Normalized Maximum 
Slope 
A semi-quantitative estimation of BF. It is the maximum 
slope of a tissue time-contrast enhancement curve 
normalized by the maximum of the arterial time-contrast 
enhancement curve. 
Peak Height (PH) A measure of maximum contrast enhancement from the 
baseline signal during the first pass of contrast.  
Normalized Peak 
Height 
PH of the tumour can be normalized to the contralateral 
normal brain to give the normalized peak height. 
Percent Recovery It is the measure of how much signal has recovered from the 
baseline signal after the first pass of contrast. It is a semi-
quantitative measure of microvascular leakage in DSC-MR. 
Permeability Unidirectional flux rate of contrast agent from the blood 
plasma into the brain parenchyma (i.e. interstitial space) 
normalized by the total surface area of capillaries per unit 
mass of tissue. It is often estimated using the parameters 
permeability-surface area product (PS) and transfer rate 
constant (Ktrans). 
Permeability-surface 
area product (PS) 
Product of permeability and total surface area of capillaries 
per unit mass of tissue (ml∙min∙100g-1). 
Efflux Rate constant 
(kep) 
Rate constant of contrast efflux rate from the brain 
parenchyma back into the blood plasma (min-1). 
Transfer Constant 
(Ktrans) 
Flow rate constant of contrast from the blood plasma to the 
brain parenchyma (min-1). 
Vp Volume of ‘flowing’ blood within the vasculature per unit 
mass or volume of tissue (ml∙100g-1 or unitless) 
Extravascular volume 
(ve) 
Volume of extravascular extracellular space per unit volume 
of tissue for contrast to distribute into (ml∙100g-1 or unitless). 
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Abbreviations: EES, extravascular extracellular space; DCE-MR, dynamic contrast-
enhanced magnetic resonance; BBB, blood brain barrier; DSC-MR, dynamic 
susceptibility-contrast magnetic resonance 
 
1.8.1 Dynamic Susceptibility-Contrast Magnetic Resonance (DSC-
MR) 
DSC-MR imaging measures signal change during the first passage of contrast 
through the tissue vasculature when the contrast remains intravascular using a T2- or 
T2*-weighted sequence. At high concentration (0.1 – 0.2 mmol/kg), the contrast agent 
creates a susceptibility gradient in tissue that decreases T2* signal intensity. A temporal 
resolution of 1 – 2 s is required because the minimum transit time of contrast agent in 
brain tissue is a few seconds. A typical scan duration of 1 – 2 minutes is used. The 
indicator dilution method is appropriate for calculating BF and BV in DSC-MR imaging 
(104). DSC-MR assumes that the degree at which contrast is diluted in the blood is a 
function of blood flow (BF) and blood volume (BV) and that contrast remains 
intravascular during imaging. BV is estimated from the ratio of the areas under the tissue 
time-concentration curve Ct(t) and the arterial time-concentration curve Ca(t). BF can be 
solved by the deconvolution of Equation 1-1. DSC-MR assumes that the contrast agent 
compartmentalizes in the intravascular space and does not leak into the brain 
parenchyma. However, violation of this assumption can underestimate BV when high 
leakage of contrast material occurs (105). This effect can be minimized by pre-saturating 
the brain parenchyma with a pre-loading dose of contrast agent, dual echo sequence, or 
post-processing mathematical correction (105,106). 
 
17 
 
 
1.8.2 Dynamic Contrast-Enhanced Magnetic Resonance (DCE-
MR) 
DCE-MR refers to the acquisition of serial MR images using a T1-weighted 
sequence. The increase in T1 relaxation rate from corresponding increase in contrast 
concentration is measured as an increase in signal intensity. DCE-MR scan duration is 5 
– 10 min in order to measure the rate of extravasation of contrast from the intravascular 
space into the extravascular extracellular space (EES) (i.e. PS or Ktrans). By assuming the 
intravascular space and the EES as two well-mixed tissue compartments, the 
compartmental model is used to estimate the rate of contrast transfer from the 
intravascular space into the EES (107). This quantity is commonly called Ktrans and can 
be solved using the following equation: 
𝐶𝑡(𝑡) = 𝐵𝑉 ⋅ 𝐶𝑎(𝑡) + 𝐾
𝑡𝑟𝑎𝑛𝑠 ∫ 𝐶𝑎(𝑢)𝑒
−
𝐾𝑡𝑟𝑎𝑛𝑠
𝑣𝑒
(𝑡−𝑢)
𝑑𝑢
𝑡
0
… Equation 1-2 
where ve is the volume of extravascular extracellular space per unit volume of tissue. 
Ktrans is generally interpreted as a measure of tissue permeability (107). However, Ktrans is 
the product between BF and extraction fraction (E). Thus, Ktrans should be used for 
permeability interpretation with caution because either BF or E may be the dominating 
factor. A temporal resolution of 5 – 10 s per image is commonly used to balance spatial 
resolution, scan coverage, and signal-to-noise ratio, but it is too slow for the 
measurements of BF and BV where a finer temporal resolution (1 – 2 s) is required (108). 
However, techniques such as multi-channel parallel imaging and compressed sensing can 
achieve a finer temporal resolution (109). 
 
1.8.3 Dynamic Contrast-Enhanced Computed Tomography (DCE-
CT) 
DCE-CT refers to the acquisition of serial CT images to track the passage of a 
bolus of iodinated contrast agent. The typical DCE-CT protocol takes 2 – 3 minutes, and 
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it involves rapid acquisition of images (1 – 2 s per image) during the initial phase of 
imaging (45 s) to capture the first pass of contrast for the calculation of BF and BV. A 
second phase that involves less frequent acquisition (10 – 15 s per image) is required to 
calculate PS or Ktrans (110). Both compartmental and distributed parameter models have 
been used to calculate tracer kinetic parameters from DCE-CT images. The Johnson and 
Wilson model (111) is an example of a distributed parameter model. An adiabatic 
approximation to the Johnson and Wilson model allows the simultaneous determination 
of BF, BV, and permeability-surface area product (PS) by giving a closed-form solution 
to the impulse residue function R(t) (112). The R(t) is defined as: 
𝑅(𝑡) = {
1                                        0 < 𝑡 ≤
𝐵𝑉
𝐵𝐹
𝐸𝑒
−
𝐵𝐹⋅𝐸
𝑣𝑒
(𝑡−
𝐵𝑉
𝐵𝐹
)
                       𝑡 >
𝐵𝑉
𝐵𝐹
 … Equation 1-3 
The extraction fraction E is calculated as: 
𝐸 = 1 − 𝑒−
𝑃𝑆
𝐵𝐹 … Equation 1-4 
The distributed parameter model enables the separation of BF and E; thus, enabling the 
calculation of the permeability-surface area product (PS). It assumes a contrast 
concentration gradient inside the intravascular space along the length of capillaries (110). 
An advantage of the distributed parameter model is the determination of BF, BV, and PS 
from a single perfusion scan.  
The clinical use of DCE-CT was slow to progress initially due to its relatively 
limited scan volume (2 – 4 cm coverage) and associated radiation dose (2 – 5 mSv) (113). 
The advent of large multi-row detector technology enables the coverage of 16 cm of 
anatomy (114). Shuttle mode imaging can also increase the scan coverage (115). 
Reconstruction methods such as adaptive statistical iterative reconstruction technique 
(116) and reducing the temporal resolution of image acquisition (≤ 3 s) in the first phase 
(117) are effective ways to reduce radiation dose. Figure 1-3 shows maps of BF, BV, and 
PS from a DCE-CT study of a patient with GBM. Table 1-3 summarizes and compares 
the key aspects of DSC-MR, DCE-MR, and DCE-CT.  
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Figure 1-3: Blood flow (BF), blood volume (BV), and permeability-surface area (PS) 
product maps calculated from dynamic contrast-enhanced computed tomography 
(DCE-CT) images of the same patient as Figure 1-2. 
 
Table 1-3: Comparison of typical brain perfusion imaging techniques. 
Parameter DSC-MR DCE-MR DCE-CT 
Typical contrast 
agent 
Gadopentetate 
dimeglumine  
Gadopentetate 
dimeglumine 
Iopamidol 
Tracer kinetic 
analysis 
method 
Indicator dilution theory Compartmental model Compartmental and 
distributed parameter 
models 
Scan coverage 8 – 10 or 16 – 20 slices 
covering the entire brain 
(~ 10 cm) 
16 – 32 slices covering 
3 to 16 cm of anatomy 
4, 8, and 16 cm 
coverage with multi-
detector CT.  
Shuttle mode imaging 
can achieve whole 
brain coverage  
Molecular 
weight of 
contrast agent 
938 g/mol  
(0.938 kDa) 
938 g/mol  
(0.938 kDa) 
777 g/mol  
(0.777 kDa) 
Typical 
temporal 
resolution 
1 – 2 s 5 – 10 s First phase: 1 – 2 s 
Second phase: ≤ 5 s for 
Patlak analysis and 10 
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– 15 s for Johnson and 
Wilson model 
Typical scan 
duration 
1 – 2 min 5 – 10 min  2 – 3 min 
Source of signal Decrease in T2* (or T2) of 
surrounding water 
molecules  
Decrease in T1 of 
surrounding water 
molecules 
Attenuation of x-ray by 
iodinated contrast 
Change in signal 
intensity 
Signal loss Signal gain Signal gain 
Signal-to-
contrast 
concentration 
relationship 
 
 
 
*
2
*
2
0
ln
1
RkC
S
tS
TE
tR








 
1
1
1
1
1
0
R
TT
C










 
Linear 
Quantitative 
Techniques 
Mostly relative Relative and absolute Relative and Absolute  
Abbreviations: DSC-MR, dynamic-susceptibility contrast magnetic resonance; DCE-MR, 
dynamic contrast-enhanced magnetic resonance; DCE-CT, dynamic contrast-enhanced 
computed tomography; ΔR2*, Change in relaxation rate; S(0), baseline signal intensity; 
S(t), signal intensity at time t; R1, longitudinal relaxivity of the contrast agent; C, 
concentration; Hct, hematocrit; k, proportionality constant that depends on the tissue, 
contrast agent, field strength, and pulse sequence parameters. 
 
1.8.4 Other Important Perfusion Imaging Techniques 
Arterial spin labeling (ASL) is a promising technique that can measure BF in 
brain tumours. ASL uses arterial blood water as an endogenous tracer by magnetically 
labeling blood water that is proximal to the tissue of interest. ASL is a technology that is 
gaining interest in neuro-oncology in recent years (118,119) since it does not require the 
injection of exogenous contrast agent and it has no radiation dose. The ASL method 
makes serial perfusion scans even more feasible for monitoring treatment response. 
Tumour perfusion can also be investigated using nuclear medicine techniques. 
Positron emission tomography (PET) using 15O-labeled water has been used in previous 
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reports (120,121), and is considered to be the “gold standard” in quantitative perfusion 
imaging. However, the need for an onsite cyclotron and the short half-life of 15O (2 
minutes) limits its feasibility in the clinic. Limited spatial resolution is also a 
disadvantage of PET when compared to CT and MR.  
 
1.9 Literature Review of Perfusion Imaging  
Here, we provide a review of the literature in perfusion imaging of malignant 
gliomas. To comprehensively survey the literature, a PubMed search was performed from 
January 2002 to May 2012 using the terms (‘glioma’ OR ‘glioblastoma’) AND 
(‘perfusion imaging’, ‘dynamic contrast-enhanced’, ‘DCE’, ‘computed tomography’, 
‘CT’, ‘dynamic susceptibility’, ‘DSC’, ‘magnetic resonance’, OR ‘MR’) to identify 
relevant clinical studies. The search was limited to include studies that involved human 
subjects and published in the English language. Preclinical studies, studies that evaluated 
only low-grade gliomas, and studies with a sample size ≤ 5 patients were excluded.  
We categorized each article according to the investigated application. Five key 
areas were identified; they are 1) correlations with molecular and histopathologic 
markers, 2) diagnostic efficacy of differentiating high grade from low grade gliomas, 3) 
differentiation of malignant gliomas from other malignant lesions, 4) differentiation of 
true progression from post-treatment effects, and 5) prediction of survival. Literature 
search for applications 4 and 5 were extended to include studies published before January 
2014. When considering articles that evaluated tumour grade, only articles that reported 
the sensitivity and specificity to differentiate high and low grade gliomas were included. 
The article selection process is summarized in Figure 1-4.  
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Figure 1-4: Article selection flowchart according to the Preferred Reporting Items 
for Systematic Reviews and Meta-analysis (PRISMA) guidelines. 
 
1.9.1 Correlation with Molecular and Histopathologic Markers 
An understanding of the relationships between histopathologic markers and 
perfusion imaging could justify the use of perfusion imaging as non-invasive surrogates 
for these tissue assays (Table 1-4). 
 
Table 1-4: Correlation of perfusion imaging parameters with histopathologic 
markers. 
Histopathologic 
Markers 
Techniques Parameters 
Correlation 
coefficients (range) 
References 
Tumour cellularity or 
cell density 
DSC-MR nBV 0.57 (122) 
DCE-CT 
BF 0.498 
(123) 
BV 0.482 
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PS 0.409 
Microvessel density 
(MVD) 
DSC-MR nBV 0.32 – 0.46   (122,124) 
DCE-MR nBV 0.821 – 0.896 (125,126) 
DCE-CT 
BF 0.527 
(123) 
BV 0.649 
Microvessel area 
(MVA) 
DSC-MR nBV 0.83 (124) 
Microvascular 
cellular proliferation 
(MVCP) 
DSC-MR nBV 
nBV were higher in 
the presence of 
MVCP 
(127) 
DCE-CT PS 0.647 (123) 
Vascular endothelial 
growth factor (VEGF) 
DSC-MR nBV 
nBV values 
correlated with 
VEGF expression 
(128) 
DCE-MR 
nBV 0.765 – 0.884 (125,126,129) 
nBF 0.849 (129) 
Matrix 
metalloproteinase-9 
(MMP-9) 
DCE-MR 
Ktrans 0.585 (130) 
kep 0.765 – 0.871 (129,130) 
ve 0.509 (130) 
Hypoxia inducible 
factor 1-alpha (HIF1-
α) 
DCE-MR nBV 0.557 (129) 
Ki-67 DSC-MR 
nBV 
0.628 (marginal 
significance) 
(131) 
nMTT 
0.644 (marginal 
significance) 
MIB-1 DSC-MR nBV 0.66 (132) 
 
Abbreviations: DSC-MR, dynamic susceptibility-contrast magnetic resonance; DCE-MR, 
dynamic contrast-enhanced magnetic resonance; DCE-CT, dynamic contrast-enhanced 
computed tomography; nBV, normalized blood volume; BF, blood flow; PS, 
permeability-surface area product; nBF, normalized blood flow; Ktrans, transfer constant; 
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kep, efflux rate constant; ve, volume of extravascular extracellular space per unit volume 
of tissue; nMTT, normalized mean transit time. 
 
Microvessel density (MVD) is a histopathologic measure of angiogenesis and a 
prognosticator of survival (133). Correlations between MVD and BV were weak for 
DSC-MR (< 0.4), moderate for DCE-CT (< 0.7), and strong for DCE-MR (> 0.8). 
Microvessel area (MVA) is a more useful predictor of survival than MVD because MVD 
cannot characterize the morphological complexity of tumour blood vessels, which are 
often tortuous and different in sizes (134). Tumour normalized BV (nBV) showed a 
stronger correlation with MVA than MVD (r = 0.83 and 0.32, respectively; p ≤ 0.05) 
(124). Moreover, nBV and MVA correlated with overall survival (OS) while MVD did 
not. Microvascular cellular proliferation and VEGF expression also showed correlations 
with perfusion imaging parameters (Table 1-4). Together, these studies suggest that 
perfusion imaging-based measure of BV may be a surrogate marker of the degree of 
angiogenesis, which in turn is a predictor of patient survival.  
One DCE-CT study explored the associations between the expression of genes 
that regulate angiogenesis in GBM and different DCE-CT parameters (135). Nineteen 
and nine genes showed significant associations with PS and BV, respectively. BV and/or 
PS correlated positively with some pro-angiogenic genes (e.g. KDR (VEGFR-2) and 
HIF1A) and negatively with some anti-angiogenic genes (e.g. VASH2 and C3). This 
study suggests a molecular genetic basis for PS and BV as candidate imaging biomarkers. 
Angiogenesis is crucial for the proliferation and invasion of malignant gliomas, 
and it was demonstrated that MVD correlated with tumour proliferation (136). For this 
reason, studies have investigated the associations between perfusion imaging parameters 
and proliferative potential of malignant gliomas. Tumour cellularity or cell density is a 
histologic method to quantify the number of tumour cells. Moderate correlations between 
DSC-MR or DCE-CT parameters and tumour cellularity (0.4 < r < 0.6) were reported 
(122,123) (Table 1-4). However, cell density cannot distinguish between proliferative, 
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apoptotic, and senescence cells. Ki-67 or MIB-1 are cellular markers of proliferation, and 
moderate correlations with DSC-MR parameters have been reported (r > 0.6) (131,132). 
 
1.9.2 Differentiation of Tumour Grade 
Stereotactic biopsy of tumour specimens for grading can be prone to sampling 
error. In a study that compared biopsied specimens with surgically resected specimens, as 
much as 60% of anaplastic astrocytoma (WHO grade III) were upgraded to GBM (137). 
Imaging techniques that can determine tumour aggressiveness can provide 
complementary information to establish grade and guide biopsy to sample the most 
anaplastic part of the tumour. Functional image-guidance can potentially improve the 
accuracy of diagnosis.  
We found 20 studies that reported the sensitivities and specificities of using 
perfusion imaging to differentiate high versus low grade gliomas (Table 1-5). The 
sensitivities ranged from 68 to 100% and specificities ranged from 40 to 100% (138–
157). Different thresholds were used for differentiating high from low grade gliomas. 
Thus, while perfusion imaging showed promise for grading, standardization of imaging 
protocols and consensus thresholds for differentiating tumour grade need to be 
established.  
Not all malignant gliomas are enhancing on post-gadolinium T1-weighted MR 
images. About 9% of malignant gliomas lack contrast-enhancement and can be mistaken 
as low-grade gliomas that do not enhance (158). Perfusion imaging can be an important 
tool in this regard. Using DSC-MR, patients with non-enhancing anaplastic gliomas 
(WHO grade III) had significantly higher nBV than those with low-grade astrocytomas 
(WHO grade II) (159). In a study using DCE-CT, nBV demonstrated a sensitivity and 
specificity of 90.9% and 83.3% for differentiating non-enhancing grade III vs. II gliomas 
(157). 
26 
 
 
Table 1-5: Summary of sensitivities and specificities of perfusion imaging in differentiating high grade versus low grade 
gliomas. 
Modality Parameter  
Median sensitivity and 
specificity (ranges) (%) 
References‡ Key points from the literature 
DSC-MR 
*nBV 
Sensitivity: 94 (67 – 100) 
Specificity: 86 (50 – 100) 
(138–151) 
 Regions-of-interest are usually placed in visually contrast-
enhancing regions only 
 BV and BF values are generally higher in high-grade 
gliomas than low-grade gliomas. 
 Permeability values (i.e. PS and Ktrans) are higher in high-
grade gliomas than low grade gliomas. 
 Oligodendrogliomas may demonstrate foci with high blood 
volume regardless of tumour grade. 
 Optimal thresholds for differentiating high grade versus 
low grade gliomas have not been tested in a prospective 
study   
 Standardization of imaging protocol is need to reduce the 
variability in sensitivity and specificity observed in studies 
nBF 
Sensitivity: 86 (73 – 100) 
Specificity: 95 (91 – 100) 
(138,142) 
DCE-MR 
Ktrans 
Sensitivity: 89 (89 – 89) 
Specificity: 79 (75 – 82) 
(152,153) 
Vp 
Sensitivity: 68 (N/A) 
Specificity: 89 (N/A) 
(153) 
ve 
Sensitivity: 82 (N/A) 
Specificity: 94 (N/A) 
(152) 
DCE-CT 
†BV  
Sensitivity: 89 (83 – 100)  
Specificity: 92 (75 – 100) 
(154–157) 
†BF 
Sensitivity: 83 (71 – 90)  
Specificity: 94 (82 – 100) 
(155–157) 
Ktrans  
Sensitivity: 97 (N/A) 
Specificity: 100 (N/A) 
(156) 
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Modality Parameter  
Median sensitivity and 
specificity (ranges) (%) 
References‡ Key points from the literature 
PS  
Sensitivity: 100 (N/A) 
Specificity: 83 (N/A) 
(154) 
MTT 
Sensitivity: 93 (N/A) 
Specificity: 40 (N/A) 
(155) 
 
Abbreviations: nBV, normalized blood volume; nBF, normalized blood flow; Ktrans, transfer constant between blood plasma and 
extravascular extracellular space; Vp, volume of ‘flowing’ blood within the vasculature per unit mass; ve, volume of extravascular 
extracellular space per unit volume of tissue; PS, permeability-surface area product; MTT, mean transit time; DSC-MR, dynamic-
susceptibility contrast magnetic resonance; DCE-MR, dynamic contrast-enhanced magnetic resonance; DCE-CT, dynamic contrast-
enhanced computed tomography; N/A, not applicable. 
 
*nBV refers to mean or maximum nBV 
†BV and BF refers to absolute or normalized BV and BF, respectively 
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Almost all low-grade gliomas eventually progress to high-grade gliomas at an 
unpredictable time. In a cohort of low-grade glioma patients that received repeated DSC-
MR, a continuous increase in nBV was found in those with malignant transformation up 
to the point when contrast-enhancement became apparent on post-gadolinium T1-
weighted images. The nBV for transformers significantly increased to 5.36 at the time of 
transformation (p < 0.05), while nBV remained stable and increased to only 1.52 in non-
transformers  (p > 0.05) (160). Together, these studies suggest perfusion imaging is a 
useful method for grading gliomas even in cases where the tumours lack contrast-
enhancement, and can be an important tool for active surveillance of low grade gliomas.  
Perfusion imaging differentiation of tumour grade in oligodendroglial tumours 
should be interpreted with caution. Oligodendroglial tumours can have higher BV than 
astrocytic tumours irrespective of tumour grade (161) while high grade oligodendroglial 
tumours may or may not have higher BV than low grade oligodendroglial tumours 
(161,162). Thus, perfusion imaging of oligodendroglial tumours should be considered 
separately from astrocytic tumours, and perfusion imaging alone is not reliable for 
differentiating oligodendroglial tumour grade. 
 
1.9.3 Differentiation of Malignant Brain Lesions 
Solitary brain metastases with no history of primary cancer are found in 
approximately 15% of patients and may appear similar to primary malignant gliomas on 
MR images (163). We found 18 studies that used perfusion imaging to differentiate brain 
metastases from malignant gliomas. Two factors should be considered when using 
perfusion imaging to differentiate these two entities. Firstly, current evidence suggests 
that BV in the contrast-enhancing lesion of metastasis depends on the site of origin. 
Metastases from melanoma and renal carcinoma are reported to have higher BV than 
malignant gliomas (164). Studies that considered different sites of origin as one entity (or 
those that did not mention the sites of origin) showed that BV of the enhancing metastatic 
lesions were either similar (165–168) or lower (141,169,170) than malignant gliomas. For 
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example, nBV in studies with mostly lung and breast cancer metastases may be similar to 
(164,171) or lower than malignant gliomas (141,169). Together, these studies suggest 
that the differentiation of brain metastasis from malignant glioma based on BV of the 
contrast-enhancing lesion alone is challenging.  
Secondly, BV in the non-enhancing lesion shows more promise for distinguishing 
metastases from primary malignant gliomas. The non-enhancing lesion is the 
hyperintense region on T2 or FLAIR images outside the contrast-enhancing lesion. BV in 
the non-enhancing lesion of brain metastases were lower than that of malignant gliomas 
(141,166,170–177). T2/FLAIR changes primarily represent edema without tumour 
infiltration in brain metastases (178). In contrast, the high BV in the non-enhancing 
lesion of malignant gliomas can be attributed to their aggressive and infiltrative growth, 
which often extends into the T2-hyperintense region. The median sensitivity and 
specificity for distinguishing the two entities using non-enhancing lesion nBV were 90% 
(range, 77 – 100%) and 95% (64 – 100%), respectively (141,169,170). In contrast, the 
median sensitivity and specificity for contrast-enhancing lesion  nBV were 87% (80 – 
91%) and 72% (64 – 88%), respectively (141,171,174–176) . 
Perfusion imaging has also been used to differentiate malignant gliomas from 
other primary brain tumours. These included differentiating primary lymphomas from 
malignant gliomas (165,168,176,177,179–183), meningiomas from malignant gliomas 
(165,167,184), hemangioblastomas from malignant gliomas (165), and schwannomas 
from malignant gliomas (165). A few studies have used perfusion imaging to differentiate 
subtypes of primary brain tumours (161,185–189). Grade II and III oligodendroglial 
tumours showed higher nBV than both grade II and III oligoastrocytic and astrocytic 
tumours, and oligoastrocytic tumours showed higher maximum nBV than astrocytic 
tumours (161). A sensitivity and specificity of 100 and 88% were found when nBV was 
used to differentiate grade II and III oligodendroglial tumours from astrocytic tumours. 
Although there were differences in BV between different types of primary brain tumours, 
the number of brain tumour types make this method of differentiation impractical. 
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1.9.4 Differentiation of Progression from Post-treatment Effects 
A change in the size of the contrast-enhancing tumour is used as a radiologic 
measure of progression, but it can be confounded by other causes of contrast 
enhancement. Pseudoprogression and treatment-induced necrosis (TIN) are post-
treatment scenarios with a better prognosis than true progression, but their changes in 
contrast enhancement can be indistinguishable from progression. Erroneous diagnosis of 
pseudoprogression or TIN as tumour progression can lead to unnecessary treatment or 
premature abandonment of treatment while the opposite scenario will delay treatment. 
Pseudoprogression occurs in 20 – 30% of malignant glioma patients treated with 
chemoirradiation and manifests as a transient increase in tumour contrast-enhancement at 
one to three months post-treatment that eventually subsides (92,190,191). Although its 
pathophysiology remains unclear, chemoirradiation is believed to induce a transient local 
inflammatory reaction, edema and increased vessel permeability, which manifests as 
increased contrast-enhancement (192). Using DSC-MR, true progression showed a higher 
maximum nBV than pseudoprogression when confirmed by radiologic and clinical 
follow-ups (sensitivity and specificity of 81.5% and 77.8%, respectively) (191,193). 
Another study showed that both nBV and normalized peak height (definition in Table 
1-2) could distinguish pseudoprogression from progression with sensitivities and 
specificities ≥ 75% (194). Histogram analysis of nBV to characterize percent changes in 
nBV skewness and kurtosis is also a potential biomarker to differentiate 
pseudoprogression from true progression (195). 
In a prospective study, a decrease in nBV at week three of chemoirradiation was 
associated with a higher risk of early progression (190). It is unclear why a decrease in 
nBV during chemoirradiation is associated with progression (190) while a higher nBV is 
found at the time of progression in other studies (191,193). These results suggest that the 
vascular response to chemoirradiation is complex, and the time of imaging must be 
considered when using perfusion imaging to distinguish between tumour progression and 
pseudoprogression. 
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TIN occurs three to 12 months after radiotherapy in 3 – 24% of patients (192). 
Histopathologic confirmation of necrosis and recurrence were available in some or all of 
the patients in each study. Table 1-6 summarizes the performance of 12 perfusion 
imaging studies for differentiating TIN from progression (118,196–206). Radiation-
induced necrosis and pseudoprogression were collectively defined as radiation-induced 
injury in eight DSC-MR studies (196,207–213). Mean and maximum nBV were reported 
to differentiate radiation-induced injury from true progression with sensitivities and 
specificities ranging from 86 – 100% and 80 – 100%, respectively (207–213). Radiation-
induced injury and true progression often co-exist in patients. Hu et al. showed that DSC-
MR was able to estimate the fractional tumour burden (i.e. progression) and post-
treatment effect (i.e. radiation-induced injury) within the same MR contrast-enhancing 
lesion (213). This fractional tumour burden strongly correlated with the histologic tumour 
fraction obtained from stereotactic biopsy (r = 0.82, P < 0.0001) and correlated with the 
OS (P < 0.02). These results demonstrate that DSC-MR may be a useful clinical tool to 
differentiate progression from post-treatment effects. 
 
Table 1-6: Differentiation between treatment-induced necrosis and true progression. 
Modality Parameter 
Sensitivity and specificity ranges 
(%) 
References† 
DSC-MR 
*nBV 
Sensitivity: 67 – 100% 
Specificity: 70 – 100% 
(118,196–200) 
% Recovery 
Sensitivity: 78% 
Specificity: 76% 
(198) 
Peak Height 
Sensitivity: 89% 
Specificity: 81% 
(198) 
DCE-MR 
Ktrans 
Sensitivity: 100% 
Specificity:  83% 
(202) 
iAUC 
Sensitivity: 71 – 85% 
Specificity: 71 – 78% 
(201,202) 
32 
 
mAUCRH 
Sensitivity: 94% 
Specificity: 88% 
(203) 
Normalized 
maximum slope 
Sensitivity: 95% 
Specificity: 78% 
(201) 
BV 
Sensitivity: 100% 
Specificity: 100% 
(204) 
DCE-CT 
BF 
Sensitivity: 94% 
Specificity: 88% 
(206) 
BV 
Sensitivity: 82 – 83%  
Specificity: 90 – 100% 
(205,206) 
PS 
Sensitivity: 82% 
Specificity: 82% 
(205) 
MTT 
Sensitivity: 94% 
Specificity: 75% 
(206) 
Abbreviations: DSC-MR, dynamic susceptibility-contrast magnetic resonance; DCE-MR, 
dynamic contrast-enhanced magnetic resonance; DCE-CT, dynamic contrast-enhanced 
computed tomography; nBV, normalized blood volume; Ktrans, transfer constant between 
blood plasma and extravascular extracellular space; iAUC, initial area under curve; 
mAUCRH, see Table 1-2 for definition; BF, blood flow; PS, permeability-surface area 
product; MTT, mean transit time. 
*nBV refers to mean or maximum nBV 
 
1.9.5 Survival after Radiotherapy and Chemotherapy 
The value of perfusion imaging in predicting progression-free survival (PFS) and 
OS has been investigated in numerous studies (124,130,140,148,214–237). The 
interpretation of perfusion imaging data for predictive survival depends on treatment 
regimen and imaging schedule. Three perfusion imaging schedules for predicting 
outcomes have been reported; they are 1) pre-treatment, 2) pre-treatment + mid-
treatment, and 3) pre-treatment + post-treatment. 
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When pre-chemoirradiation DSC-MR images were considered, a higher mean and 
maximum nBV were associated with poor PFS and OS for gliomas of all grades 
(140,148,216,221–224,228,235,236). This is also true for gliomas of the same grade. The 
2-year OS rate for grade III astrocytomas was significantly lower for patients with 
maximum nBV > 2.3 (33% vs. 100%, P < 0.01), and it was also lower for GBM (5% vs. 
25%, P = 0.013) (221). Using DCE-CT, a combination of high BV and PS was associated 
with poor OS for grade III and IV gliomas and grade IV gliomas alone (232,233). In 
patients with GBM, kep values ≤ 1.2, between 1.21 – 2.0, and > 2.0 min-1 had 1-year OS 
rate of 59%, 33%, and 15%, respectively (P value was not reported) (130). These studies 
suggest that pre-treatment BV, PS, and kep were associated with more aggressive 
phenotypes that conferred poor survival. 
The prognostic value of comparing pre- and mid-radiotherapy perfusion imaging 
parameters have been investigated (215,219,220). Based on parametric response map 
analysis, a decrease in tumour BV and blood flow (BF) at one and three weeks into 
chemoirradiation were predictive of poor OS (219,220). Specifically, patients with > 
6.8% of tumour volume showing a decrease in nBV had shorter OS than those with ≤ 
6.8% of tumour volume showing a decrease in nBV (median OS = 7.1 and 20.4 months, 
respectively; P = 0.001) (219). A drop in BV during treatment suggest increased tumour 
hypoxia leading to resistance to chemoirradiation. These studies suggest DSC-MR can 
potentially identify patients with poor survival even before the completion of 
chemoirradiation.  
Tumour perfusion after the completion of chemoirradiation and its association 
with survival have also been investigated (225–227,231,237). An increase in maximum 
nBF between baseline and follow-up (Hazard ratio [HR] = 2.67, P = 0.010) was a better 
prognosticator of shorter PFS than an increase in tumour diameter (HR = 1.14, p = 0.049) 
(231). At one month post-radiotherapy, Mangla et al. showed that an increase in nBV was 
predictive of poor 1-year OS (sensitivity = 90% and specificity = 69%) while tumour size 
was not (227). One study showed that perfusion imaging was not predictive of survival 
while T1 and T2-weighted tumour diameters were (225). Using Ferumoxytol as the 
contrast agent, post-radiotherapy tumour nBV predicted patients with longer OS (P < 
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0.001) (237). In the non-enhancing lesion, Li et al. showed that a higher median nBV 
immediately after radiation was associated with shorter PFS (p = 0.026) (226). 
In summary, a high BV before and after chemoirradiation and a decrease in BV 
during chemoirradiation were associated with poor survival. A high BV before and after 
treatment is characteristic of tumour growth and progression, while a decrease in BV 
during treatment could be indicative of tumour hypoxia.  
 
1.9.6 Survival After Anti-angiogenic Therapies 
Radiologic assessment of response to anti-angiogenic agents, especially those that 
target VEGF, should be interpreted with caution because a drop in contrast-enhancement 
is not necessarily indicative of true response (i.e. pseudoresponse) (92). Batchelor et al. 
showed that patients treated with Cediranib demonstrated decreased gadolinium 
enhancement as early as one day after the initiation of treatment despite considerable 
variability in tumour response (238). Given the vascular effects of anti-angiogenic agents, 
perfusion imaging could play an important role in assessing response to these agents. 
For recurrent GBM, high nBV and Ktrans prior to anti-VEGF monotherapy or in 
combination with Temozolomide were associated with poor survival (239,240). Tumour 
BF (238), nBV (238,241), Ktrans (238,240,242–246), and ve (238,242,243,247) decreased 
shortly after the initiation of Bevacizumab or Cediranib. In the non-enhancing lesion, 
nBV could also decrease after Bevacizumab treatment suggesting an anti-edema effect 
(statistical significance was not reported) (248).  
There is no consensus on whether a decrease in these parameters is a positive 
prognosticator. A decrease in Ktrans and nBV after Bevacizumab treatment did not show a 
significant association with PFS or OS in some studies (239,240,246). In another study, a 
decrease in tumour subvolume with nBV > 1.00 after Bevacizumab treatment was 
associated with longer time-to-progression (229). A reduction in Ktrans after Cediranib 
treatment was associated with improved PFS and OS (244). A moderate correlation 
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(Spearman’s ρ = 0.58, P = 0.036) between OS and Ktrans at 1 week after stereotactic 
radiosurgery and Bevacizumab was reported in patients with recurrent malignant gliomas 
(234). 
The inconsistent relationships between perfusion imaging parameters and survival 
suggest that not all patients responded equally to anti-angiogenic agents. Sorensen et al. 
showed that 25% of patients with recurrent GBM treated with Cediranib exhibited 
elevated perfusion, and these patients had higher PFS and OS than those with stable or 
decreased perfusion (230,238,244). This was demonstrated again in patients with newly 
diagnosed GBM that were treated with radiotherapy, Temozolomide, and Cediranib. 
Patients with increased perfusion had a significantly longer median OS than patients with 
decreased perfusion (OS = 504 vs. 321 days; log-rank P < 0.05) (249). Increased 
perfusion was also associated with improved tumour oxygenation, which could 
potentially improve the sensitization of tumour cells to chemoirradiation and enhance the 
delivery of Temozolomide to the tumour. In a study involving patients with recurrent 
malignant gliomas, independent component analysis of DSC-MR images was used to 
characterize the extent of abnormal vasculature before and after Bevacizumab treatment. 
A decrease in the arterio-venous overlap (i.e. a decrease of abnormal vasculature) was 
associated with longer OS in these patients (P < 0.04), whereas a change in the tumour 
volume and nBV was not predictive of OS (250). These results suggest that perfusion 
imaging may be a tool for selecting the appropriate patients for anti-angiogenic therapies. 
 
1.9.7 Future of Perfusion Imaging 
Our review reflected the results from more than 6500 brain tumour patients 
scanned using CT or MR perfusion. These studies were primarily conducted in small 
cohorts of patients (median N = 31 patients) in a research setting. Different perfusion 
imaging protocols were used, and these variations could have led to uncertainties in the 
measurements of different perfusion imaging parameters (117,251). Standardization of 
imaging protocol is very important for incorporating perfusion imaging into prospective 
multi-institutional trials (252). In addition, different perfusion imaging software packages 
36 
 
were used in these studies. It has been shown that BF and BV values calculated from 
different commercial software packages can deviate from the true values (253). The 
uncertainties in the acquisition and analysis of these perfusion imaging studies make 
optimization and standardization difficult. 
In a clinical trial, the imaging protocol should be consistent across the study 
population. The software and version used to calculate tumour perfusion parameters 
should also be consistent and reported. Quality control should be performed to ensure 
consistency in image quality. For example, the Radiation Therapy Oncology Group 
(RTOG) 0825 trial comparing “radiation + Temozolomide” versus “radiation + 
Temozolomide + Bevacizumab” is incorporating DSC-MRI and DCE-MRI to study these 
patients. Participating sites must be qualified through the American College of Radiology 
Imaging Network (ACRIN). The participating site must perform all advanced MR (e.g. 
perfusion MR) scans following the protocol-specific parameters, and one set of test MR 
images acquired from the designated MR scanner must be approved by ACRIN. This 
study will yield valuable information on the value of serial perfusion imaging.   
Our literature review on perfusion imaging showed that perfusion changes in 
response to chemoirradiation and in combination with anti-angiogenic therapies are 
complex. Optimization and standardization of image acquisition and analysis can help 
facilitate the implementation of perfusion imaging in clinical settings. Serial imaging of 
perfusion changes in response to treatment will improve the understanding of the effect 
of treatment on tumour hemodynamics, and determine the optimal time for evaluating 
response and prognosis in patients.  
 
1.10 Animal Models of Malignant Glioma 
Animal models of brain tumours play very important roles in understanding the 
pathophysiology cancer, and in evaluating the safety and efficacy of treatments. There are 
three general categories of brain tumour models: 1) xenograft models, 2) chemically 
induced syngeneic models, and 3) genetically engineered mouse models (254). Rat 
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models have several advantages over mouse models. The rat brain is about three times 
larger than the mouse brain (1200 vs. 400 mg, respectively) (255). This allows more 
precise implantation of tumour cells in rat brains and stereotactic radiosurgery of 
tumours. A larger brain also permits a longer time period for tumour growth before death, 
and better visualization and localization of the tumour using a variety of imaging 
modalities. In addition, there are more in vitro and in vivo studies of rat brain tumours 
than mouse brain tumours (255). 
Xenograft tumour models refer to the growth of human brain tumours within the 
brains of immunodeficient rats. For example, the U87MG cell line is a commonly used 
xenograft GBM model. These models exhibit some features of human GBMs, including 
the expression of mutated genes and display some levels of angiogenesis. However, they 
do not display many characteristics that are typical in human GBM. For instance, growth 
patterns are often circumscribed with limited single cell infiltration that are not as 
extensive as spontaneous human GBM (256,257). Necrosis and microvascular 
abnormalities, which are typical in human GBM, are also limited or absent in many 
human cell-derived xenografts (254,256,257).  
Chemically induced syngeneic rat models have been used extensively since the 
1970s (255). Popular examples include C6, 9L, BT4C, F98, RT-2, and CNS-1 gliomas 
(255). The C6 glioma model was created by administering methylnitrosourea to rats 
(258,259). It was morphologically similar to GBM, and showed overexpression of many 
genes that are also overexpressed in human gliomas. This model has been widely used to 
evaluate the safety and efficacy of a variety of treatments including radiotherapy (260–
262), chemotherapy (263,264), and anti-angiogenic therapy (265,266). Chemically 
induced syngeneic models can grow in immunocompetent rats; thus, spontaneous tumour 
rejection is a drawback. A previous report showed that 11% of rats survived after 
implantation of C6 glioma cells (267). Another drawback of chemically induced 
syngeneic models is their growth patterns. For example, both C6 and 9L tumour models 
demonstrate circumscribed masses as opposed to the highly infiltrative growth of human 
gliomas (255). Despite these drawbacks, the C6 model remains attractive because it is 
useful for the study of glioblastoma growth, angiogenesis, and development of new 
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therapies (266). The C6 glioma model is used in the preclinical work presented in this 
thesis. 
 
1.11 Research Goals and Objectives 
The work presented in this thesis is focused on two major goals: 1) improving 
measurements of DCE-CT parameters, and 2) using DCE-CT to assess treatment 
response in malignant gliomas. This was accomplished by achieving the following 
objectives which span the spectrum from technical optimization to preclinical imaging to 
pilot clinical studies: 
1. To improve the measurements of BF, BV, and PS by evaluating the effect of 
DCE-CT scan duration on these measurements. 
2. To reduce measurement errors of BF, BV, and PS by filtering DCE-CT images 
using principal component analysis.  
3. To show that DCE-CT can be used as a potential early imaging biomarker of 
response to stereotactic radiosurgery in the C6 malignant rat glioma model.  
4. To assess the relationship between DCE-CT imaging measurements and eventual 
sites of tumour progression in patients with malignant gliomas. 
5. To correlate patient survival with DCE-CT and MR volumetric imaging 
measurements. 
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1.12 Thesis Outline 
1.12.1 The Effect of Scan Duration on the Measurement of DCE-CT 
Parameters (Chapter 2) 
Scan duration is a key factor that influences the measurement of different 
perfusion parameters. We investigated the effect of scan duration on BF, BV, and PS 
measurements in human gliomas and evaluated the systematic and random errors 
associated with reduced scan durations. This chapter is adapted from the published paper 
entitled “The effect of scan duration on the measurement of perfusion parameters in CT 
perfusion studies of brain tumours”, published in Academic Radiology 20(1): 69-65 
(2013) by Yeung TPC, Yartsev S, Bauman G, He W, Fainardi E, and Lee TY.  
 
1.12.2 Improving Quantitative DCE-CT Measurements Using 
Principal Component Analysis (Chapter 3) 
The measurements BF, BV, and PS are affected by DCE-CT image contrast-to-
noise ratio (CNR). We validated whether principal component analysis (PCA) filtering 
can improve the accuracy and precision of these measurements by using a digitally 
designed CT phantom. We then evaluated the improvement in image CNR and changes 
in tumour BF, BV, and PS after filtering DCE-CT images of tumour bearing rats. This 
chapter is adapted from the published paper entitled “Improving quantitative CT 
perfusion parameter measurements using principal component analysis”, published in 
Academic Radiology 21(5): 624-632 (2014) by Yeung TPC, Dekaban M, De Haan N, 
Morrison L, Hoffman L, Bureau Y, Chen X, Yartsev S, Bauman G, and Lee TY.  
 
40 
 
1.12.3 DCE-CT Imaging as an Early Biomarker of Differential 
Response to Stereotactic Radiosurgery (Chapter 4) 
Stereotactic radiosurgery delivers radiation in one or few large dose fractions of 8 
to 30 Gy that can result in vascular damage. Timely and accurate assessment of tumour 
response is crucial for treatment modification if no response to radiation is detected. This 
chapter evaluated serial vascular changes following stereotactic radiosurgery using DCE-
CT, and determined whether DCE-CT can be an early predictor of survival. This chapter 
is based on the paper entitled “CT perfusion imaging as an early biomarker of differential 
response to stereotactic radiosurgery”, which will be submitted to the journal PLOS ONE 
in July 2014 by Yeung TPC, Kurdi M, Wang Y, Al-Khazraji B, Morrison L, Hoffman L, 
Jackson D, Crukley C, Lee TY, Bauman G, and Yartsev S. 
 
1.12.4 Relationship of DCE-CT and PET to Tumour Progression in 
Malignant Glioma (Chapter 5) 
Over 80% of malignant gliomas progress within 2 cm of the irradiated volume 
after chemoirradiation. Although an increase in the size of the contrast-enhancing lesion 
is one of the criteria for diagnosing progression, early changes in contrast-enhancement 
during and after radiotherapy lack utility in identifying active tumour sites that are likely 
to persist and progress. This chapter investigates whether multiparametric imaging with 
DCE-CT and 18F-Flurodeoxyglucose PET can identify tumour sites that are likely to 
correlate to the eventual sites of tumour progression. The chapter is based on the 
published paper entitled “Relationship of computed tomography perfusion and positron 
emission tomography to tumour progression in malignant glioma”, published in the 
Journal of Medical Radiation Sciences 61(1): 4-13 (2014) by Yeung TPC, Yartsev S, Lee 
TY, Wong E, He W, Fisher B, VanderSpek L, Macdonald D, and Bauman G.  
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1.12.5 Treatment Monitoring of Malignant gliomas in using DCE-CT 
and MR (Chapter 6) 
Using DCE-CT, this is the first study to evaluate serial changes in tumour BF, 
BV, and PS in the contrast-enhancing lesion and the non-enhancing lesion of patients 
with malignant gliomas for up to a year after radiotherapy. This study also tested the 
predictive values of these data in relation to OS. The chapter is based on the paper 
entitled “Treatment monitoring in high-grade gliomas: A serial CT perfusion and MR 
study”, which will be submitted to the Journal of Neuro-Oncology in July 2014 by Yeung 
TPC, Wang Y, Urbini B, Yartsev S, Bauman G, Lee TY, Fainardi E, and The Project of 
Emilia-Romagna region on Neuro-Oncology (PERNO) study group.  
 
1.12.6 Conclusion and Future Work (Chapter 7) 
In the final chapter, major findings of this thesis are summarized, and their 
clinical and experimental relevance are discussed. Future investigations pertaining to 
perfusion imaging of brain tumours are proposed.  
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Chapter 2  
2 The Effect of Scan Duration on the Measurement of 
Perfusion Parameters in CT Perfusion Studies of Brain 
Tumours 
This chapter is adapted from the research article, “The effect of scan duration on 
the measurement of perfusion parameters in CT perfusion studies of brain tumours” 
published in Academic Radiology, 2013;20(1):59-65 by Yeung TPC, Yartsev S, Bauman 
G, He W, Fainardi E, Lee TY.  
 
2.1 Introduction 
Malignant gliomas are highly aggressive brain tumours that are characterized by 
increased vascularity with immature and highly permeable blood vessels (1). Given that 
blood-brain barrier disruption and neovascularity play an essential role in the progression 
of malignant gliomas, recent studies have investigated the use of perfusion imaging for 
evaluating brain tumours. Blood flow (BF), blood volume (BV), and permeability–
surface area product (PS) obtained from computed tomography (CT) perfusion studies 
have been demonstrated to be useful in differentiating glioma grade (2–4) and 
distinguishing treatment-induced necrosis from recurrent or progressive tumours (5). CT 
perfusion parameters have also demonstrated correlations with microvascular cellular 
proliferation (6) and proangiogenic gene expressions (7). 
Although CT perfusion may be helpful in providing important physiologic 
information for evaluating brain tumours, there is no consensus regarding the optimal 
scan protocol. A scan duration of ≥2 minutes has been suggested for accurate calculation 
of tumour permeability (8,9), but scan durations in the range of 45 to 199 seconds have 
been used to evaluate tumour perfusion parameters for brain and other tumour sites 
(7,10). For example, a 65-second scan was recommended when the Johnson-Wilson 
model was used for the calculation of permeability (ie, PS) in colorectal cancer (11), 
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while a scan duration of ≥40 seconds was recommended when the Patlak method was 
used to calculate permeability (ie, Ktrans, transfer constant) in lung cancer (12). 
Given that scan duration is a key factor influencing perfusion measurements, it 
would be beneficial to investigate the effect of scan duration on CT perfusion studies of 
brain tumours. Standardizing a CT perfusion protocol for diagnostic and research settings 
could facilitate comparison among different studies. We evaluated the effect of scan 
duration (≤150 seconds) on perfusion parameter measurements in human gliomas and 
evaluated the systematic and random errors associated with different reduced scan 
durations (<150 seconds) relative to the values obtained from the 150-second scans. 
 
2.2 Materials and Methods 
 
2.2.1 CT Perfusion Imaging 
The local research ethics boards approved this study, and all patients provided 
written informed consent prior to imaging. Patients (n = 14) with histopathologically 
confirmed malignant glioma (World Health Organization grade III and IV) underwent CT 
perfusion imaging. Eight patients were scanned on a hybrid positron emission 
tomography/CT scanner (Discovery VCT; GE Healthcare, Waukesha, WI) with a 
nonionic contrast bolus (Omnipaque, 300 mg iodine/mL, 60–70 mL; GE Healthcare, 
Princeton, NJ), and six patients were scanned on a CT scanner (GE LightSpeed VCT; GE 
Healthcare, Waukesha, WI) with a nonionic contrast bolus (Iomeron, 350 mg iodine/mL, 
40 mL; Bracco Imaging Scandinavia, Göteborg, Sweden). A two-phase CT perfusion 
scan, guided by a prior noncontrast CT scan that identified eight 5-mm sections to 
maximally cover the tumour, was performed for each patient. The bolus of contrast was 
injected into the antecubital vein at a rate of 2 to 4 mL/s at 3 to 5 seconds after the first 
phase started. The preselected brain sections were scanned for 45 seconds at 1-second 
intervals during the first phase and for a period of 105 seconds at 15-second interval 
during the second phase. A tube current of 190 mA was used for the hybrid positron 
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emission tomography/CT scanner, and 100 mA was used for the CT scanner. All patients 
were scanned at 80 kVp with a 25-cm field of view. 
 
2.2.2 Image Analysis 
The 150-second human CT perfusion studies were truncated to scan times of 120, 
90, and 60 seconds to simulate the effect of shorter scans. Fifty-six CT perfusion studies 
were analyzed using the prototype version of CT Perfusion 4D (GE Healthcare, 
Waukesha, WI), which is based on the Johnson-Wilson model and is insensitive to the 
delay between arterial and tissue time-attenuation curve (TAC) to generate maps of BF, 
BV, and PS. 
For each patient, the arterial and venous regions of interest (ROIs) were 
automatically chosen by the software from the 150-second study, and the same ROIs 
were used for the truncated studies to minimize estimated parameter variability due to 
differences in arterial and venous TACs. The arterial and venous ROIs were usually 
found in one of the anterior cerebral arteries and the posterior superior sagittal sinus, 
respectively. Partial volume averaging of the arterial TAC was corrected using the 
venous TAC as a reference (8). Tissue TACs were measured from 2 × 2 pixel blocks of 
CT images. Parametric maps of BF, BV, and PS were calculated by deconvolving the 
arterial TAC with each tissue TAC using the Johnson-Wilson model (8). The generation 
of parametric maps was repeated for different scan durations by using the same arterial 
and venous ROIs for each patient. ROIs of 15 mm2 were randomly placed in the normal 
white and gray matter and contrast-enhanced tumour rim and nonenhancing tumour core 
to measure BF, BV, and PS (20 ROIs per tissue). 
 
2.2.3 Measurement Errors of Perfusion Parameters Due to 
Truncation 
We used the systematic and random errors to evaluate the mean and standard 
deviation of measurement errors associated with a reduced scan time relative to the 150-
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second scan time, respectively. The differences between parameter values obtained from 
the original study and the truncated study in the same ROI of the same tissue type were 
accepted as the measurement error. The mean and standard deviation of measurement 
errors were, respectively, the systematic and random errors for each tissue type for each 
patient. 
We also used the percentage error to examine whether the differences in 
parameter values associated with a reduced scan time were clinically meaningful. The 
percentage error for each parameter in each ROI was calculated using the equation 
 
 
100
2scan original  thefrom valuescanshorter  a from value
scan original  thefrom  value-scan shorter  a from value
%ErrorPercent 

    
(2.1) 
2.2.4 Statistical Analysis 
Values of BF, BV, and PS were first transformed using the Box-Cox 
transformation to obtain a normal distribution (13). The normality of the Box-Cox–
transformed data for each parameter and each tissue type was checked using the Shapiro-
Wilk test (P > .05). Student's t test confirmed that there was no difference between the 
hybrid positron emission tomography/CT and CT scanners when measuring BF, BV, and 
PS in the different tissue types at 150 seconds (P > .05). Differences in each parameter 
obtained from different scan durations were tested using repeated-measures analysis of 
variance with post hoc paired t test and Bonferroni correction applied. Systematic and 
random errors were correlated with scan durations using Spearman's rank correlation. All 
statistical tests were done using SPSS version 19.0 (SPSS, Inc, Chicago, IL), and P 
values < .05 were considered significant. 
 
2.3 Results 
Box plots of BF, BV, and PS values of different tissue types measured from 
different scan durations are shown in Figure 2-1. BF and BV values were not affected by 
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shorter scan durations (P > .05). PS values in the tumour rim at 60 seconds were 
significantly higher than in the 150-second scans (P < .01). Median percentage errors and 
interquartile ranges associated with different scan durations are presented in Table 2-1. 
Median percentage error was highest at 60 seconds for tumour core PS (median, 32.1%; 
interquartile range, 16.5%–43.0%). Systematic and random errors associated with 
different scan durations are displayed in Figure 2-2 and Figure 2-3, respectively. Tumour 
rim BV and PS and tumour core BF systematic errors were correlated with scan durations 
(r = 0.42, −0.50, and −0.50, respectively; P < .01). Random errors were negatively 
correlated with scan durations for all tissue types (P ≤ .01) except for white matter BV 
(Table 2-2). Figure 2-4 demonstrates the visual differences in the maps of BF, BV, and 
PS due to scan-time truncation in a sample patient. 
 
 
 
 
 
Figure 2-1: Box plots of (a) blood flow (BF), (b) blood volume (BV), and (c) 
permeability–surface area product (PS) values measured from different scan 
durations. Outliers (circles) are defined as data that are 1.5 box lengths away 
from the 25th or 75th quartile. ∗Significantly different from the 150-second scan 
(P < .01). 
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Figure 2-2: Box plots of (a) blood flow (BF), (b) blood volume (BV), and (c) 
permeability–surface area product (PS) systematic errors associated with different 
scan durations. Outliers (circles) are defined as data that are 1.5 box lengths away 
from the 25th or 75th quartile. Extreme outliers that are three box lengths away 
from the quartiles are not displayed. 
 
 
 
 
Figure 2-3: Box plots of (a) blood flow (BF), (b) blood volume (BV), and (c) 
permeability–surface area product (PS) random errors associated with different 
scan durations. Outliers (circles) are defined as data that are 1.5 box lengths away 
from the 25th or 75th quartile. Extreme outliers that are three box lengths away 
from the quartiles are not displayed. 
Table 2-1: Median (interquartile range) percentage errors associated with scan 
durations of < 150 seconds. 
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Table 2-2: Spearman's rank correlation of systematic and random errors with scan 
duration. 
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2.4 Discussion 
There is no consensus regarding the optimal CT perfusion scan duration, and 
durations of 45 to 199 seconds have been reported in the literature for calculating tumour 
perfusion parameters (7,10). This study sought to investigate the effect of scan duration 
on the measurements of BF, BV, and PS.  
Perfusion parameters were calculated using the Johnson-Wilson model (8,14). It 
models the diffusion of a bolus of contrast across the capillary endothelium into the 
interstitial space as it traverses from the arterial to the venous end of a tissue region. A 
theoretical function, called the impulse residue function, represents the fraction of 
contrast that remains in the tissue as a function of time after a bolus injection of a unit 
amount of contrast into the arterial inlet. The impulse residue function has two distinct 
phases. The first phase is a rectangular function at a height of unity that represents the 
retention of the contrast in the tissue region, regardless of its distribution either in the 
vascular or extravascular space, before any venous outflow occurs. The duration (or 
width) of the first phase is the minimum transit time of this bolus. The second phase 
starts at a height of the extraction fraction at the minimum transit time and decays 
exponentially toward baseline with time. This describes the clearance of the extravasated 
Figure 2-4: Differences between perfusion maps obtained from a 150-second 
scan versus a 60-second scan. The 15-mm2 regions of interest in the contrast-
enhancing rim (1) and nonenhancing core (2) are displayed. Maps of blood 
flow (BF), blood volume (BV), and permeability–surface area (PS) are 
enlarged and centered at the tumour. White arrows point to regions with PS 
values that appeared to be higher at 60 seconds relative to 150 seconds. The 
window and level used for computed tomography, BF, BV, and PS were 20 to 
100 Hounsfield units, 0 to 180 mL/min/100 g, 0 to 12 mL/100 g, and 0 to 25 
mL/min/100 g, respectively. 
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contrast from the interstitial space via back flux into the bloodstream. The BF-scaled 
impulse residue function is derived by deconvolving the arterial TAC with the tissue 
TAC (8). The peak value and area under the first phase of the BF-scaled impulse residue 
function are the BF and BV, respectively. PS is obtained using the equation PS = −BF × 
ln(1 − extraction fraction). 
We did not find a statistical difference in BF and BV when comparing the 150-
second to the 120-second, 90-second, and 60-second studies. Hirata et al (15) found that 
the first circulation time is approximately 40 seconds in brain tissue, and scanning up to 
the first circulation time is sufficient for measurements of BF and BV. Our results are 
consistent with their results and are expected given that a scan time of 60 seconds is well 
beyond the first circulation time of contrast through the brain and would permit an 
accurate determination of the first phase of the impulse residue function. 
A scan time of 60 seconds is not adequate for the estimation of PS in brain tumour 
rim. The significantly higher permeability that we observed with a shorter scan is 
consistent with other studies (11,12). Goh et al (11) found that 45 seconds was too short 
for PS measurements in colorectal cancer. The longer scan time required could be 
explained by the fact that the accumulation of contrast in a brain tumour is much slower 
than that of colorectal cancer because PS is lower in a brain tumour. A longer scan 
duration is required to have sufficient signal-to-noise ratio to estimate PS values 
accurately and reproducibly. PS values in the normal brain, which should be close to 
zero, were unaffected by scan duration because the estimation algorithm was constrained 
only to give nonzero PS values. 
The effect of scan duration on the systematic and random errors of CT perfusion 
parameters was also investigated. With the exception of white matter BV, the random 
error of perfusion parameter measurements increased with shorter scan duration. 
Systematic error in tumour rim BV and PS and tumour core BF also increased with 
shorter scan durations because fewer data were available for estimating BF, BV, and PS. 
The optimization algorithm for estimating these parameters was a constrained 
optimization algorithm, in which all parameters were constrained to give only values that 
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are zero or higher. The random error increased with a shorter scan time because the 
signal-to-noise ratio deteriorated with a shorter scan time. This is analogous to the 
decrease in the standard error when more samples are used to estimate the mean. With the 
use of a constrained optimization algorithm, the random error would not go up as much 
as a nonconstrained optimization process, because all parameter values had to be zero or 
higher. This constraint led to the increase in systematic bias that we observed when the 
signal-to-noise ratio deteriorated with reduced scan time. 
Other technical settings of a CT perfusion protocol can also affect perfusion 
parameter values. For instance, the frequency of image acquisition, particularly in the 
first circulation phase, could result in significantly different values of BF and BV (16-
18). The molecular weight of contrast agent can influence the estimation of tissue 
permeability as well. Most iodinated CT contrast agents are low–molecular weight agents 
(about 0.75 kDa) and leak more easily from the blood into the interstitial space compared 
to higher molecular weight contrast agents (19,20). Because endothelial permeability is 
dependent on the molecular weight of a contrast agent, PS values measured with a lower 
molecular weight agent will be higher than the values measured with a higher molecular 
weight agent. As such, perfusion protocols to measure PS need standardization with 
respect to contrast agent used as well as scan time. 
Radiation dose is of concern when performing a CT perfusion scan. At 80 kVp 
and 190 mA, the estimated effective doses for scan durations of 150, 120, 90, and 60 
seconds are 5.4, 5.2, 5.0, and 4.8 mSv, respectively. Similarly, the imaging doses at 80 
kVp and 100 mA are 2.9, 2.7, 2.6, and 2.5 mSv, respectively. Because the second phase 
of a CT perfusion scan involves x-ray exposures that are taken every 15 seconds, the 
reduction in radiation dose by truncating the scan time is minimal. Reducing the scan 
time is not an effective way to reduce radiation dose. Adaptive statistical iterative 
reconstruction and reducing the imaging frequency during the first phase are more 
effective at reducing the radiation dose (17,21). 
Some limitations of this study must be considered. The number of patients was 
relatively small, and there was little variation in terms of brain tumour types, because all 
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patients were diagnosed with malignant glioma, which accounts for approximately 70% 
of all adult primary brain tumours (22). In addition, patients were not scanned with the 
same CT scanner or the same contrast agent. As the molecular weights for the two 
contrast agents used in this study were both approximately 0.8 kDa, the small difference 
in molecular weights should have minimal effect on the measurement of CT perfusion 
parameters. Although there was no statistical difference in terms of perfusion parameter 
values measured from the two scanners using two different tube currents, a simulation 
study showed that x-ray tube current could potentially affect the accuracy of perfusion 
parameters in the brain (23). A subgroup analysis using the patients acquired with 100-
mA tube current showed that BF and BV at 60 seconds were significantly different from 
the values obtained at 150 seconds (data not shown). A lower signal-to-noise ratio due to 
a lower tube current could have affected the measurement of BF and BV when the scan 
time was reduced. Our recommendation of 90 seconds is a conservative estimate of the 
shortest scan time required to be consistent with the above results. In both cases (100 and 
190 mA), the 120-second and 90-second data were not significantly different from the 
150-second data. Additional study scanning patients with various types of brain tumours 
using the same scanner and contrast agent is needed to confirm the current results. 
 
2.5 Conclusions 
Relative to a 150-second scan duration, BF and BV values in the normal brain and 
brain tumours were not affected by reducing scan duration to 60 seconds, whereas PS 
values in the tumour rim were significantly higher at 60 seconds. The random errors 
associated with BF, BV, and PS could suffer with shorter scan durations. A scan duration 
of ≥90 seconds is recommended, and investigation of the effects of other scanning 
parameters on the measurement of perfusion parameters is warranted. 
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Chapter 3  
3 Improving Quantitative CT Perfusion Parameter 
Measurements Using Principal Component Analysis 
This chapter is adapted from the research article, “Improving quantitative CT 
perfusion parameter measurements using principal component analysis” published in 
Academic Radiology, 2014;21(5):624-632 by Yeung TPC, Dekaban M, De Haan N, 
Morrison L, Hoffman L, Bureau Y, Chen X, Yartsev S, Bauman G, Lee TY.  
 
3.1 Introduction 
Computed tomography (CT) perfusion is a diagnostic tool for the evaluation of 
acute ischemic stroke, and it is becoming increasingly used for measuring blood flow 
(BF), blood volume (BV), and permeability–surface area product (PS) in malignant brain 
tumours (1). The measurements of BF, BV, and PS in tumours are affected by CT 
perfusion image contrast-to-noise ratio (CNR). Recently, Balvay et al. (2) showed that 
filtering CT perfusion images with principal component analysis (PCA) improved CNR 
in CT perfusion images of patients with ovarian and metastatic renal tumours. It is not 
known whether PCA can improve CNR of CT perfusion images of patients with 
malignant brain tumours, which have a lower CNR because of lower tumour blood flow 
in the brain compared to other malignancies such as metastatic renal tumours (3-6). In 
preclinical imaging of cancer models with a clinical CT scanner, a high spatial resolution 
is desirable to detect small tumours. However, CNR from scanning small animals is low 
because: (1) image noise increases with higher spatial resolution (ie, smaller pixel size); 
and (2) the effect of partial volume averaging is more prominent in small animals than in 
humans. Therefore, we hypothesized that CT perfusion images of a preclinical model of 
malignant glioma are useful to evaluate the ability of PCA in improving image quality 
under low-CNR condition. It has not been demonstrated that an increase in CNR after 
PCA filtering improves the measurements of BF, BV, and PS. Accurate and precise 
measurements of these parameters are important because they have been shown to be 
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valuable for grading gliomas (1,6) and for distinguishing recurrent tumour from 
treatment-induced necrosis (7). 
In this study, we first designed a digital phantom to validate PCA image filtering 
by comparing the accuracies and precisions of BF, BV, and PS without and with PCA 
filtering of simulated CT perfusion images. We then evaluated the improvement in CNR 
and changes in BF, BV, and PS measurements after PCA filtering CT perfusion images 
of a malignant rat glioma model. 
 
3.2 Materials and Methods 
3.2.1 Validation of PCA by Simulation 
A digital phantom of CT perfusion images with time-attenuation curves (TAC) 
reflecting known values of BF, BV, and PS was developed. The phantom consisted of 16 
CT slices and 44 sequential images for each slice simulating a two-phase CT perfusion 
protocol. Images were simulated at 1.4-second intervals during the first phase of 30-
seconds and then at 15-second intervals during the second phase of 300-seconds. Each 
image contained 3 × 4 tiles of 10 × 10 pixels, which resembled the number of pixels in an 
axial rat brain CT image. Pixels in each tile had the same TAC simulating known values 
of BF, BV, and PS. Each tile was assigned with increasing mean transit times (MTTs; 4, 
4.5, 5.0, …, 9.5 s) and extraction fraction (E; 0.05, 0.06, …, 0.14, 0.3, 0.4). Each slice 
was assigned to two different BV values, the range of values were 0.5, 1.0, 1.5, …, 8 
mL/100 g. BF values (3.2–120 mL/min/100 g) were calculated as BV/MTT, and PS 
values (0.4–25.8 mL/min/100 g) were obtained using −BF × ln(1−E) (8). Based on the 
Johnson–Wilson model, these values were used to simulate different impulse residue 
functions for each tile (9). A population-averaged arterial TAC was generated by 
averaging TACs from carotid arteries of nine Wistar rats.  
Each impulse residue function was convolved with the population-averaged 
arterial TAC to generate a tissue TAC. A time-attenuation curve (TAC), Q(t), can be 
described by the following equation:  
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𝑄(𝑡) = 𝐵𝐹 ⋅ 𝐶𝑎(𝑡)⨂𝐻(𝑡) = 𝐶𝑎(𝑡)⨂[𝐵𝐹 ⋅ 𝐻(𝑡)]    Equation 3-1  
where BF is blood flow, Ca(t) is the arterial TAC (also known as the arterial input 
function), ⊗ is the convolution operator, H(t) is the impulse residue function. This 
mathematical operation is graphically illustrated in Figure 3-1. 
 
Figure 3-1: Graphical illustration showing how a tissue time-attenuation curve 
(TAC), Q(t), is simulated from a population-averaged arterial TAC, Ca(t), and a 
blood flow–scaled impulse residue function, H(t), with known values of blood flow 
(BF), blood volume (BV), permeability–surface area product (PS), extraction 
fraction (E), and mean transit time (MTT). 
The arterial TAC used in this simulation was a population-averaged arterial TAC. 
The impulse residue function describes the fraction of contrast that remains in the tissue 
as a function of time after a bolus injection into the arterial inlet. The blood flow–scaled 
impulse residue function, BF⋅H(t), has two phases. The first phase is a rectangular 
function with a height of BF that is maintained for the duration of the mean transit time 
and has an area equal to blood volume (BV). It represents the retention of contrast in the 
tissue region before venous outflow. The second phase starts at a height of the extraction 
fraction and decays exponentially; it describes the back flux of extravasated contrast from 
the interstitial space into the intravascular space. The values of the TACs at different time 
points were embedded into the corresponding pixels to generate CT perfusion images of 
the digital phantom. In total, the set of noise-free CT perfusion images in the digital 
phantom gave rise to 192 different TACs with different combinations of BF, BV, and PS 
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values. This phantom reflected values of BF, BV, and PS in the physiological range of a 
rat. The design of this phantom is illustrated in Figure 3-2. 
 
 
Figure 3-2: An example of one slice (out of 16 slices) of the digital computed 
tomography (CT) perfusion phantom with image noise. Each tile contains tissue-
enhancement curves reflecting a combination of extraction fraction (E), mean 
transit time (MTT), blood volume (BV), blood flow (BF), and permeability–surface 
area product (PS). 
 
To add image noise to the set of noise-free CT perfusion images, a rat was 
scanned without contrast injection in high-resolution mode with a clinical CT scanner 
(Discovery 750 HD; GE Healthcare, Waukesha, WI) using the same two-phase CT 
perfusion protocol as the simulation. The scanning parameters were 80 kVp, 120 mAs, 
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0.4 s/rotation, 10 cm field of view, 16 slices, and 1.25 mm slice thickness (voxel size is 
0.2 × 0.2 × 1.25 mm). A high-definition bone filter with a limiting in-plane resolution of 
0.33 mm was used to reconstruct the images. Adaptive statistical iterative reconstruction 
(ASIR) was used to reconstruct the images. The skull was used to rigidly register the 
images using the prototype version of CT Perfusion 4D (GE Healthcare) to minimize 
misregistration due to motion in the axial plane. A “noiseless” CT image for each slice 
was generated by averaging the series of noncontrast CT images of the same slice. The 
set of noise only images of each slice was obtained by subtracting the average CT image 
from each CT image of the same slice. This set of noise images was added one by one to 
the set of noise-free CT perfusion images. The final set of noisy images was designated 
as the unfiltered CT perfusion images of the digital phantom, and they were then filtered 
using PCA. 
 
3.2.2 Principal Component Analysis 
Principal component analysis (PCA) is a statistical technique that linearly 
transforms a set of multidimensional observations into different principal components 
that describe the variance of the original set of observations (2). In the context of a series 
of m dynamic images from a computed tomographic perfusion study, attenuation in each 
pixel p as a function of time was measured as a time-attenuation curve (TAC). If one 
interprets a TAC as a set of observations of x-ray attenuation changes (due to contrast) 
versus time, then each TAC consists of m number of variables and can be written as an m 
× 1 vector Qp with p as the index for the image pixel. PCA linearly transforms the 
possibly correlated m variables into a set of transformed variables called principal 
components, which are linear combinations of the original variables and are uncorrelated 
with each other. These linear transformations are defined so that the first principal 
component has the largest variance. Each subsequent principal component would 
describe the next largest variance with the condition that it is uncorrelated to all the 
previous principal components.  
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It can be shown that the coefficients defining these linear transformations are the 
eigenvectors of the covariance matrix of the TACs whereas the corresponding 
eigenvalues are the variances of the principal components. In addition, each TAC can be 
noise filtered by expressing it as the weighted sum of the eigenvectors with the weights 
given by the scores of the TAC on the principal components (or loadings of the 
eigenvector in the TAC): 

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         Equation 3-2 
where N  is the number of principal components with the largest variances used to noise 
filter Qp, ai is the i
th eigenvector and wip is the corresponding weight which can be 
calculated as: 
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where  is the mean of all TACs and  is the transpose of ai. 
CT perfusion images can be noise filtered using the first few principal 
components. In general, more temporal TAC smoothing is achieved with lesser number 
of principal components used. CT perfusion images of each slice of the phantom were 
analyzed with an in-house PCA program developed using the C++ programming 
language. Two, four, six, eight, and ten principal components were used to reconstruct 
five different sets of noise-filtered CT perfusion images. 
 
3.2.3 In Vivo Experiments 
All experiments were approved by the Animal Use Subcommittee of the Canadian 
Council on Animal Care at our institution. C6 glioma cells (106 cells in 10 μL) were 
stereotactically implanted into the right caudate putamen of eight Wistar rats (10). At an 
average of 13 days (range, 11–17 days) after tumour implantation, the brain of each 
animal was scanned in high-resolution mode with a clinical CT scanner using the same 
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two-phase protocol as the simulation. A bolus of contrast (Isovue; Bracco Diagnostics 
Inc, Vaughan, Canada; 300 mg iodine/mL, 2.5 mL/kg body weight) was injected into the 
lateral tail vein at a rate of 8 mL/min, at 3–4 seconds after the start of the first phase. 
Two, four, and six principal components were used to reconstruct three different sets of 
noise-filtered CT perfusion images for each animal. 
 
3.2.4 Assessment of Image Quality and Information Loss after 
PCA Filtering 
For both simulation and in vivo experiments, pixel noise and CNR were used to 
evaluate the image quality of CT perfusion images after PCA noise filtering (2). To 
evaluate the enhancement of contrast, the mean baseline attenuation is subtracted from 
the TAC to give the corresponding time-enhancement curve. The standard deviations 
(SD) of the baseline (first four to five time points) and the late steady state phase (last 10 
time points) were calculated and averaged for each of the original and filtered image sets 
to give 𝑆𝐷𝑜̅̅ ̅̅ ̅ and 𝑆𝐷𝑓̅̅ ̅̅ ̅, respectively. These values (𝑆𝐷𝑜̅̅ ̅̅ ̅ and 𝑆𝐷𝑓̅̅ ̅̅ ̅) were used as 
measurements of pixel noise.  
For each CT perfusion image set, the average norm of the time-enhancement 
curves ‖𝑄‖̅̅ ̅̅ ̅̅  is composed of the average norm of signal ‖𝑆‖̅̅ ̅̅ ̅ and average norm of noise 
√𝑚 ∙ 𝑆𝐷2̅̅ ̅̅ ̅, where m is the number of time points. The average norm of signal ‖𝑆‖̅̅ ̅̅ ̅ was 
estimated using √‖𝑄‖̅̅ ̅̅ ̅̅ − 𝑚 ∙ 𝑆𝐷2̅̅ ̅̅ ̅. The CNR of the original and filtered image sets were 
defined as 
‖𝑆‖̅̅ ̅̅ ̅𝑜
𝑚∙𝑆𝐷𝑜̅̅ ̅̅ ̅̅
2 and 
‖𝑆‖̅̅ ̅̅ ̅𝑓
𝑚∙𝑆𝐷𝑓̅̅ ̅̅ ̅̅
2, respectively.  
The fractional residual information (FRI) was described by Balvay et al (2) and 
was used to evaluate the amount of information loss due to filtering. The residual signal 
of pixel p, Rp, was the difference between the original TAC, Qp, and the filtered TAC  
( pQ
~
). The residual signal (Rp) of pixel p has two components: informative signal (Sp) and 
noise (Np). The FRI for a pixel (FRIp) after filtering with PCA was defined as:  
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FRIp ranges from 0 to 1, and the optimal number of principal components that 
should be used for filtering TACs minimizes the FRI in order to keep as much valuable 
information as possible in the filtered data in both the tumour and normal brain tissue. To 
estimate 
2
pS we used the autocorrelation function of the residual, Rp, between the 
original and filtered TAC of pixel p, which is defined as: 
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where m is the number of time points, k is the time lag and Rp(i) is the i
th element of the m 
× 1 residual vector Rp. Cp(k) can identify signal (Sp) hidden in the noise (Np) of Rp in the 
following way. In general, the autocorrelations of Np and Sp are approximately zero for 
time lag k > kn and ks, respectively. If ks > kn, then the autocorrelation of the residual 
Cp(k) can be used to approximate Sp for time lag kn < k < ks. In particular, extrapolation of 
Cp(k) in the range kn < k < ks to k = 0 will give the autocorrelation of Sp at k = 0, which by 
analogy to Equation 3-5 gives 
2
pS when multiplied by (m-|k|). We used a second order 
polynomial to extrapolate Cp(k) in the range kn < k < ks to k = 0. The kn and ks used were 
fixed to 1 and 30 time lags, respectively. 
 
3.2.5 Calculation of BF, BV, and PS 
 
For both simulation and in vivo experiments, maps of BF, BV, and PS of the 
unfiltered and filtered image sets were generated using CT Perfusion 4D. Tissue TACs 
were measured from 2 × 2 pixel blocks of CT images. Parametric maps of BF, BV, and 
PS were calculated by deconvolving the arterial TAC with each tissue TAC using the 
Johnson–Wilson model (8,9). The population-averaged TAC was used for the simulation 
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while a region of interest (ROI) was placed in the carotid artery to measure the arterial 
TAC for each animal. 
 
3.2.6 Statistical Analysis 
For digital phantom maps, a square-shaped ROI of 8 × 8 pixels was placed at the 
center of each tile to measure the mean BF, BV, and PS. Intraclass correlation coefficient 
was used to assess the reliability of measurements between the simulated true values and 
the values obtained without or with PCA filtering (11). Measurement error was the 
difference between the mean with the simulated true value of each tile. Map noise was 
the SD of each tile. The agreement in measurement errors and map noises in BF, BV, and 
PS without and with PCA filtering was assessed using Bland–Altman analysis (12). 
Repeated measures analysis of variance (ANOVA) followed by Bonferroni multiple 
comparisons was used to compare the differences in absolute measurement errors and 
map noise before and after PCA filtering (SPSS, version 20.0; SPSS, Chicago, IL) (13). 
For animal experiments, the tumour and contralateral normal brain were 
delineated. Noise level, CNR, BF, BV, and PS in each ROI were expressed as mean ± 
SD. These metrics before and after filtering were compared using repeated measures 
ANOVA followed by Bonferroni multiple comparisons to evaluate the differences 
between the normal brain and tumour without or with PCA filtering. The mean 
percentages of pixels that had an FRI ≥ 5% in the normal brain and tumour were 
calculated. All statistical tests were done using SPSS (SPSS, version 20.0; SPSS, 
Chicago, IL), and a P ≤ .05 was considered significant.  
 
3.3 Results 
For simulation, filtering with four or lesser principal components resulted in intraclass 
correlation coefficients that were significantly greater than the intraclass correlation 
coefficients without PCA filtering for BF, BV, and PS (Table 3-1).  Figure 3-3 illustrates 
91 
 
visual improvements in maps of BF, BV, and PS after PCA filtering. The mean error and 
the 95% limits of agreement (mean ± 2 SD) decreased after PCA filtering and with lesser 
number of principal components (Figure 3-4). Similarly, the mean map noise and 95% 
limits of agreement decreased after PCA filtering (Figure 3-5). Reductions in absolute 
measurement errors and map noises for BF, BV, and PS were significant (P < .05). The 
mean FRI ± SD was ≤0.5% ± 0.7% after filtering with any number of principal 
components. The maximum mean FRI for ten, eight, six, four, and two principal 
components were 3.0%, 2.9%, 3.7%, 4.9%, and 6.5%, respectively. 
 
Table 3-1: Intraclass correlation coefficient of different CT perfusion parameters 
with the true values. 
Number 
of PCs 
BF BV PS 
Intraclass 
correlation 
coefficient (95% 
CI) 
P 
value* 
Intraclass 
correlation 
coefficient (95% 
CI) 
P 
value† 
Intraclass 
correlation 
coefficient (95% 
CI) 
P 
value‡ 
No PCA 
0.73 
(0.34 – 0.86) 
0.57 
0.96 
(0.95 – 0.97) 
0.42 
0.77 
(0.16 – 0.91) 
0.59 
10 PCs 
0.79 
(0.64 – 0.87) 
0.19 
0.98 
(0.96 – 0.98) 
0.05 
0.87 
(0.73 – 0.93) 
0.06 
8 PCs 
0.79 
(0.68 – 0.86) 
0.12 
0.98 
(0.97 – 0.99) 
0.00# 
0.91 
(0.83 – 0.95) 
0.00# 
6 PCs 
0.79 
(0.66 – 0.86) 
0.15 
0.98 
(0.97 – 0.99) 
0.00# 
0.91 
(0.84 – 0.94) 
0.00# 
4 PCs 
0.82 
(0.75 – 0.87) 
0.01# 
0.98 
(0.97 – 0.98) 
0.00# 
0.90 
(0.87 – 0.93) 
0.00# 
2 PCs 
0.82 
(0.77 – 0.86) 
0.00# 
0.98 
(0.97 – 0.98) 
0.00# 
0.92 
(0.89 – 0.94) 
0.00# 
*Statistical comparison with intraclass correlation coefficient = 0.73 
†Statistical comparison with intraclass correlation coefficient = 0.96 
‡Statistical comparison with intraclass correlation coefficient = 0.77 
#Statistically significant at a P < 0.01 
 
Abbreviations: PCs = principal components; BF = blood flow; BV = blood volume; PS = 
permeability-surface area product; PCA = principal component analysis; CI = confidence 
interval 
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Figure 3-4: Mean error and 95% limits of agreement (ie, mean ± 2 standard 
deviation from Bland–Altman analysis) without and with principal component 
analysis (PCA) filtering for (a) blood flow (BF), (b) blood volume (BV), and (c) 
Figure 3-3: Maps of blood 
flow (BF), blood volume (BV), 
and permeability–surface 
area product (PS) of the 
digital phantom without noise 
(ie, truth), with noise, and 
after principal component 
analysis (PCA) filtering with 
four principal components. 
Some values of BF, BV, and 
PS are labeled. 
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permeability–surface area product (PS). Solid line is the mean and dashed lines are 
the upper and lower limits of agreement. 
 
Figure 3-5: Mean map noise and 95% limits of agreement (ie, mean ± 2 standard 
deviation from a Bland–Altman analysis) without and with principal component 
analysis (PCA) filtering for (a) blood flow (BF), (b) blood volume (BV), and (c) 
permeability–surface area product (PS). Solid line is the mean and dashed lines are 
the upper and lower limits of agreement. 
 
For experiments, Figure 3-6 shows the removal of noise from a sample time-
enhancement curve in the tumour. Figure 3-7 shows examples of source CT perfusion 
images and maps of BF, BV, and PS without and with PCA filtering; the first four 
principal components used for filtering are also shown. Table 3-2 reports the significant 
improvements in noise reduction and CNR in animal CT perfusion images. The loss of 
signal was minimal after filtering the images with four or more principal components, in 
which no >1% of pixels had an FRI of ≤5% in both the normal brain and the tumour. An 
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average of 26% (range, 11%–49%) of pixels in the tumour had an FRI of ≥5% when 
filtering with only two principal components (Table 3-2). PCA showed significant effect 
on BV and PS irrespective of ROI (ie, normal brain vs. tumour), and ROI had a 
significant effect on BF, BV, and PS irrespective of PCA (Table 3-3). Although PCA had 
no overall effect on BF, the interaction between PCA and ROI had a significant effect, 
suggesting that ROI had an effect on PCA filtering. Figure 3-8 shows that there was no 
regional difference in BF without PCA (P = .72), but tumour BF was significantly 
different than brain BF after filtering with four or lesser principal components (P < .03). 
This supports the effect of region on the PCA as indicated in Table 3-3, which led to a 
higher contrast between tumour and normal brain tissue in BF maps. Figure 3-8 also 
illustrates measurements of BV and PS in the normal brain and tumour before and after 
PCA filtering. 
 
Figure 3-6: Examples of tumour time-enhancement curves obtained without and 
with principal component analysis (PCA) filtering. Filtering with two principal 
components can lead to loss of information as represented by the reduced height in 
the time-enhancement curve. 
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Figure 3-7: (A) Examples of source computed tomography (CT) images and maps of 
blood flow (BF), blood volume (BV), and permeability–surface area product (PS) 
without and with filtering using four principal components (PCs) . (B) The first four 
PCs as a function of time.    
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Table 3-2: Evaluation of quality of computed tomography perfusion image filtering. 
Number of 
PCs 
Noise level ± SD (HU) CNR ± SD % of voxels with FRI ≥ 5% 
Brain Tumour Brain Tumour Brain Tumour 
No PCA 
16.9 ± 0.5 16.6 ± 0.6 0.6 ± 0.1 1.4 ± 0.4 N/A N/A 
6 PCs 
5.2 ± 0.6* 5.6 ± 0.6* 1.9 ± 0.3* 3.8 ± 1.2* 0.2 ± 0.2 0.3 ± 0.5 
4 PCs 
3.3 ± 0.4* 3.9 ± 0.7* 2.9 ± 0.4* 5.5 ± 2.4* 0.5 ± 0.3 1.1 ± 1.0 
2 PCs 
1.6 ± 0.3* 2.2 ± 0.6* 6.2 ± 1.3* 6.5 ± 1.8* 4.2 ± 2.2 26.4 ± 14.2 
*Significantly different than No PCA of the same region (P < 0.05) 
Abbreviations: PCA = principal component analysis; PCs = principal components; SD = 
standard deviation; HU = Hounsfield unit; CNR = contrast-to-noise ratio; FRI = 
fractional residual information; N/A = not applicable 
 
Table 3-3: P values of repeated-measures ANOVA for measurements of BF, BV, and 
PS. 
Factor 
BF BV PS 
PCA  
0.21 <0.02 <0.01 
Region  
<0.05 <0.03 <0.01 
Interaction between PCA and region 
<0.01 <0.01 <0.01 
Abbreviations: BF, blood flow; BV, blood volume; PCA, principal component analysis; 
PS, permeability–surface area product. 
97 
 
 
Figure 3-8: Brain and tumour blood flow (BF), blood volume (BV), and 
permeability–surface area product (PS) before and after filtering with different 
number of principal components. Asterisk (*) indicates a marginal significance of P 
= .06. Dagger (†) indicates 0.01 ≤ P < .03. Double dagger (‡) indicates P < .01. 
 
3.4 Discussion 
CT perfusion provides crucial information regarding brain tumour hemodynamics 
for the evaluation of tumour angiogenesis (1). The visualization of small objects of 
interest, such as tumours and ischemia, and accurate and precise measurements of BF, 
BV, and PS require good CNR. Balvay et al. (2) demonstrated an automated method to 
perform PCA. Our simulation provides the first evidence that PCA is effective in 
improving the reliability, accuracy, and precision of BF, BV, and PS measurements. 
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We applied PCA in this study to improve CNR of CT perfusion images of 
malignant rat gliomas that have an even lower CNR than previously reported (2). PCA is 
a statistical technique that separates image noise from signal by determining principal 
components with successively decreasing variance. Filtering with too many principal 
components results in ineffective denoising of the data whereas filtering with too few 
principal components runs the risk of removing genuine signal from the original data. We 
used the noise level, CNR, and FRI as metrics to evaluate the tradeoff between the 
improvement in image contrast and the loss of information. In this study, both image 
noise and CNR of CT perfusion images were improved after PCA. Filtering with only 
two principal components resulted in substantial information loss in the tumour that was 
not observed with greater than four principal components. Rat brain CT perfusion images 
required few principal components for filtering because there are few tissue types with 
different patterns of contrast enhancement in rat brain tissues. Unlike human brain, which 
has substantial amount of white matter, the rat brain consists mostly of gray matter (14). 
Furthermore, the rat brain, like human brain, is not permeable to most exogenous 
molecules including iodinated contrast. The shape of the time-enhancement curve in the 
normal rat brain is mainly governed by that of the arterial input and venous output. 
However, in the implanted glioma, contrast agent is able to extravasate into the brain 
parenchyma. The extravasation of contrast agent contributes to the higher contrast 
enhancement during the latter phase of the time-enhancement curves. Because there are 
only two major tissue types (normal and tumour) with two different patterns of contrast 
uptake (minimal vs. high extravasation) in the rat gliomas of this study, four principal 
components were able to filter the CT perfusion images without substantial loss of 
information. After filtering the CT perfusion images, differences in BF, BV, and PS 
measured in the tumour and contralateral normal brain were consistent with reported data 
measured using synchrotron radiation CT perfusion of the same tumour model (15). 
There have been advances in the development of new CT reconstruction methods 
that can improve CT image quality. ASIR is one example of these advances and has been 
shown to provide equal image quality in brain imaging with ≥30% reduction in radiation 
dose when compared to filtered back projection (16). Images from this study were 
reconstructed with 80% ASIR. Thus, the improvement in image quality from PCA was 
99 
 
additional gain in CNR of the time-enhancement curves after ASIR was applied, 
suggesting that PCA further contributes to the improvement in CT perfusion image 
quality. 
PCA has important potential application for lowering radiation dose when 
performing repeated CT perfusion studies to evaluate treatment response. A typical 
human brain CT perfusion protocol produces an effective dose of 2.9–5.4 mSv (17). 
Radiation dose is inversely proportional to the square of image noise. For instance, a 
nine-fold reduction in radiation dose can be achieved by filtering CT perfusion images 
with six principal components to achieve a three-fold improvement in image noise (Table 
3-2). PCA filtering of CT perfusion images can improve the accuracy and precision of 
BF, BV, and PS measurements obtained with low CNR CT perfusion images; thus, 
making repeated low dose CT perfusion studies feasible. Lowering radiation exposure for 
better radiation safety or increasing spatial resolution of CT images will increase image 
noise, which in turn lowers CNR. Effective filtering of CT perfusion source images 
without the loss of information to obtain more accurate and precise measurements of BF, 
BV, and PS is imperative for both improving visibility of small objects of interest and for 
lowering radiation dose. 
There are several limitations in this study. A simulation was performed to 
evaluate the improvement in accuracy and precision of BF, BV, and PS measurements. 
Although we did not perform an in vivo validation, CT perfusion imaging of brain 
tumour tissue has been validated in vivo (18). PCA analysis of the experimental data was 
applied to each slice of the brain separately (ie, two-dimensional analysis). A three-
dimensional PCA of the entire brain could improve the quality of filtering by increasing 
the number of pixel TACs used to determine the principal components. It is important to 
note that the simulation results obtained in this study may not be applicable to other 
pharmacokinetic models (ie, the analysis software). Using a similar digital phantom, 
Kudo et al. (19) showed that different commercial software packages showed 
discrepancies in BF and BV measurements from simulated values. This is because 
available commercial software may or may not correct the arrival delays of the TACs, 
and the impulse residue functions are constrained differently in these software packages 
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because of the different assumptions used in their tracer kinetic models. A separate 
simulation using our digital phantom is needed to validate the measurement of different 
tracer kinetic parameters after PCA filtering of CT perfusion images for each commercial 
software. 
 
3.5 Conclusions 
PCA filtering of CT perfusion images improved CNR in vivo and reduced 
measurement errors of BF, BV, and PS by simulation. PCA is an effective tool for 
filtering CT perfusion images of malignant rat gliomas with low CNR. Filtering with four 
principal components could achieve the gain in CNR without substantial loss of 
information. 
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Chapter 4 
4 CT Perfusion Imaging as an Early Biomarker of 
Differential Response to Stereotactic Radiosurgery 
This chapter is adapted from the manuscript entitled “CT perfusion imaging as an 
early biomarker of differential response to stereotactic radiosurgery”. This manuscript 
will be submitted to the journal PLOS ONE in July 2014 to be considered for publication. 
The authors of this manuscript are Yeung TPC, Kurdi M, Wang Y, Al-Khazraji B, 
Morrison L, Hoffman L, Jackson D, Crukley C, Lee TY, Bauman G, Yartsev S.  
 
4.1 Introduction 
Patients with glioblastoma multiforme, the most common form of adult brain 
tumours, have a median survival of approximately 12 – 15 months (1). Radiotherapy has 
played an important role in prolonging the survival of these patients since the 1970s (2). 
Magnetic resonance (MR) and computed tomography (CT) are currently the standard 
imaging modalities for assessing treatment response. Tumour progression is usually 
detected by increased contrast-enhancement on gadolinium-enhanced T1-weighted MR 
images, and T2-weighted or fluid-attenuated inversion recovery MR images (3). 
However, early changes in contrast enhancement after radiotherapy is not a specific tool 
to predict treatment failure as changes in contrast enhancement can occur in 
pathophysiological processes that disrupt the blood brain barrier. For instance, radiation-
induced injury (e.g. radiation-induced necrosis and pseudoprogression) can mimic the 
appearance of tumour progression on T1-weighted MR (3). 
Due to the poor survival rates, timely and accurate assessment of response to 
radiation is important as treatment can be altered if a non-responder to radiation can be 
identified early enough. In preclinical studies, radiotherapy is usually delivered using a 
technique called stereotactic radiosurgery (SRS). It is delivered in one or few large dose 
fractions of 8 – 30 Gy and would result in tumour growth delay and survival benefit (4-
7). Radiotherapy, particularly SRS, can result in vascular damage in the irradiated area 
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(4, 8-10), and radiosensitivity of tumour vasculature can augment response to SRS (11). 
Hypofractionation schemes that also use a large dose per fraction to treat patients with 
malignant gliomas is also an attractive treatment strategy. Recently, clinical studies have 
investigated the use of hypofractionated intensity modulated radiotherapy to treat these 
patients (12-14). Hypofractionation have some advantages over conventional 
fractionation. Hypofractionation is expected to increase the biological effect of radiation 
due to increased cell damage resulting from a higher dose per fraction (15). It also 
reduces the effect of tumour repopulation by reducing treatment time (16). Thus, imaging 
of tumour perfusion is a promising biomarker of response to high dose per fraction 
radiotherapy (e.g. SRS and hypofractionation) that warrants investigation.   
The C6 rat glioma is a widely used experimental model for the study of malignant 
glioma (17), including the effects of SRS (6,7,9,10). Tumour microcirculation can be 
noninvasively measured by CT or MR perfusion imaging techniques. In particular, CT 
perfusion imaging is a validated method that allows simultaneous mapping of blood flow 
(BF), blood volume (BV), and permeability-surface area product (PS) (18,19). CT 
scanners and iodinated contrast agents are also widely available, and they are ubiquitous 
in radiation oncology departments. The purpose of this study was to evaluate vascular 
changes following SRS using CT perfusion, and determine whether acute vascular 
changes within one week of SRS is predictive of survival. In addition, early (four days 
post-SRS) and late (eight weeks post-SRS) histopathologic findings were examined.  
 
4.2 Materials and Methods 
4.2.1 C6 Glioma Model 
All experiments were compliant with our institutional Animal Use Subcommittee 
guidelines. Wistar rats weighing 300 – 400 g (N = 33) were used in this study. The 
animals were anaesthetized with 2% isoflurane during all procedures. C6 glioma cells 
(American Type Culture Collection, Manassas, VA) were cultured in F12k 15% horse 
serum, 2.5% bovine serum, and 1% penicillin-streptomycin. For the implantation of C6 
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glioma cells, each animal was secured into a stereotactic surgical frame. After scalp 
incision at midline and exposing the bregma, a 1 mm diameter burr hole was drilled at 1 
mm anterior and 3 mm right of the bregma. A total of 106 C6 glioma cells were slowly 
injected for 5 minutes at 3 – 4 mm below the burr hole, which corresponded to the 
location of the caudate putamen (20). The burr hole was sealed with bone wax, and the 
scalp was closed with sutures.   
 
4.2.2 Baseline CT Perfusion Imaging 
All rats underwent the first CT perfusion scan on an average of 11 days (range, 7 
– 16 days) after implantation of C6 glioma cells to monitor tumour growth and prepare 
for SRS. The rats were scanned using a clinical CT scanner (Discovery 750 HD, GE 
Healthcare, Waukesha, WI). A two-phase CT perfusion scan, guided by a prior non-
contrast CT scan that identified 16 × 1.25 mm thick sections to cover the entire brain, was 
performed for each animal. The brain was scanned with high resolution mode for 32 s at 
1.4 s intervals during the first phase and for a period of 165 s at 15 s intervals during the 
second phase. A bolus of contrast (Isovue, Bracco Diagnostics Inc, Vaughan, Canada, 
300 mg iodine/ml, 2.5 mL/kg body weight) was injected into the lateral tail vein at a rate 
of 8 mL/min at 3 – 4 s after the start of the first phase. The scanning parameters were 80 
kVp, 120 mAs, 10 cm field of view, and high-definition bone filter. The visibly 
distinguishable spatial resolution was 1 line pair per 500 μm measured on a rat-size 
phantom (21). 
CT perfusion images of the same slice were averaged over the whole scan 
duration using the prototype version of CT perfusion 4D (GE Healthcare) to produce a set 
of contrast-enhanced images called averaged CT images. The tumour diameter on the 
averaged CT images was measured immediately after the scan. The rats were assigned 
randomly to either the control group (N = 8) or the SRS group (N = 25) once a tumour 
diameter of 4 mm was reached. 
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4.2.3 Stereotactic Radiosurgery 
A custom-made plastic stereotactic frame was used to secure the animals for 
treatment planning. A non-contrast helical CT scan was performed (25 cm field-of-view, 
80 kV, 110 mAs, 1.25 mm slice thickness) for treatment planning. CT images were 
transferred to the Helical Tomotherapy Treatment Planning System (Accuray Inc, 
Madison, WI, USA). Using the averaged CT images for anatomical guidance, a dose of 
12 Gy was prescribed to at least 80% of the contrast-enhanced tumour volume with the 
brainstem receiving no more than 4 Gy and less than 10% of the normal brain receiving 
more than 8 Gy.  
For SRS, the rats were fixed in the same plastic stereotactic frame. A 3.5 MV CT 
study was acquired prior to treatment. This MV CT study was co-registered with the 
planning kV CT study and couch position was shifted in the lateral, anterior-posterior, 
and superior-inferior directions. The rats were repositioned in the stereotactic frame if 
there were rotational positioning errors. The average SRS delivery time was 6 minutes. 
Rats in the control group were put under anesthesia and secured in the stereotactic frame 
for 6 minutes to mimic the procedure without radiation. 
 
4.2.4 Follow-up CT Perfusion Imaging 
Rats in the SRS group were further assigned to either 1) acute imaging group (N = 
12) or 2) the longitudinal imaging group (N = 13). Rats in the acute imaging group were 
imaged with CT perfusion at 4 days post-SRS, and were euthanized on the same day.  
Rats in the longitudinal group and control group were imaged for a maximum of 8 weeks 
post-SRS to monitor tumour changes and survival. Rats were euthanized if they showed 
any of the following signs and symptoms: weight loss of ≥ 15% from the heaviest 
recorded weight, lethargy, refusal to eat, neurologic signs such as one-sided limb 
weakness.  
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4.2.5 Image Analysis 
Maps of BF, BV, and PS were generated using the prototype version of CT 
perfusion 4D (GE Healthcare). The time-attenuation curve (TAC) from the carotid artery 
was selected as the arterial input. The arterial TAC was deconvolved with tissue TACs 
measured from 2 × 2 pixel blocks of CT images using the Johnson-Wilson model to 
produce maps of BF, BV, and PS (18,22). Using the averaged CT images for anatomical 
guidance, tumour volume, BF, BV, and PS in the tumour, peritumoural region, and 
contralateral normal brain were measured. Peritumoural region was defined as normal 
brain that is 2 – 3 mm adjacent to the tumour. Mean BF and BV values were normalized 
to the contralateral normal brain to obtain the relative BF (rBF) and relative BV (rBV) 
values.  
 
4.2.6 Histopathologic Examination 
On the same day as the last CT perfusion scan, the animals were euthanized with 
an overdose of potassium chloride. The animals were perfusion-fixed with phosphate 
buffered saline followed by 4% paraformaldehyde. The brains were removed and fixed in 
4% paraformaldehyde for 24 hours. The brain specimens were sectioned into 3 mm thick 
blocks, paraffin-embedded, then sectioned at 5 μm. Hematoxylin and eosin stain (H&E) 
was applied on each section.  
A blinded neuropathology resident (M.K.) examined all H&E slides at different 
magnifications (20x and 40x) to evaluate histologic signs of radiation damage. The 
presence of tumour was evaluated as “no”, “yes”, or “diminished due to radiation effect”. 
“Diminished due to radiation effect” means the presence of a circumscribed hypocellular 
lesion showing features of irradiation. The diameter of each lesion (control and SRS-
treated animals) was measured. Tumour cellularity was defined as 1) hypercellular when 
less than 30% of the tumour area appeared pale or major tumour was found, and 2) 
hypocellular when more than 50% of the tumour area appeared pale excluding necrosis. 
Tumour was graded based on the World Health Organization criteria (23). Tumour 
edema was defined as the presence of extensive intracellular cytoplasmic swelling or 
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intercellular spaces between tumour cells. Peritumoural edema was defined as 
intracellular cytoplasmic swelling or presence of intercellular spaces and reactive gliosis 
in the peritumoural region. Necrosis was described as 1) pseudopalisading necrosis that 
indicates high-grade glioma, 2) fibrinoid necrosis, or 3) background necrosis (neither 
pseudopalisading nor fibrinoid necrosis) that indicate post-radiation effect. 8) Presence of 
endothelial hyperplasia was recorded as a feature of angiogenesis in high-grade glioma. 
Increased vascularity and hyalinzed blood vessels were recorded as features of post-
radiation effect. Percentage of animals exhibiting these signs was calculated. Mean 
percent necrosis by area was also calculated.  
The brain sections were also stained with monoclonal anti-actin, α-smooth muscle 
antibody (α-SMA) (1:500, clone 1A4, Sigma-Aldrich) to identify mature vessels (24-26). 
The α-SMA positive vessels were qualitatively classified as intact or fragmented vessels. 
α-SMA positive vessel density was defined as the number of vessels that stained positive 
for α-SMA in 6 separate fields (20×) in the most vascular region of the tumour and 
peritumoural region. Intact and fragmented α-SMA positive vessel densities were 
measured separately. The percentage of fragmented α-SMA positive vessels was also 
recorded. 
 
4.2.7 Statistical Analysis 
The Shapiro-Wilk test was used to test the normality of the data. Temporal 
changes in the acute imaging group were tested by the Wilcoxon signed-rank test. The 
end point of the longitudinal imaging group was survival at 8 weeks post-SRS. The 
longitudinal group was also subdivided into those that survived more than 2 weeks 
(responder group), and those that survived less than 2 weeks post-SRS (nonresponder 
group). The omnibus Kruskal-Wallis test was used for comparisons between groups 
followed by the Mann-Whitney U test. The omnibus Friedman test was used for 
longitudinal comparisons within-group followed by the Wilcoxon signed-rank test. All 
data were reported as mean ± standard error of the mean (SE). Survival of the groups was 
compared using the log-rank test. Spearman’s rank correlation was used to assess the 
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associations between different imaging parameters (tumour volume, rBF, rBV, PS) and 
the percentage of fragmented α-SMA positive vessels. PS is the product between 
microvessel surface area and permeability, and BV has been shown to correlate with 
microvessel area (27). We used the PS:BV ratio as a surrogate of permeability and 
correlated this parameter with the percentage of fragmented α-SMA positive vessels as 
well.  
We investigated whether the imaging parameters correlated with overall survival, 
and whether these parameters on day 7 post-SRS could predict survival. Each imaging 
parameter was assessed by applying a threshold that is below the lower 50% confidence 
interval (CI) boundary of the variations across all treated animals derived from the 
between-subject variation on day 7 post-SRS. This threshold was used to categorize each 
animal into two groups (i.e. higher or lower than the threshold). Survivals of the different 
groups were compared. The sensitivity, specificity, and accuracy of each parameter in 
predicting survival were assessed. A P ≤ 0.05 was considered statistically significant. 
 
4.3 Results 
4.3.1 Acute Vascular Changes and Histopathologic Features 
Irradiated rats received 12 Gy in the tumour and peritumoural region, and 
different CT perfusion changes were observed in these two regions. Tumour volume, 
rBF, and rBV decreased significantly while peritumoural rBF, rBV, and PS increased 
significantly in the SRS group (Table 4-1). These opposite CT perfusion changes in the 
tumour and peritumoural regions are illustrated in Figure 4-1.  
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Table 4-1: Acute changes (± standard error) in CT perfusion parameters. 
  Percent Change (%) 
Regions-of-interest Treatment Tumour volume rBF rBV PS 
Tumour 
SRS -37.3 ± 13.2* -18.2 ± 7.9* -23.1 ± 7.6* -9.2 ± 9.7 
Control 95.1 ± 34.7* -13.1 ± 9.3 -6.4 ± 9.4 7.4 ± 15.1 
Peritumoural 
SRS N/A 20.9 ± 7.9* 28.7 ± 7.7** 54.3 ± 11.6** 
Control N/A -5.0 ± 5.3 2.0 ± 5.0 13.9 ± 20.2 
Abbreviations: SRS, stereotactic radiosurgery; rBF, relative blood flow; rBV, relative 
blood volume; PS, permeability-surface area product. 
* Significantly different compared to baseline at P ≤ 0.05 level 
** Significantly different compared to baseline at P ≤ 0.01 level 
 
Figure 4-1: Acute CT perfusion changes on the fourth day after stereotactic 
radiosurgery (SRS). Tumour relative blood flow (rBF) decreased from 1.48 to 0.68, 
relative blood volume (rBV) decreased from 1.70 to 0.78, while permeability 
surface-area (PS) decreased from 4.67 to 3.87 ml/min/100g. On the contrary, 
peritumoural rBF increased from 0.96 to 1.49, rBV increased from 1.06 to 1.52, and 
PS increased from 2.13 to 3.81 ml/min/100g. 
H&E histological examination revealed that all tumours were grade IV gliomas. 
Hypercellularity, mitosis, pseudopalisading necrosis, and endothelial hyperplasia were 
observed as signs of grade IV glioma in the control animals. For the acute imaging group 
that received SRS, fibrinoid or background necrosis, increased vascularity, and 
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hyalinized blood vessels were identified. Atypical nuclei, calcification, and gliosis were 
also observed in some lesions. Examples of H&E images of unirradiated tumour, acute 
effects of SRS, and late effects of SRS are demonstrated in Figure 4-2, and a summary of 
histological findings is provided in Table 4-2. 
 
Figure 4-2: Histological examples of stereotactic radiosurgery (SRS) effects. 
Representative Hematoxylin & Eosin images of an untreated control, acute 
histological change at 4 days post-SRS, and late histological change at 59 days post-
SRS. Hypercellularity (four point star) and pseudopalisading necrosis (five point 
star) are classic signs of grade IV glioma, and these were observed in the control 
animals. Hyalinized blood vessels (arrow) and hypocellularity can be observed 
shortly after SRS. Regression of tumour and hyalinization of tissue were observed at 
a later stage after SRS. 
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Table 4-2: Summary of histological finding on Hematoxylin and Eosin (H&E) specimens. 
 Presence of 
Tumour 
Tumour 
Diameter 
(mm) 
Hypo-
cellularity 
Types of 
Necrosis 
% Area 
Necrosis 
Vascularity Tumour 
Edema 
Peritumoural 
Edema 
Controls 88% Yes 
0% Diminished 
7.3 ± 4.0 0%  
 
88% PPN 
13% FN 
46 ± 27 75% EH 
25% Increased 
25% HBV 
0% 0% 
Acute 
Histology 
75% Yes 
25% Diminished 
5.8 ± 3.0 25% 50% PPN 
25% FN 
33% BN 
37 ± 19 58% EH 
58% Increased 
100% HBV 
25% 42% 
Responder 0% Yes 
0% Diminished 
N/A N/A 
 
None 
 
N/A 
 
0% EH 
43% Increased 
14 % HBV 
0% 
 
0% 
Non-responder 50% Yes 
33% Diminished 
4.6 ± 1.5 33% 67% PPN 
0% FN 
17% BN 
55 ± 13 67% EH 
50% Increased 
67% HBV 
17% 33% 
Abbreviations: PPN, pseudopalisading necrosis; FN, fibrinoid necrosis; BN, background necrosis; EH, endothelial hyperplasia; HBV, 
hyalinized blood vessels 
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Immunohistochemical staining revealed fragmented α-SMA positive vessels were 
identified mostly in the SRS-treated tumours (Figure 4-3). Fragmented α-SMA positive 
vessel densities in the tumour (P = 0.006) and peritumoural regions (P < 0.001) were 
significantly higher in the irradiated animals than the control animals (Figure 4-4). In the 
tumour, a positive borderline significant correlation between the percentage of 
fragmented α-SMA positive vessels and PS:BV ratio was identified for the treated 
animals (ρ = 0.58, P = 0.06) while a significant negative correlation was found for the 
control animals (ρ = -0.84, P = 0.02). However, the amount of fragmented α-SMA 
positive vessels in the controls was very small (Figure 4-4). In the peritumoural region of 
the treated animals, negative correlations were found between the percentage of 
fragmented α-SMA positive vessels with rBF (ρ = -0.62, P = 0.03) and rBV (ρ = -0.58, P 
= 0.05).  
 
Figure 4-3: α-smooth muscle actin (α-SMA) positive vessels in the normal brain, 
peritumoural region, and tumour of a control and a treated animal after stereotactic 
radiosurgery (SRS). Intact α-SMA positive vessels were observed in control animals, 
but fragmented coverage of vessels by α-SMA is mostly seen in treated animals (red 
arrow). 
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Figure 4-4: Boxplots of intact and fragmented α-smooth muscle actin (α-SMA) 
positive vessels in the control and SRS groups. Pairs with P < 0.01 are connected by 
black lines.  
 
4.3.2 Treatment Response, Longitudinal Changes, and Late 
Histopathologic Features 
Median survival of the control group was 10 days post-baseline scan (95% CI = 6 – 
14 days), and median survival of the SRS group was not reached (log-rank P < 0.04). 
However, survival in the SRS group was heterogeneous with 46% of the animals not 
surviving for more than 15 days. We designated these relative low survival animals as 
non-responders and animals with survival > 15 days as responders. Statistical 
comparisons were performed for the first 4 time points because all controls died before 
the 5th time point. Changes in tumour volume, rBF, rBV, and PS of these three groups are 
shown in Figure 4-5. Significant tumour growth was observed in the controls (Friedman 
P = 0.001, Wilcoxon signed-rank P < 0.03). Significant tumour shrinkage was observed 
in the responders (Friedman P = 0.04, Wilcoxon signed-rank P < 0.05). There was no 
significant tumour volume change in the non-responders. Tumour rBF in the responders 
was significantly lower than the non-responders and controls on day 14 post-SRS 
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(Kruskal Wallis P = 0.01, Mann-Whitney U P < 0.04). Tumour rBV in responders were 
significantly lower than the non-responders and controls on day 4 (Kruskal Wallis P = 
0.04, Mann-Whitney U P < 0.04) and day 7 post-SRS (Kruskal Wallis P = 0.01, Mann-
Whitney U P = 0.01). Responders’ tumour PS was significantly lower than the other 
groups on day 7 post-SRS (Kruskal Wallis P = 0.007, Mann Whitney U P ≤ 0.008). 
Between-group differences and longitudinal changes in PS:BV ratio in the tumour were 
not significant. 
 
Figure 4-5: Changes in (i) tumour volume, (ii) relative blood flow (rBF), (iii) relative 
blood volume  (rBV), and (iv) permeability-surface area (PS) in the tumour for 
controls, responders, and non-responders. *Significantly different from baseline 
(Friedman test and Wilcoxon-signed rank test). †Significantly different from 
controls and #significantly different from non-responders (Kruskal-Wallis followed 
by Mann-Whitney U test). 
 
Figure 4-6 shows an elevation in peritumoural rBF in both responders and non-
responders on days 4 and 7 post-SRS compared to the controls (Kruskal Wallis P ≤ 
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0.006, Mann-Whitney U P ≤ 0.008). Significant elevation was observed in peritumoural 
rBV of responders when compared to controls (Kruskal Wallis P < 0.01, Mann-Whitney 
U P = 0.001), and a similar trend was observed for peritumoural PS albeit not significant. 
This elevation in CT perfusion parameters eventually dissipated with time. Between-
group differences and longitudinal changes in PS:BV ratio in the peritumoural region 
were not significant. 
 
 
Figure 4-6: Changes in (i) rBF, (ii) rBV, and (iii) PS in the peritumoural region for 
controls, responders, and non-responders. *Significantly different from baseline 
(Friedman test and Wilcoxon-signed rank test). †Significantly different from 
controls (Kruskal-Wallis followed by Mann-Whitney U test). 
 
Histological examination revealed no presence of tumour in any of the responders. 
Increased vascularity was the major sign of late radiation-induced histologic change 
(Table 4-2). Figure 4-2 shows an example of late radiation-induced damage after the 
regression of tumour. For the non-responders, tumours were detected on H&E histology; 
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pseudopalisading necrosis was the major type of necrosis observed. Increased vascularity, 
endothelial hyperplasia, and hyalinized blood vessels were also observed.  
 
4.3.3 Early Prediction of Survival after Stereotactic Radiosurgery 
Tumour volume, rBF, rBV, PS, and PS:BV ratio at baseline and on day 4 post-
SRS did not correlate with overall survival. However, tumour rBV (ρ = -0.61, P < 0.05) 
and PS (ρ = -0.85, P = 0.001) on day 7 post-SRS correlated with overall survival. We 
evaluated whether each of the imaging parameter was predictive of overall survival by 
grouping the treated animals based on the measurement on day 7 post-SRS. Kaplan-
Meier survival plots are shown on Figure 4-7. SRS-treated animals with lower tumour 
rBF, rBV, and PS had significantly longer survival than SRS-treated animals with higher 
rBF, rBV, and PS (log-rank P ≤ 0.02). Treated animals with lower tumour volumes were 
associated with longer survival than those with higher tumour volumes, but this was not 
significant. Similarly, animals with a low PS:BV ratio did not have significantly different 
survival than those with high PS:BV ratio. In terms of predictive performance, both rBV 
and PS had the highest sensitivity (86%), specificity (100%), and accuracy (92%). rBF 
had a sensitivity, specificity, and accuracy of 71%, 100%, and 83%, respectively. Tumour 
volume had a sensitivity, specificity, and accuracy of 57%, 80%, and 67%, respectively. 
The PS:BV ratio had sensitivity, specificity, and accuracy of 67%, 60%, and 64%, 
respectively. 
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Figure 4-7: Kaplan-Meier plots of response to treatment categorized by (A) tumour 
volume, (B) relative blood flow (rBF), (C) relative blood volume (rBV), and (D) 
permeability-surface area product (PS). For each imaging parameter, two response 
groups were identified based on whether the measured value was less than the lower 
50% confidence interval of variations across all treated animals derived from the 
between-subject variation on day 7 post-SRS. Those that met this criteria were 
ranked as “low” by applying this threshold, and the others were ranked as “high”. 
Animals with low rBF, rBV, and PS on day 7 post-SRS showed significantly longer 
survival than the rest of the treated animals (i.e. high rBF, rBV, and PS) and control 
animals. *Significantly different from control group. †Significantly different from 
the other treated animals with a “high” value. Significant at P ≤ 0.02 level (log-rank 
test). 
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4.4 Discussion 
Although radiotherapy offers an overall survival benefit at the population level, 
accurate assessment of tumour response for each patient is crucial for treatment 
modification if no response to radiation is detected. Therefore, we need to develop non-
invasive imaging biomarkers as early indicators of response to radiation. Such 
biomarkers may help design combination therapies (drugs + radiation) in future clinical 
trials. Combining SRS with an anti-angiogenic agent is an attractive treatment option (28) 
because Bevacizumab appeared to ameliorate radiation-induced necrosis (29). Preclinical 
studies also suggested that anti-angiogenic agent like DC101 is a radiosensitizer to SRS 
(30). 
From preclinical studies, overall survival benefits post-SRS are commonly 
reported, with some treated animals surviving substantially longer than others (4-6). In 
our study, SRS demonstrated an overall survival benefit and histological confirmation of 
radiation-induced damage. Similar to previous studies, we observed substantial 
heterogeneity in treatment response. We found that CT perfusion can be a potential 
noninvasive imaging method to predict response to SRS, and that rBF, rBV, and PS 
showed better predictive performance of survival than tumour volume.  
In clinical studies, the survival benefit of SRS in combination with fractionated 
radiotherapy is unclear with some studies suggesting a 2-year overall survival benefit 
(31,32), while randomized trials showed that SRS did not confer a survival benefit over 
fractionated radiotherapy alone (33,34). Current clinical evidence from fractionated 
radiotherapy support our preclinical results in that a higher rBV after the completion of 
radiotherapy is associated with poor survival (35,36). However, the correlation between 
survival post-SRS and perfusion imaging parameters is lacking in the clinical literature, 
and there is no imaging biomarker to assess patients who might respond to SRS. Our 
results provide corroborating evidence to support the hypothesis that CT perfusion is an 
early biomarker of response to SRS. Use of CT perfusion parameters to characterize 
tumour vascular profiles and correlate with treatment response might identify patients 
who would benefit from SRS or hypofractionation treatment schemes. The use of an early 
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imaging biomarker to assess response to SRS or hypofractionated treatment schemes in 
randomized clinical trials might better define the role of altered fractionation schemes in 
this group of patients.  
From the acute imaging study, PS did not correlate with the percentage of 
fragmented α-SMA positive vessels, this could because PS is the product between 
permeability and surface area of the endothelium (18). Since BV has been shown to 
correlate with microvessel area (27), we investigated the PS:BV ratio as a surrogate 
marker of permeability. After SRS, a positive correlation between PS:BV and the 
percentage of fragmented α-SMA positive vessels points to the effect of radiation on the 
permeability of the blood-tumour barrier. From our survival study, it is PS that correlated 
with survival and not the PS:BV ratio. This suggests a low permeability (i.e. poor 
delivery) but a high surface area of SMA coverage after SRS is associated with poor 
survival. Vessels that are covered by SMA are mature vessels (24-26), and tumour vessel 
maturity is associated radiation resistance (8,37-38). Together, this points to a possible 
link between the vessel SMA coverage and survival. We were unable to show a 
correlation between survival and SMA coverage of mature vessels directly since any 
assessment of tumour vessels would require the sacrifice of animals. Further investigation 
into the direct associations between tumour PS and SMA coverage of mature vessels with 
tumour response is warranted.  
It is important to study the effect of radiation on the adjacent normal brain tissue 
(i.e. peritumoural region) because it is usually included in the irradiated volume that 
receives a significant dose of radiation in clinical practice, particularly for linear 
accelerator-based SRS. Complications and radiation-induced changes of brain tissue, 
such as edema and blood-brain barrier breakage, after SRS of arteriovenous 
malformations correlated with the volume of irradiated tissue that received 12 Gy (39-
40). The effect of SRS on peritumoural normal brain region in malignant glioma is not 
well understood and seldom reported (10). Zawaski et al. showed that radiation caused 
significant changes in permeability and leukocyte-endothelial interactions in the 
peritumoural normal brain that were indicative of acute inflammatory reaction and 
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radiation-induced astrogliosis. Our study provides supporting evidence by showing an 
increase in blood-brain barrier PS.  
A few limitations of this study must be considered. First, a relationship exists 
between radiation effect and dose (2,4). We chose 12 Gy because this dose can be 
delivered safely using Helical Tomotherapy, and it is used in the SRS boost of newly 
diagnosed glioblastoma (31-32) and salvage therapy of recurrent glioblastoma for linear 
accelerator-based SRS (41). Second, different tumour cell lines display different 
radiosensitivities (42). Therefore, dose-response of vascular changes measured by CT 
perfusion in other glioma models could be different. Thirdly, the sample size was 
relatively small and all untreated rats and most of the non-responders have died after the 
fourth CT perfusion scan. Thus, we could not compare the imaging data between these 
groups at later time points. Finally, while we used stereotactic techniques for radiation of 
the tumours, treatment volumes were still large relative to the size of the rat brain with 
the irradiated volume encompassing the ipsilateral cerebral hemisphere. Thus, the volume 
of normal brain irradiated was larger than would be the case in clinical radiosurgery 
treatments. It is possible that these volume differences have contributed to the perfusion 
changes seen in the peritumoural region. 
 
4.5 Conclusions 
This study showed that CT perfusion is a candidate to be an early biomarker of response 
to SRS. A CT perfusion imaging study in the clinical setting would potentially allow for 
timely and accurate assessment of early response to radiosurgery. It could help 
understand the role of SRS in these patients and also in combination with anti-angiogenic 
therapies. Evaluation of CT perfusion in prospective clinical studies are necessary to 
validate this technique as a predictive assay. Validation of the relevant CT perfusion 
indices used in this study for response assessment is warranted. 
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Chapter 5 
5 Relationship of Computed Tomography Perfusion and 
Positron Emission Tomography to Tumour Progression 
in Malignant Glioma 
This chapter is adapted from the research article, “Relationship of computed 
tomography perfusion and positron emission tomography to tumour progression in 
malignant glioma” published in Journal of Medical Radiation Sciences, 2014;61(1):4-13 
by Yeung TPC, Yartsev S, Lee T-Y, Wong E, He W, Fisher B, VanderSpek LL, 
Macdonald D, Bauman G. 
 
5.1 Introduction 
In malignant glioma, over 80% of tumour progression occurs within 2 cm of the 
original tumour site after radiotherapy and concurrent and adjuvant temozolomide 
chemotherapy (1). Radiological assessment of tumour progression is primarily based on 
gadolinium-enhanced magnetic resonance (MR) or iodinated contrast-enhanced 
computed tomography (CT) (2). An increase in the size of the contrast-enhancing lesion 
is one of the criteria for diagnosing progression (2). However, early changes in contrast 
enhancement after treatment lack utility in identifying active tumour sites that are likely 
to persist after treatment. 
Functional imaging is gaining popularity as it has demonstrated utility in 
differentiating tumour grade, predicting treatment response and survival and in 
identifying active tumour after treatment prior to progression (3). Pre-treatment 
functional imaging measurements of tumour perfusion and metabolism have been shown 
to predict survival in newly diagnosed and recurrent malignant glioma (4-7). Similarly, 
changes in blood flow (BF) and blood volume (BV) during radiotherapy have been 
shown to be predictive of survival (8,9). The use of multiparametric imaging data may 
have an added value for predicting survival. For example, tumour metabolism and BF 
were combined into a metric called the metabolism-flow ratio, and this was found to be 
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predictive of poor survival in pancreatic cancer (10). Metabolism and BF are usually 
tightly coupled in normal tissue; however, an increase in metabolism in the presence of 
low BF may be indicative of a tumour's adaptation to hypoxia (11). This suggests that the 
metabolism-flow ratio may be a valuable biomarker of hypoxia, which is associated with 
treatment resistance. 
CT perfusion can simultaneously measure BF, BV and permeability-surface area 
product (PS) in brain tumours (12), and 18-Fluorodeoxyglucose positron emission 
tomography (FDG-PET) is in routine clinical use for measuring tumour metabolism. The 
combination of FDG-PET and CT perfusion using a hybrid PET/CT scanner is a practical 
technique for assessing metabolism and perfusion in quick succession. This can also be 
used to calculate the metabolism-flow ratio, which circumvents the need for specialized 
synthesis capabilities to produce hypoxia tracers such as 18-Fluoro-azomycin 
arabinoside. 
No functional imaging studies have been reported near the completion of 
radiotherapy as an attempt to detect residual malignant gliomas. This study investigated 
the associations between the pre-radiotherapy gross tumour as defined on contrast-
enhanced MR, near-end-of-radiotherapy enhancing lesion as defined on contrast-
enhanced CT, near-end-of-radiotherapy CT perfusion and FDG-PET parameters with 
post-treatment MR-defined tumour progression. We then assessed the value of using 
these imaging parameters for predicting post-treatment MR-defined tumour progression. 
Therefore, the goal of this study was to assess whether functional imaging has the 
potential in predicting sites of future progressive tumour on a voxel-by-voxel basis after 
radiotherapy and chemotherapy. This can help identify biologically significant volumes 
of disease present at the end of conventional radiotherapy that could serve as a target for 
treatment intensification. 
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5.2 Methods 
5.2.1 Patients 
All study procedures were approved by Institutional Research Ethics Board. 
Patients with newly diagnosed malignant glioma were prospectively recruited to the 
study with informed consent prior to the last week of radiotherapy. The inclusion criteria 
were: (1) at least 18 years of age, (2) histologically confirmed malignant glioma, (3) 
Karnofsky Performance Status ≥60, (4) no previous cranial radiotherapy and (5) pre-
radiotherapy MR were performed within 12 weeks of radiotherapy treatment planning. 
Recurrent gliomas, multiple intracranial lesions, or patients that were not suitable for 
radical radiotherapy (40–60 Gy in 15–30 fractions) were excluded. 
5.2.2 Multi-modality Imaging Schedule 
After surgery but before radiotherapy, each patient underwent a standard MR 
imaging comprised of at least one series of T1- and T2-weighted images using a 1.5 T 
MR scanner (Signa Excite, General Electric Medical Systems, Milwaukee, WI). This MR 
scan was performed within 12 weeks of the treatment planning CT. Contrast-enhanced 
T1-weighted images were acquired using a fast spoiled gradient echo sequence 
(repetition time = 10 msec, echo time = 4 msec and flip angle = 15°) after an intravenous 
injection of gadopentetate dimeglumine (0.2 mL/kg; Magnevist; Berlex Laboratories, 
Wayne, NJ). 
A FDG-PET and CT perfusion scan was performed during the final week of 
radiotherapy using a hybrid PET/CT scanner (Discovery VCT, General Electric 
Healthcare, Waukesha, WI). After an intravenous injection of FDG (385 MBq), positron 
emission data were collected in list mode for 60 min and binned into 5 min frames in the 
last 40 min. Each PET data set consisted of 47 axial PET images with a 3.26 mm slice 
thickness and a 26 cm axial field of view (FOV). 
The FDG-PET CT attenuation correction maps in the FDG-PET study were used 
to select eight 5 mm sections to maximally cover the tumour for a 150 sec two-phase CT 
perfusion scan. A non-ionic contrast bolus (Omnipaque, General Electric Healthcare, 
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Princeton, NJ, 300 mg iodine per mL, 0.8 mL/kg of body weight) was injected at a rate of 
2–4 mL/sec at 3–5 sec before the start of the scan. While the selected brain sections were 
scanned continuously for 45 sec and the images reconstructed at 1-sec intervals during 
the first phase, the same sections were scanned once every 15 sec for seven times during 
the second phase. The scanning parameters for both phases were 80 kVp, 190 mA, 1 sec 
per rotation and a 25-cm FOV. 
Post-radiotherapy follow-ups were both clinical and radiological. Routine MR 
images were obtained at 4–6 weeks post-radiotherapy and every 3 months thereafter, and 
were reviewed by a neuro-oncologist or radiation oncologist. Tumour progression was 
defined as a continual enlargement of new enhancing lesion (without subsequent 
resolution) on serial MR imaging along with deterioration of clinical signs and symptoms 
(2). 
 
5.2.3 Image Processing 
CT perfusion images were analyzed using the prototype version of CT Perfusion 
4D (Advantage Windows, GE Healthcare, Waukesha, WI). Arterial and venous time-
attenuation curves were measured from an anterior cerebral artery and the posterior 
superior sagittal sinus respectively. BF, BV and PS maps were calculated by 
deconvolving the arterial time-attenuation curve with the tissue time-attenuation curve 
from 2 × 2 voxel blocks of CT images (12). The CT images were averaged together to 
produce average CT images, which have better grey and white matter contrast than 
conventional contrast-enhanced CT images. 
Software provided with the PET/CT scanner was used to correct the PET 
emission data for random and scatter coincidences, dead time and attenuation. PET 
images from the last 5 min bin were rigidly co-registered with the average CT using the 
3D Slicer software (13). The registered PET voxel values were converted to standard 
uptake values (SUV) corrected for body surface area (14). SUV maps were divided by 
the BF maps to generate SUV:BF ratio maps. 
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Gadolinium-enhanced T1-weighted MR images from pre-radiotherapy and at 
progression were rigidly co-registered with the near-end-of-radiotherapy average CT. All 
images (MR and average CT) and functional maps (CT perfusion and PET SUV) were 
then resampled to 170 × 170 voxels to minimize registration error. From here on, the 
contrast-enhancing lesion in the pre-radiotherapy T1-weighted MR lesion is the gross 
tumour, the contrast-enhancing lesion on the average CT acquired at the last week of 
radiotherapy is the near-end-of-radiotherapy enhancing lesion, and the contrast-
enhancing lesion on follow-up T1-weighted MR at the time of progression is the 
progressive tumour. Contours around the pre-radiotherapy gross tumour, near-end-of-
radiotherapy enhancing lesion and progressive tumour were delineated by a radiation 
oncologist (G.B.). Table 5-1 summarizes the labelling and time of acquisition of the 
images. 
 
Table 5-1: Summary of images acquired in this study. 
Name 
Type of 
Image(s) 
Image signal Time of acquisition 
Gross tumour 
volume 
T1-
weighted 
MR 
Gadolinium 
enhancement 
Post-surgery/biopsy and pre-
radiotherapy (must be within 12 
weeks of treatment planning CT) 
Near-end-of-
radiotherapy 
enhancing lesion 
Averaged 
CT  
Iodine 
enhancement 
(HU) 
Last week of radiotherapy 
BF BF map  mL/min/100g Last week of radiotherapy 
BV BV map  mL/100g Last week of radiotherapy 
PS PS map  mL/min/100g Last week of radiotherapy  
PET  SUV map FDG uptake Last week of radiotherapy 
Progressive 
tumour 
T1-
weighted 
MR 
Gadolinium 
enhancement 
Time of progression based on routine 
clinical and radiological follow-up 
assessments (4 – 6 weeks post-
radiotherapy and every 3 months 
after) 
Abbreviations: MR, magnetic resonance; CT, computed tomography; BF, blood flow; 
BV, blood volume; PS, permeability-surface area product; PET, positron emission 
tomography; SUV, standard uptake value; FDG, 18-Fluorodeoxyglucose. 
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5.2.4 Logistic Regression 
A custom MATLAB (MathWorks Incorporated, Natick, MA) program was 
developed for this analysis. A 2-cm bounding box around the union of the pre-
radiotherapy gross tumour and the progressive tumour was created to reduce the amount 
of information for analysis for each patient. Major blood vessels, surgical cavities, 
ventricles and voxels outside the bounding box were excluded. Each voxel inside the 
bounding box was assigned three binary statuses: pre-radiotherapy gross tumour (yes/no), 
near-end-of-radiotherapy enhancing lesion (yes/no) and progressive tumour (yes/no). 
Logistic regression was used to assess the association between tumour progression and 
the following sets of independent imaging variables: (1) pre-radiotherapy gross tumour, 
(2) near-end-of-radiotherapy enhancing lesion, (3) BF, BV, PS and SUV and (4) BV, PS, 
SUV:BF (15). The last regression was used to investigate the association between tumour 
progression and SUV:BF as a marker of hypoxia. The strength of association between 
each parameter and progressive tumour status was evaluated by the odds ratio. Odds 
ratios were converted to probabilities of recurrence for easier interpretations. 
 
5.2.5 Cross-validation 
Leave-one-out cross-validation was used to assess the value of using different 
imaging parameters to predict tumour progression (16). Each round of cross-validation 
used one patient data set as the validation set and the data sets from the other patients as 
the training set. Probability maps of progression for an individual patient (i.e. the 
validation set) were calculated using the logistic regression equation from the training set. 
We first considered seven single variable models: (1) Pre-radiotherapy gross tumour, (2) 
Near-end-of-radiotherapy enhancing lesion, (3) BF, (4) BV, (5) PS, (6) SUV and (7) 
SUV:BF. We then considered two multivariate models: (1) BV, PS, SUV:BF and (2) BF, 
BV, PS and SUV. Using receiver operating characteristic (ROC) analysis, the area under 
the ROC (AUC) curve was calculated. The optimal sensitivity and specificity was 
calculated using the Youden Index, which is the probability threshold that maximizes the 
sum of sensitivity and specificity for all possible probabilities from 0% to 100% (16). 
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5.2.6 Statistical Analysis 
Pre-radiotherapy gross tumour, near-end-of-radiotherapy enhancing lesion and 
progressive tumour volumes within the 4 cm CT perfusion scan length were compared 
using the Wilcoxon signed-rank test. AUCs of the different logistic models were 
compared using the Friedman test followed by the Wilcoxon signed-rank test. Models 
with AUCs that are significantly higher than the AUCs of the pre-radiotherapy gross 
tumour and end-of radiotherapy enhancing lesion were reported. All statistical tests were 
done using SPSS version 19.0 (SPSS Incorporated, Chicago, IL), and P-values <0.05 
were considered significant. 
 
5.3 Results 
Ten patients with newly diagnosed malignant glioma were prospectively recruited to the 
study between the years 2008 and 2011. After surgery, all patients underwent 
radiotherapy (60 Gy in 30 fractions) with concurrent and adjuvant temozolomide 
chemotherapy. Patient characteristics are listed in Table 5-2. Tumour progression with no 
evidence of necrosis was histopathologically confirmed in two patients (Patient 9 and 10 
in Table 5-2); the remaining patients had tumour progression defined on clinical and 
imaging grounds only. 
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Table 5-2: Patient Characteristics. 
Patient 
No. 
Age WHO 
Grade 
Tumour Location Type of 
Resection 
Months Between 
RT and Appearance 
of Progressive 
Tumours 
Site of 
Tumour 
Progression 
Treatment Steroid 
Use 
Survival 
Status 
1 36 3 Left Frontal 
Temporal 
Partial 8.6 aIn-field RT, TMZ Yes Deceased 
2 47 4 Left Parietal Partial 12.0 In-field RT, TMZ Yes Deceased 
3 55 4 Left temporal Partial 2.3 In-field RT, TMZ Yes Deceased 
4 37 3 Left frontal temporal Partial 8.4 In-field and 
bout-of-field 
RT, TMZ No Deceased 
5 50 4 Left Frontal lobe Partial 5.0 In-field RT, TMZ Yes Deceased 
6 71 4 Right temporal 
parietal 
Biopsy 2.1 In-field RT, TMZ Yes Deceased 
7 71 4 Left frontal Biopsy 4.3 In-field RT, TMZ Yes Deceased 
8 61 4 Left posterior frontal 
parietal inter-axial 
tumour 
Partial 14.8 In-field RT, TMZ Yes Deceased 
9 60 4 Left Frontal Parietal Partial 11.0 In-field RT, TMZ Yes Alive 
10 54 4 Left Temporal Partial 15.6 In-field RT, TMZ Yes Alive 
Abbreviations: WHO, World Health organization; RT, radiation therapy; TMZ, concurrent + adjuvant temozolomide 
aIn-field = within 2 cm of the primary contrast-enhancing tumour; bOut-of-field = beyond 2 cm of the primary contrast-enhancing 
tumour 
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The mean volumes ± standard deviation (SD) of pre-radiotherapy gross tumour, 
near-end-of-radiotherapy enhancing lesion and the progressive tumour within the CT 
perfusion scan volume were 10.8 ± 11.1, 14.1 ± 20.8 and 16.1 ± 18.0 cm3 respectively. 
The differences in volumes were not significant (P > 0.05). Figure 5-1 displays the 
images of patient 3. 
 
Figure 5-1: Pre-radiotherapy gross tumour (T1-weighted MR), near-end-of-
radiotherapy enhancing lesion (averaged CT) and progressive tumour (T1-weighted 
MR); and the corresponding parametric maps of blood flow (BF), blood volume 
(BV), permeability-surface area (PS) product, standard uptake value (SUV) and 
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SUV:BF acquired using CT perfusion and FDG-PET. Blue outlines show the 
contrast-enhancing lesions delineated by a radiation oncologist. Yellow outline is the 
2-cm bounding box that was set for performing logistic regression. MR, magnetic 
resonance; CT, computed tomography; FDG-PET, 18-Fluorodeoxyglucose positron 
emission tomography. 
 
5.3.1 Multivariate Logistic Regression 
When compared with normal brain tissue, the pre-radiotherapy gross tumour and the 
near-end-of-radiotherapy enhancing lesion had odds ratios of 12.7 (95% confidence 
interval [CI], 12.1–13.4) and 43.3 (95% CI, 41.4–45.3), respectively, for tumour 
recurrence. These odds can be expressed as recurrence probabilities of 54.4% and 69.8% 
respectively. Multivariate logistic regression showed that the odds of tumour progression 
increased with lower BF, BV and SUV; and with higher PS and SUV:BF (P < 0.0001) 
(Table 5-3).  
 
Table 5-3: Multivariate logistic regression. 
Model Parameter P 
aRegression 
Coefficients (β) 
Odds 
Ratio 
(eβ) 
95% 
Confidence 
Interval 
Probability 
(%) 
+95% -95% 
1 
BV <0.0001 -0.15 0.86 0.84 0.87 7.1 
PS <0.0001 0.41 1.51 1.49 1.52 11.9 
SUV:BF <0.0001 2.63b 13.88 11.38 16.94 55.4 
Constant <0.0001 -2.41 0.09 0.09 0.09 8.2 
2 
BF <0.0001 -0.01 0.99 0.99 0.99 23.1 
BV <0.0001 -0.07 0.93 0.91 0.95 22.1 
PS <0.0001 0.39 1.48 1.47 1.50 31.0 
SUV <0.0001 -0.93 0.39 0.37 0.41 10.7 
Constant <0.0001 -1.19 0.30 0.29 0.32 23.3 
Abbreviations: BV, blood volume; PS, permeability-surface area product; SUV, standard 
uptake value; BF, blood flow. 
aDegrees of freedom = 128,330 
bAn increase in SUV:BF value by 0.01 was associated with an odds ratio = 1.03; this 
corresponded to a probability of 8.4%.  
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5.3.2 Cross-validation 
The AUCs for the three models (1) PS alone, (2) BV, PS, SUV:BF and (3) BF, 
BV, PS and SUV were 0.72 ± 0.12, 0.74 ± 0.13 and 0.77 ± 0.11 respectively. These 
AUCs were significantly higher than the AUCs of the pre-radiotherapy gross tumour and 
near-end-of-radiotherapy enhancing lesion (Friedman P < 0.001; Wilcoxon signed-rank P 
≤ 0.03), which were 0.64 ± 0.14 and 0.65 ± 0.14 respectively. Although the AUCs of the 
two multivariate models were higher than that of PS, the differences were not statistically 
significant (P > 0.05). Table 5-4 shows model pairs that are significantly higher than the 
pre-radiotherapy gross tumour and the end-of-radiotherapy enhancing lesion. The model 
using PS alone had a sensitivity and specificity of 0.6 ± 0.1 and 0.7 ± 0.1, respectively 
(Figure 5-2). The model using BF, BV, PS and SUV had the highest combination of 
sensitivity and specificity (0.7 ± 0.1 and 0.7 ± 0.1). Probability maps of progression were 
generated using these logistic models, examples of probability maps for patient 3 are 
shown in Figure 5-3. 
 
Table 5-4: Statistical differences in area under the receiver operating characteristics 
curve. 
Model 1 Model 2 
% Difference = (Model 2 – 
Model 1)/(Model 1)×100 ± SD p 
Pre-radiotherapy gross 
tumour 
PS 14.2 18.1 0.03 
BV, PS, SUV:BF 16.4 18.6 0.03 
BF, BV, PS, SUV 21.4 18.6 < 0.01 
End-of-radiotherapy 
enhancing lesion 
PS 12.7 10.7 0.02 
BV, PS, SUV:BF 15.4 16.7 0.03 
BF, BV, PS, SUV 21.1 20.4 0.02 
PS 
BV, PS, SUV:BF 2.1 7.2 0.29 
BF, BV, PS, SUV 7.5 15.9 0.29 
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Figure 5-2: Area under the operating characteristic curve (AUC) (top), sensitivities 
(middle) and specificities (bottom) for the selected logistic regression models. 
Models with an AUC that is significantly higher than the pre-radiotherapy gross 
tumour and the end-of-radiotherapy enhancing lesion are indicated with an asterisk 
(*). 1, Pre-radiotherapy gross tumour; 2, End-of-radiotherapy enhancing lesion; 3, 
BF; 4, BV; 5, PS; 6, SUV; 7, SUV:BF; 8, BF, PS, SUV:BF; 9, BF, BV, PS, SUV. 
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Figure 5-3: Probability of tumour progression (patient 3) within the 2-cm bounding 
box generated using the different logistic regression models. Black line outlines the 
boundary of the progressive tumour. Based on cross-validation, the magenta line 
delineates the region with the probability threshold that maximizes the sum of 
sensitivity and specificity in predicting progression. 
 
5.4 Discussion 
We investigated whether near-end-of-radiotherapy CT perfusion and FDG-PET 
can add value to the assessment of malignant glioma in terms of predicting voxels that 
are likely to progress after treatment. PS alone was found to be the best predictor of 
tumour progression when compared to other CT perfusion and FDG-PET parameters; 
however, voxel-based prediction of progression had only modest sensitivity and 
specificity. 
PS describes the unidirectional flow of contrast as it leaks from the intravascular 
space into the interstitial space (i.e. brain parenchyma) (12). It is not the same as contrast 
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enhancement because it quantitatively measures the rate of contrast extravasation. In this 
study, not only did PS show a significant association with progressive tumour but it had a 
higher AUC than the pre-radiotherapy gross tumour and near-end-of-radiotherapy 
enhancing lesion for identifying tumour voxels that are more likely to progress. This 
suggests that PS adds value to contrast enhancement in determining active tumour 
regions after treatment, and also provides corroborating evidence to support that PS is 
associated with tumour aggressiveness. PS can be a potential biomarker of tumour 
aggressiveness because of the underlying pathological aspect that it represents. PS has 
larger value in high-grade gliomas compared to low-grade gliomas (17), which is 
important for prognosis. It also showed correlations with aggressive phenotypes 
including microvascular cellular proliferation (18) and the expression of pro-angiogenic 
genes (19). Finally, PS has been used to distinguish true tumour progression from 
treatment effect like treatment-induced necrosis (20). 
The observation that both lower BF and BV showed significant associations with 
tumour progression is noteworthy. A lower BF and BV may suggest resistance to therapy 
due to the presence of hypoxia. In support of this, dynamic susceptibility contrast MR 
studies at pre- and mid-radiotherapy showed that a drop in relative BF and BV were 
predictors of poor survival (8,9). However, the associations observed in this study were 
obtained from one time point only, and they do not suggest a causal relationship with 
progression. 
We found that a lower SUV, when considering the entire tumour, is associated 
with an increased risk of progression. This is contrary to studies that showed an increased 
FDG uptake is associated with poor survival in patients at various stages of treatment 
(21) or in patients with recurrent tumours (7,22). In these prior studies, FDG uptake in the 
hypermetabolic region was used to assess correlation with survival. This usually 
coincides with the contrast-enhancing region of the tumour where the perfusion is high; 
hence, an FDG delivery was unimpeded. Our results suggest that when considering the 
tumour as a whole, a lower FDG uptake is associated with higher odds of progression. A 
low FDG uptake does not necessarily infer a lack of metabolic demand. We instead 
showed a higher SUV:BF ratio was associated with an increased risk of recurrence, 
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which suggests that a low SUV was due to poor delivery resulting in uncoupling between 
metabolism and perfusion. This is consistent with PET-based measure of SUV:BF in 
pancreatic cancer in which a higher SUV:BF was associated with poor survival (10). 
These observations provide evidence to support the Warburg Effect hypothesis (10,11). 
Cancer cells can maintain anaerobic respiration to keep up with its metabolic demand 
under hypoxic stress and can be therapeutically resistant. This could lead to tumour 
regions that remain active despite treatment. 
Some limitations of this study must be considered. Although the AUCs of the 
multivariate models were higher than those of the univariate PS model, we were unable 
to demonstrate the statistical significance of multivariate models superiority. A larger 
sample size is required to determine whether (1) BF, BV, PS and SUV and (2) BV, PS 
and SUV:BF can provide more information than PS alone for identifying tumour regions 
that are likely to progress. Other radiotracers with a higher tumour-to-background ratio in 
the brain can improve the detection of residual tumour at the end of radiotherapy. For 
example, both 3′-Deoxy-3′-18F-fluorothymidine (FLT) (23) and 11C-methionine PET 
(24) were reported to be more sensitive than FDG in evaluating progressive tumours. 
Deformable registration could potentially improve the quality of registration. Most 
deformation of the tumour would occur from before and after surgery. This study used 
only post-surgery images; thus, physical deformation of the tumour is minimal. In 
addition, the majority of patients received dexamethasone during radiotherapy, which 
could decrease tumour permeability resulting in less edema and hence less deformation 
(25). The use of dexamethasone can also decrease cerebral glucose metabolism (26,27). 
The effect of dexamethasone on glucose metabolism is global rather than localized; it is 
unlikely to affect the current results because the logistic regression is based on imaging 
data obtained from both the normal brain and tumour tissues. Finally, we focused our 
investigation on the tumour site and its immediate surroundings, the potential effects of 
radiation on normal brain tissue perfusion and metabolism were not investigated in detail. 
A small radiation dose-dependent relationship (<10%) was observed for both brain tissue 
metabolism and perfusion (28). We evaluated the relationship between normal brain 
tissue BF, BV and PS with radiation dose in seven patients and did not find a significant 
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relationship (data not shown). Thus, the effect of radiation on normal tissue BF, BV and 
PS is unlikely to affect the current results. 
 
5.5 Conclusions 
We developed a technique for voxel-wise analysis of CT perfusion and FDG-PET images 
acquired at the end of radiotherapy for patients treated for malignant glioma. On the basis 
of our analysis, near-end-of-radiotherapy PS was the best predictor of tumour progression 
on a voxel-by-voxel basis when compared to other CT perfusion and FDG-PET 
parameters. However, voxel-based analysis had only modest sensitivity and specificity. 
Exploration of these findings among a larger patient cohort would help confirm the value 
of PS imaging in predicting recurrence and in confirming the trend towards improved 
prediction with multivariate imaging data. 
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Chapter 6 
6 Treatment monitoring in high-grade gliomas: A serial CT 
perfusion and MR study 
This chapter is adapted from the manuscript entitled “Treatment monitoring in 
high-grade gliomas: A serial CT perfusion and MR study”. This manuscript will be 
submitted to the Journal of Neuro-Oncology in July 2014 to be considered for 
publication. The authors of this manuscript are Yeung TPC, Wang Y, Urbini B, Yartsev 
S, Bauman G, Lee TY, Fainardi E, and the Project of Emilia-Romagna region on Neuro-
Oncology (PERNO) Study Group. Member of the PERNO Study Group is provided in 
Appendix E. 
 
6.1 Introduction  
High-grade gliomas account for over 70% of all malignant brain tumours, and 
survival rates remain dismal even after maximal safe resection, radiotherapy, and 
temozolomide chemotherapy. The typical median survival for patients with World Health 
Organization (WHO) grade IV gliomas is typically 12 – 15 months, and it is 2 – 5 years 
for those with WHO grade III gliomas (1). However, there is considerable heterogeneity 
in patients’ treatment response. At present, widely accepted prognostic factors of survival 
in high-grade gliomas are WHO grade, extent of surgical resection, age, and performance 
status (2). Molecular biomarkers, such as isocitrate dehydrogenase 1 (IDH1) methylation 
status, O6-methylguanine-DNA-methyltransferase (MGMT) methylation status and 
1p19q loss of heterozygosity, are also recognized as predictive and prognostic biomarkers 
in these patients (3). 
 High-grade gliomas, particularly WHO grade IV gliomas, are highly infiltrative 
tumours with recurrence typically arising within 2 cm of the irradiated volume (4,5). 
Magnetic resonance (MR) imaging is the standard imaging method for brain tumour 
diagnosis, treatment planning, and response assessment. The typical MR protocol 
involves a T2-weighted or fluid-attenuated inversion recovery (FLAIR) MR and a 
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gadolinium-enhanced T1-weighted MR (6). Following this protocol is preferable because 
it detects two types of anatomical abnormalities. The gadolinium-enhanced T1-weighted 
MR images depict the contrast-enhancing lesion (CEL) with disrupted blood-brain 
barrier. The T2-weighted or FLAIR MR images detect regions of T2 hyperintensity that 
are suspicious of tumour infiltration and vasogenic edema. Such T2 hyperintense region 
is the non-enhancing lesion (NEL) that cannot be seen on T1-weighted MR. 
 Functional imaging techniques are non-invasive methods to provide quantifiable 
information regarding tumour biology that may be related to tumour aggressiveness and 
patient prognosis (7). One important functional imaging technique is perfusion imaging.  
Measurements of perfusion imaging parameters such as tumour blood flow (BF), blood 
volume (BV), and permeability have been shown to correlate with WHO grade (8,9), 
histopathologic marker of tumour angiogenesis (e.g. microvessel density) (10,11), and 
survival (12,13,14). Most perfusion imaging studies that evaluated the relationships 
between tumour perfusion parameters and overall survival (OS) have focused on MR 
perfusion at a single time point (15) or two time points (16). CT perfusion has not been 
studied extensively (17) despite the ubiquity of CT scanners in radiation oncology 
departments. However, CT perfusion can help distinguish between high and low grade 
gliomas (8,18-20) and between tumour recurrence and radiation necrosis (21,22). In 
addition, CT perfusion can simultaneously measure absolute BF, BV, and permeability-
surface area (PS) in a single scan. Therefore, CT perfusion should be considered as a 
valuable perfusion imaging modality in oncology. 
This study is the first study to evaluate serial changes in tumour BF, BV, and PS 
in the CEL and NEL of patients with high-grade gliomas for up to a year after 
radiotherapy. The objective of this study was to evaluate the prognostic value of CT 
perfusion for predicting overall survival (OS) of patients with high-grade gliomas.  
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6.2 Materials and Methods 
6.2.1 Patient Population 
This study was conducted in compliance with the local research ethics committee, 
and informed consent was obtained from patients. Patients with suspected WHO grade III 
and IV gliomas were prospectively recruited prior to surgery. Exclusion criteria were 1) a 
brain lesion that is not WHO grade III and IV gliomas after histopathologic confirmation, 
2) prior diagnosis or therapy of brain lesion, 3) unwillingness to participate during 
follow-up examinations, 4) clinically unstable, 5) contraindications to intravenous 
administration of iodinated or gadolinium contrast materials, 6) poor quality images due 
to motion artifacts, and 7) inability to undergo MR due to contraindications such as 
metallic implants, claustrophobia, and obesity. Our study included 29 patients with high-
grade gliomas. Patients with WHO grade III gliomas (N = 5) had anaplastic 
oligodendrogliomas and the rest had WHO grade IV glioblastoma multiforme. The 
median age of diagnosis was 61 years (range, 31 – 81 years). Patients underwent serial 
MR and CT perfusion examinations prior to surgery and one, three, six, nine, and 12 
months after radiotherapy. The median follow-up was 18.2 months (range, 4.7 – 60.4 
months). 
After the pre-surgery MR and CT perfusion examinations, all patients underwent 
surgery followed by external beam radiotherapy (60 Gy in 30 fractions, N = 28; 45 Gy in 
15 fractions with stereotactic boost of 24 Gy in 3 fractions, N = 1). Twenty-six patients 
received concurrent and adjuvant temozolomide chemotherapy. Six patients underwent 
additional surgery after radiotherapy, and corticosteroids were administered to patients 
before the second surgery. At the time of progression, glioblastoma patients were given 
Fotemustine while anaplastic oligodendroglioma patients were given Procarbazine + 
CCNU (Lomustine).  
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6.2.2 Conventional MR and CT Perfusion Examinations 
MR images were acquired with either a 1.5T Signa HDXT (GE Healthcare, 
Milwaukee, WI) or a 1.5 T Achieva scanner (Philips Medical Systems, Best, The 
Netherlands). The MR protocol consisted of the following sequences: axial T1-weighted 
spin-echo, axial T2-weighted spin-echo or axial FLAIR, coronal FLAIR, and post-
gadolinium axial T1-weighted spin echo.  
All CT perfusion studies were performed using a multidetector-row CT scanner 
(Lightspeed VCT, GE). A noncontrast CT scan (350 mA, 120 kV, 5 mm slice thickness) 
of the head was acquired to locate the brain volume for the CT perfusion scan that would 
cover eight 5-mm sections of tissue. Ten patients were imaged with a one-phase CT 
perfusion protocol while 19 patients were imaged with a two phase CT perfusion 
protocol. A bolus of non-ionic contrast (Iomeron, Bracco Imaging, Konstanz, Germany; 
350 mg I/ml, 40 ml) was injected at a rate of 4 mL/s. For the one-phase CT perfusion 
protocol, a cine scan was initiated at 5 s after the injection. The imaging parameters were 
100 mA, 80kV, 1 rotation/s for a duration of 50 s, and images were reconstructed at 0.5 s 
intervals. For the two-phase protocol, the initial 50 s cine scan was acquired with images 
reconstructed at 0.5 s intervals, then 8 additional axial images were acquired for each 
section at 15 s intervals for another 105 s. The total scan duration was 150 s. The CT 
gantry was tilted to avoid radiation dose to the lens, signs of radiation toxicities from CT 
perfusion scans were documented. Skin erythema, dizziness, loss of equilibrium, 
modified gait, stupor of thought, loss of memory, air loss, cataract formation during the 
CT and MR follow-ups were some of the radiation-induced side effects assessed by the 
attending radiologist.  
 
6.2.3 Image Analysis 
Maps of BF, BV, and PS were computed using the prototype version of CT 
Perfusion 4D (GE Healthcare) (23,24). Averaged CT images were produced by averaging 
the cine CT images of the same sections. Axial gadolinium-enhanced T1-weighted MR 
and axial T2-weighted or FLAIR MR images were rigidly registered to the averaged CT 
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images using 3D Slicer (25). A radiologist with 8 years of experience manually 
delineated the contrast-enhancing lesion (CEL) on gadolinium-enhanced T1-weighted 
images and the non-enhancing lesion (NEL). The NEL was the entire T2 hyperintense 
lesion outside the CEL, necrosis, and surgical cavity. Mean volume, BF, BV, and PS in 
both CEL and NEL at each time point were used for statistical analysis. 
 
6.2.4 Statistical Analysis 
Statistical analysis was performed using SPSS software package (IBM® SPSS®, 
version 21.0, Chicago, IL). OS was the time between the first surgery and death. OS was 
censored for patients that were alive at their last follow-up. Patients were stratified by 
their OS using 12, 18, and 24 months OS as cut points. Longitudinal analyses examined 
the imaging parameter differences in patients with short versus long OS. The omnibus 
Friedman test followed by the Wilcoxon signed-rank test were used for longitudinal 
comparisons within-group, and the Mann-Whitney U test examined the differences 
between groups. The imaging time points that were analyzed were pre-surgery, one, 
three, and six months post-radiotherapy. Nine and 12 months post-radiotherapy data were 
not analyzed due to patient dropouts resulting from deaths or complete regression of 
tumours. 
A series of statistical analyses were carried out to evaluate whether the imaging 
parameters were prognostic of OS. Receiver operating characteristic analyses were 
performed to consider all possible cut points to differentiate patients with long and short 
OS. The imaging parameter cut points with the highest combination of sensitivity and 
specificity were selected for use in Cox proportional hazards regression and Kaplan-
Meier survival analyses. 
Cox proportional hazards regression analyses were performed to determine the 
relationships between OS and each of the imaging parameters. Separate Cox proportional 
hazards regression models were computed for each of the imaging parameters (volume, 
BF, BV, and PS) at each time point while adjusting for age, performance status 
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(Karnofsky Performance Status), extent of surgical resection, and WHO grade. The 
hazard ratios (HR) and their 95% confidence intervals (CI) were computed. We did not 
consider the impact of change in imaging parameters over time on OS by treating the 
serial imaging measurements as time-dependent covariates. This is because this study 
sought to evaluate whether one of these imaging time points can be used as an early 
biomarker of OS in a prospective setting. We then used Kaplan-Meier survival analysis 
and log-rank test to compare the OS of patients with high versus low values of imaging 
parameters. A P value ≤ 0.05 was considered statistically significant. 
 
6.3 Results 
6.3.1 Patient Characteristics and Outcomes 
A total of 150 CT perfusion and 150 MR examinations were obtained from 29 
patients. No radiation toxicity from serial CT perfusion scans was noted. The median OS 
was 18 months (range, 5 – 60 months) with three patients censored. Table 6-1 
summarizes the characteristics of this patient cohort and OS estimates based on patient 
characteristics. In univariate analyses, differences in gender, extent of surgical resection, 
Karnofsky Performance Status, and re-operation were not significant predictors of OS. 
Older patients (≥ 50 years) had worse OS than younger patients, but this was marginally 
significant (P = 0.06). Patients with WHO grade IV tumours were associated with 
significantly shorter OS compared to those with WHO grade III tumours (P = 0.04). The 
six patients who received reoperation did not show significantly different OS than the 
rest.  
 
 
Table 6-1: Patient characteristics, percentages of patients alive 12, 18, and 24 
months, and median OS estimates. 
Demographics 
n 
12 Months 
OS 
18 Months 
OS 
24 Months 
OS 
Median OS in 
months (95% CI) 
P 
Value* 
Age 
< 50 5 100% 80% 75% 32.7 (20.7 - 44.7) 0.06 
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≥ 50 24 63% 38% 23% 16.6 ( 10.1 - 23.1) 
Gender 
Female 11 55% 45% 27% 16.7 (9.4 - 24.0) 
0.58 
Male 18 78% 44% 33% 18.2 (9.8 - 26.6) 
WHO Grade 
III 5 100% 80% 67% 29.7 (13.0 - 46.4) 
0.04 
IV 24 63% 38% 26% 16.6 (10.1 - 23.1) 
Extent of resection 
Total 18 89% 56% 38% 22.3 (12.5 - 32.1) 
0.37 
Subtotal 11 36% 27% 20% 11.4 (10.0 - 12.8) 
Karnofsky Performance Status 
≤ 80 18 61% 39% 28% 16.4 (7.9 - 24.9) 
0.70 
> 80 11 82% 55% 38% 24.4 (16.9 - 31.9) 
Re-operation       
Yes 6 83% 50% 0% 16.7 (12.2 - 21.2) 
0.40 
No 23 65% 52% 38% 22.3 (12.3 - 32.3) 
Abbreviations: OS, Overall survival; CI, Confidence interval; WHO, World Health 
Organization 
 
*Log-rank P value comparing OS for the demographic factor  
 
6.3.2 Longitudinal Analysis 
Figure 6-1 shows the serial changes of each imaging parameter in the CEL in 
terms of 12, 18, and 24 months OS. Patients appeared to show a reduction in CEL 
volumes after surgery and radiotherapy compared to baseline, and this was significant for 
patients with OS over 18 months (P < 0.04). There were also decreasing trends in BF, 
BV, and PS in the CEL after surgery. These trends were significant for BF and BV in 
patients who lived over 12 (P < 0.02) and 18 months (P < 0.05 and P < 0.03, 
respectively), and for BV in patients who lived less 24 months (P < 0.04). With the 
exception of BV in the CEL of patients who survived beyond 18 months, CEL volumes, 
BF, BV, and PS were stable between one to six months post-radiotherapy. In general, 
CEL volumes, BF, BV, and PS appeared to be higher in patients that survived below 18 
and 24 months compared to other patients. BV at three months (P = 0.03) and PS at one 
month (P = 0.04) post-radiotherapy were significantly higher in patients with OS < 24 
months compared to other patients.  
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Figure 6-1: Serial changes in mean volumes (top row), blood flow (BF, second row), 
blood volume (BV, third row), and permeability-surface area product (PS, bottom 
row) in the contrast-enhancing lesions (CEL) of patients stratified by 12 (left 
column), 18 (middle column), and 24 months (mo) overall survival (OS, right 
column). Horizontal line represents significant changes between two highlighted 
time points of the same group. Dotted box represents a significant difference 
between the groups. Error bar represents one standard deviation.  
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Figure 6-2 illustrates the serial changes in the NEL by different OS. NEL volumes 
decreased after surgery and radiotherapy. This change (compared to baseline) was 
significant for patients who lived more than 12 months (P < 0.05), more than 18 months 
(P < 0.03), more than 24 months (P < 0.05), and also for patients who lived less than 24 
months (P < 0.03). However, there was no between-group difference in NEL volumes in 
patients with long (≥ 12, 18, and 24 months) versus short OS (< 12, 18, and 24 months). 
BF values in the NEL were stable over time with the exception of a significant decrease 
between pre-surgery and 6 months post-radiotherapy in patients that lived less than 24 
months (P < 0.005).  BF values in the NEL before surgery were significantly higher in 
patients that deceased before 18 (P = 0.003) and 24 months (P = 0.004); and they were 
also significantly higher at three months post-radiotherapy (P = 0.05) in patients with OS 
below 18 months. In comparison with pre-surgery measurements, BV values in the NEL 
decreased significantly (P < 0.04) at three and six months post-radiotherapy in patients 
with OS below 24 months. However, BV values in the NEL were significantly higher at 
one and three months post-radiotherapy in patients with OS below 18 months (P = 0.04 
and 0.02, respectively) when compared to those with OS beyond 18 months. BV values 
were also significantly higher at pre-surgery and one month post-radiotherapy for those 
with OS less than 24 months when compared to those that lived beyond 24 months (P = 
0.01 and 0.03, respectively). PS values in the NEL significantly decreased after surgery 
and radiotherapy in patients who survived beyond 12 and 18 months (P < 0.01, and ≤ 
0.03, respectively), and also in patients who survived less than 18 and 24 months (P < 
0.04 and < 0.04, respectively). More importantly, PS values in the NEL at one month 
post-radiotherapy were significantly higher in patients who deceased before 18 and 24 
months (P < 0.01), and these values measured at three months post-radiotherapy were 
also significantly higher in patients with OS below 18 months (P = 0.02).  
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Figure 6-2: Serial changes in mean volumes (top row), blood flow (BF, second row), 
blood volume (BV, third row), and permeability-surface area product (PS, bottom 
row) in the non-enhancing lesions (NEL) of patients stratified by 12 (left column), 18 
(middle column), and 24 months (mo) overall survival (OS, right column). 
Horizontal line represents significant changes between two highlighted time points 
of the same group. Dotted box represents a significant difference between the 
groups. Error bar represents one standard deviation.
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6.3.3 Survival Analysis 
The Cox proportional hazards regression model of the classical prognostic factors 
(i.e. age, performance status, extent of resection, and WHO grade) showed that higher 
WHO grade (HR = 49.6, 95% CI = 5.1 – 483.2, P < 0.001) and lower extent of resection 
(HR = 19.0, 95% CI = 3.6 – 99.5, P < 0.001) were associated with significant hazards of 
death. A total of 96 Cox proportional hazards regression models were considered while 
adjusting for age, performance status, extent of resection and WHO grade. Table 6-2 
reports parameters with cut points that were associated with both significant hazard ratios 
and significant differences in OS, and Figure 6-3 illustrates the Kaplan-Meier plots of 
these parameters. 
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Table 6-2: Cox proportional hazards regression and Kaplan-Meier analysis results. 
Imaging Time Region 
Cut point 
selected 
based on Parameter Cut Point 
Hazard ratios 
(95% CI) 
Cox 
regression 
P Value Median OS (95% CI) 
Log-rank P 
Value 
Pre-surgery NEL 
12 mo OS BF ≥ 16.1 ml/min/100g 10.9 (2.9 – 41.5) < 0.001 
High: 16.4 (9.3 – 23.4) 
Low: 28.8 (19.3 – 38.3) 
0.001 
18 mo OS BF ≥ 16.8 ml/min/100g 9.9 (2.3 – 42.5) 0.002 
High: 16.4 (9.8 – 23.0) 
Low: 24.4 (16.5 – 32.3) 
0.003 
24 mo OS BF ≥ 16.1 ml/min/100g 10.9 (2.9 – 41.5) < 0.001 
High: 16.4 (9.3 – 23.4) 
Low: 28.8 (19.3 – 38.3) 
0.001 
1 month post-
radiotherapy 
CEL 12 mo OS Volume ≥ 12.3 cm3 7.4 (1.9 – 28.5) 0.004 
High: 9.1 (5.8 – 12.4) 
Low: 18.0 (15.0 – 20.9) 
0.007 
NEL  18 mo OS Volume ≥ 11.6 cm3 4.1 (1.1 – 15.3) 0.04 
High: 16.6 (7.2 – 26.0) 
Low: 32.7 (26.5 – 38.9) 
0.03 
NEL 24 mo OS Volume ≥ 11.6 cm3 4.1 (1.1 – 15.3) 0.04 
High: 16.6 (7.2 – 26.0) 
Low: 32.7 (26.5 – 38.9) 
0.03 
NEL 24 mo OS PS ≥ 1.4 ml/min/100g 4.9 (1.4 – 17.3) 0.01 
High: 12.6 (6.3 – 18.9) 
Low: 28.8 (19.7 – 37.9) 
0.002 
3 months 
post-
radiotherapy 
CEL 
12 mo OS 
BV ≥ 1.7 ml/100g 5.2 (1.2 – 21.7) 0.03 
High: 11.7 (9.2 – 14.2) 
Low: 23.6 (5.6 – 41.7) 
0.007 18 mo OS 
24 mo OS 
6 months 
post-
radiotherapy 
CEL 
18 mo OS 
VOL ≥ 13.9 cm3 5.7 (1.1 – 28.7) 0.04 
High: 12.6 (6.3 – 18.9) 
Low: 18.2 (12.2 – 24.1) 
0.05 
24 mo OS 
NEL 
18 mo OS 
BV ≥ 1.3 ml/100g 12.9 (2.8 – 58.9) 0.001 
High: 12.6 (5.4 – 19.8) 
Low: 24.4 (20.7 – 28.1) 
0.004 
24 mo OS 
Abbreviations: NEL, non-enhancing lesion; CEL, contrast-enhancing lesion; mo, month, OS, overall survival; BF, blood flow; PS, 
permeability-surface area product; BV, blood volume 
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Figure 6-3: Kaplan-Meier survival plots of blood flow in the non-enhancing lesion (BFNEL), volume of the contrast-enhancing 
lesion (VOLCEL), volume in the NEL (VOLNEL), permeability-surface area product in the NEL (PSNEL), blood volume in the 
CEL (BVCEL), and BV in the NEL (BVNEL) measured at different time points. Higher values in these parameters were 
associated with worse overall survival (log-rank P < 0.05 for all comparisons). 
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Although some imaging parameters did not show a significant association with OS, they could still be useful in stratifying 
patients by OS. Table 6-3 shows the sensitivities and specificities of imaging parameters that are ≥ 70% in stratifying patients based 
on OS. While some CT perfusion parameters showed sensitivities and specificities ≥ 70%, volumes of NEL and CEL did not. In 
addition, BF in the NEL at pre-surgery and BV in the CEL at three months post-radiotherapy had the highest combination of 
sensitivities (83% and 82%, respectively) and specificities (86% and 100%, respectively) in stratifying patients based on 24 months 
OS. Figure 6-4 illustrates pre-surgery CT perfusion and MR images of two patients with different survival (16.7 vs. 41.6 months). 
Higher BF, BV, and PS in the NEL can be seen in the patient with shorter survival.  
 
Table 6-3: Receiver operating characteristic analysis of imaging parameters with sensitivities and specificities ≥ 70%. 
Imaging Time 
Region Cut-point selected based on  Parameter cut point AUC Sensitivity Specificity 
Pre-surgery NEL 18 mo OS BF ≥ 16.8 ml/min/100g 0.76 80% 77% 
24 mo OS BF ≥ 16.1 ml/min/100g 0.88 83% 86% 
CEL 24 mo OS BF ≥ 26.0 ml/min/100g 0.73 78% 71% 
1 Month Post-radiotherapy NEL 18 mo OS PS ≥ 1.4 ml/min/100g 0.76 71% 79% 
 CEL 24 mo OS PS ≥ 3.4 ml/min/100g 0.81 75% 80% 
3 Months Post-radiotherapy CEL 24 mo OS BV ≥ 1.7 ml/100g 0.85 82% 100% 
Abbreviations:  NEL, non-enhancing lesion; CEL, contrast-enhancing lesion; mo, months, OS; overall survival ; BF, blood flow; BV, 
blood volume; PS, permeability-surface area product; AUC, area under the receiver operating characteristic curve 
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Figure 6-4: Illustrative pre-surgery CT perfusion and MR images of patients with WHO grade IV gliomas. Both patients 
presented with a contrast-enhancing lesion on post-gadolinium T1-weighted MR images, which also had elevated blood flow 
(BF), blood volume (BV), and permeability-surface area product (PS). Patient A presented with low BF, BV, and PS in the 
non-enhancing lesion (NEL, asterisk). However, Patient B presented with regions of elevated BF, BV, and PS in the NEL (red 
arrows). The survival for patient A was 41.6 months and Patient B was 16.7 months. Identical window and level were used for 
the color maps.  
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6.4 Discussion 
OS in patients with high-grade gliomas remains poor despite aggressive 
treatments. Deployment of advanced functional imaging that can stratify patients by 
expected OS can potentially facilitate timely selection of appropriate treatments for these 
patients. This study examined the serial changes in CT perfusion parameters in 
conjunction with volumetric changes in the CEL and NEL of patients with high-grade 
gliomas. We also examined whether these imaging parameters could predict OS.  
 Perfusion changes after radiotherapy have previously been studied only in a few 
reports (26,27). An increase in BV was associated with progression (26) and poor 
survival (27). This is the first study to investigate serial changes in BF, BV, and PS in 
both the CEL and NEL for up to one year post-radiotherapy. The initial decline of all 
imaging parameters in the CEL after surgery and radiotherapy could be attributed to 
surgical debulking of the tumour and therapeutic effect of radiotherapy and 
chemotherapy. After stratifying patients based on 18 and 24 months OS, all three 
perfusion parameters in the CEL started to diverge three months after radiotherapy with 
elevated BF and BV seen in patients with shorter OS. On the other hand, BF, BV, and PS 
in the NEL were consistently higher in two groups of patients with shorter OS (< 18 and 
24 months). Although statistical differences were identified only at some of the time 
points, in general our data provided corroborating evidence that part of the heterogeneity 
in OS is related to variation in tumour perfusion characteristics both in the CEL and NEL 
regions. This variation in perfusion characteristics presumably reflected the differences in 
angiogenesis and vascularity between patients. Angiogenesis as a mechanism for 
promoting tumour growth is now an active target in cancer therapies (28). Angiogenesis 
leads to an increase in tumour microvessel area, which has been shown to correlate with 
tumour BV and patient survival (11). More recently, vasculogenesis, a process by which 
bone marrow-derived cells are recruited to form new tumour blood vessels, has been 
shown to govern tumour recurrence after radiotherapy (29). It is not known what 
percentage of tumour vessels are derived from vasculogenesis, but given that recurrence 
occurs within 2 cm of the irradiated volume (4,5) it is critical to assess perfusion 
parameters in both the CEL and NEL after radiotherapy.  
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None of the imaging measurements made in the CEL before surgery showed a 
significant correlation with OS. This could be because total resection of the tumour 
(mostly CEL) is a stronger predictor of OS. Over 60% of patients in this study underwent 
total resection and the extent of resection showed a significant association with OS. 
Prediction of survival using pre-surgery CT perfusion parameters in the CEL may be 
more appropriate for patients who are not candidates for total resection. For example, 
pre-surgery tumour BV is a predictor of survival in a study with a mixture of patients that 
received biopsy, subtotal resection, and total resection (12). However, pre-surgery 
measurement of BF in the NEL proved to be useful in predicting OS in this study. This 
result points to the role of tumour burden in the T2 hyperintense lesion that is not 
typically removed by surgery.  
 Although a larger sample size is required to show consistent associations between 
OS and CT perfusion parameters across all time points, our results are consistent with 
previous reports that higher BV and PS are associated with poor outcomes (12,13,26,27). 
It is also noteworthy that while we showed significant hazards of death associated with 
both volumetric and CT perfusion parameters, only CT perfusion parameters resulted in 
sensitivities and specificities ≥ 70% in predicting OS. CT perfusion parameters can 
provide complementary information to volumetric MR measurements in predicting 
survival in high-grade glioma patients. Volume of the CEL may not be a reliable 
predictor of outcome because the volume of contrast-enhancement may be affected by 
many nontumoural processes including inflammation, postsurgical changes, 
pseudoprogression, and treatment-induced necrosis (30-33). Similarly, the volume of the 
NEL encompasses many causes of T2 hyperintensity such as vasogenic edema, gliosis, 
cystic changes, inflammation, and tumour infiltration (34-36). It is evident from Figure 
6-4 that tumours can have regions of high BF, BV, and PS that are bigger than the CEL. 
These regions can potentially lead to future sites of recurrence. Although this is 
hypothesis-generating, there is preliminary evidence to suggest that there could be better 
spatial concordance between CT perfusion parameters with the site of future recurrence 
than the CEL with the site of future recurrence (23).  
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 Some limitations must be considered. Our sample size was relatively small and 
five patients had anaplastic oligodendrogliomas, which are known to have a higher BV 
than astrocytic gliomas despite better survival (37,38). This can hamper the ability to 
stratify OS based on BV. In addition, we did not have information regarding other known 
biologic biomarkers like MGMT methylation status that are associated with OS and thus 
we could not correct for those effects in our regression models. Likewise, the variable use 
of salvage therapies like second surgery and chemotherapy may have influenced OS 
although in glioblastoma patients these effects could be expected to be modest (39). 
Another limitation was the use of a one-phase CT perfusion protocol in one third of the 
patients. The duration of the CT perfusion protocol can affect the measurements of CT 
perfusion parameters, in particularly PS (24). Although we did not find a statistical 
difference in these parameters in the CEL and NEL at baseline between the two protocols 
(data not shown), it is important to use a two-phase CT perfusion protocol in future 
studies. We did not consider the impact of change in each of the imaging parameters over 
time on OS by treating the serial measurements as time-dependent covariates in a joint 
model of survival and time-dependent covariates. This is because we first want to 
evaluate the predictive value of these imaging parameters as independent predictors of 
survival in order to limit the number of CT perfusion follow-ups in future studies. 
Finally, a perfusion imaging scan at the time point of pre-radiotherapy but post-surgery 
could be a better baseline scan than a pre-surgery perfusion imaging scan. This may have 
helped extract the relative contribution of perfusion imaging parameters versus the extent 
of surgical resection in predicting survival.   
 
6.5 Conclusions 
BF, BV, PS are potential biomarkers of OS in patients with high-grade gliomas 
treated with multi-modality therapy (surgery, radiation, chemotherapy) even after 
adjustments for age, WHO grade, Karnofsky Performance Status, and the extent of 
resection. The results of this study, if verified in a larger cohort of patients, could 
establish CT perfusion imaging as a reliable predictor of survival. 
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Chapter 7 
7 Conclusion and Future Work 
7.1 Summary of Findings 
This thesis demonstrated 1) the importance of mitigating some of the uncertainties 
associated with CT perfusion imaging and 2) the possibilities of using CT perfusion 
imaging to stratify outcomes in brain tumour patients and in an experimental model of 
brain tumour. In this chapter, major findings of the five studies in this thesis are 
summarized, and future investigations are discussed.  
 
7.1.1 Mitigating Uncertainties in CT Perfusion 
Although much research has been done in the field of CT perfusion imaging, 
interpretation of these results can be confounded by variations in image acquisition 
protocols affecting the measurements of different CT perfusion parameters (e.g. blood 
flow, BF). The absence of a standardized protocol has led to the procedure variability 
observed amongst published studies. One imaging acquisition parameter that varied 
widely in the literature is the scan duration. Chapter 2 addressed the role of scan duration 
in the measurements of BF, blood volume (BV), and permeability-surface area product 
(PS). Systematic and random errors in BF, BV, and PS measurements increased with 
shorter scan duration. Tumour rim PS values computed from shorter (60 s) scans were 
significantly different from the corresponding values computed from the longer (150 s) 
scans (P < 0.01).  As a result of these analyses, a minimum scan duration of 90 s is 
recommended. 
CT image noise not only affects the visualization of anatomical structures; it 
affects the calculated BF, BV, and PS values. Chapter 3 evaluated the improvements in 
the measurements of these parameters after filtering CT perfusion images using principal 
component analysis (PCA). From the simulation, PCA filtering reduced the measurement 
errors of BF, BV, and PS. Similarly, the noise of BF, BV, and PS measurements also 
decreased after PCA filtering. From experiments, we showed that PCA improved the 
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contrast-to-noise ratio of CT perfusion images. At a noise level of 17 HU, a minimum of 
4 principal components was recommended for filtering CT perfusion images.  
While other aspects of CT perfusion imaging remain to be optimized, the 
development of recommended minimum scan duration and an optimized image noise 
filtering technique are important components of developing standardized approaches to 
perfusion imaging.  
 
7.1.2 CT Perfusion as a Biomarker of Treatment Outcomes 
Clinical outcomes of patients with malignant gliomas vary widely with some 
patients surviving longer than others despite standard treatments. Thus, a biomarker that 
can stratify patients by survival can potentially personalize treatments for these patients. 
To contribute to this goal, we examined the ability of CT perfusion in identifying “long-
term survivors” and “short-term survivors” in both malignant glioma patients and a 
preclinical animal model.  
Stereotactic radiosurgery (SRS) has garnered clinical interests over the years for 
the treatment of malignant gliomas, but clinical trials of SRS have not demonstrated 
clinically meaningful improvements in survival over conventional fractionated 
radiotherapy. Using the C6 glioma model for rats (Chapter 4), we investigated the 
efficacy of CT perfusion as a potential early imaging biomarker of response to SRS. Our 
results showed that response to SRS was heterogeneous. Stratification of treated animals 
based on 15 day survival showed that responders (surviving > 15 days) had lower relative 
BV and PS on day 7 post-SRS when compared to controls and non-responders (P < 0.05). 
In addition, relative BV and PS on day 7 post-SRS were predictive of survival with 92% 
accuracy while tumour volume was not predictive of survival. These findings point to the 
potential role of CT perfusion as an early biomarker of response to SRS.  
Identifying active tumour regions that are likely to persist after treatment can help 
tailor radiotherapy to target these regions. Chapter 5 investigated whether 
multiparametric imaging with CT perfusion and 18F-Fluorodeoxyglucose positron 
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emission tomography (FDG-PET) can identify tumour sites that are likely to correlate 
with the eventual location of tumour progression. We developed a method to generate 
probability maps of tumour progression based on CT perfusion, FDG-PET, and 
anatomical MR imaging data. Our results showed that PS had the highest area under the 
receiver operating characteristic curve for identifying tumour regions that are likely to 
coincide with future sites of progression (AUC = 0.72 ± 0.12). Although the sensitivity 
and specificity were modest for identifying tumour regions that were likely to progress, 
this study demonstrated the use of voxel-based analysis of multi-parametric imaging data 
in relations to future sites of progression.  
The final study of this thesis (Chapter 6) examined the serial changes in tumour 
volumetric and CT perfusion parameters and evaluated the predictive values of these data 
in stratifying malignant glioma patients by overall survival. Patients were imaged with 
conventional MR and CT perfusion before surgery and regularly after radiotherapy for up 
to a year. A trend towards higher BF, BV, and PS in the contrast-enhancing lesion (CEL) 
and the non-enhancing lesion (NEL) were found in patients with overall survival less 
than 18 and 24 months, and these values were significant at some time points (P < 0.05). 
Pre-surgery BF in the NEL and BV in the CEL three months after radiotherapy had the 
highest combination of sensitivities and specificities of ≥ 80% in predicting 24 months 
overall survival. These results suggest using BF, BV, and PS as early predictors of 
survival. 
 
7.2 Clinical Translational Potential 
The findings of this thesis contributed important information for the clinical 
translation of CT perfusion in brain tumour imaging. Here, we describe how this research 
is clinically relevant.  
Decision making based CT perfusion information relies on accurate and precise 
measurements of BF, BV, and PS. This thesis proposed two ways to improve the 
accuracy and precision of CT perfusion parameter measurements. Our investigation of 
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the effect of scan duration demonstrated that protocol standardization is a simple first 
step in reducing the uncertainties associated with CT perfusion parameters. This work is 
important and two more studies investigating the effect of CT perfusion scan duration 
have cited our work since our study was published in January, 2013 (1,2). Image filtering 
using PCA is another way to mitigate some of the uncertainties in the measurements of 
BF, BV, and PS. PCA filtering of CT perfusion images has important clinical relevance 
in terms of improving image quality and reducing radiation dose. Radiation dose is of 
concern when performing serial CT perfusion studies. Thus, dose reduction will facilitate 
the use of serial CT perfusion follow-ups in the clinic. Reducing the image acquisition 
frequency has been proposed as a method to reduce radiation dose (3-5). This method is 
simple to implement and reduces radiation dose effectively. However, the lesser number 
of acquired images translates into a reduction in the amount of data available for 
estimating BF, BV, and PS. As a result, it is recommended that the frequency of image 
acquisition be less than 4 s per image. Our method can be more effective in reducing 
image noise because PCA filtering is a post-image acquisition technique. Future 
investigation should examine the ability of PCA in maintaining image quality while 
reducing radiation dose. 
One of the challenges in the treatment of malignant gliomas is the heterogeneity 
in clinical outcomes. Here we propose several roles that CT perfusion imaging can play 
to improve the care of these patients in terms of spatial targeting and temporal monitoring 
of these tumours.  
Image-guidance has improved the precision of surgical resection of brain tumours 
and spatial targeting in radiotherapy. Image-guidance has largely been limited to post-
gadolinium T1-weighted and T2-weighted or fluid attenuated inversion recovery 
(FLAIR) MR. These techniques predominately assess the structural abnormalities of 
tumours. The results described in chapters 5 and 6 point to a possible spatial mismatch 
between the CEL on MR and tumour regions with high CT perfusion parameter values. 
In radiotherapy, the CEL is called the gross tumour volume. Biologic imaging modalities, 
such as CT perfusion, have been proposed to help delineate a “biologic target volume” in 
radiotherapy (6). The spatial mismatch between the gross tumour volume (i.e. CEL) and 
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the biologically active tumour volume has been studied in a few PET imaging studies (7-
10). The spatial mismatch suggested in this thesis could serve for improving the 
delineation of targets for radiotherapy dose escalation. CT perfusion is of particular 
importance in this respect because CT scanners/simulators are readily available in 
radiotherapy centers and an integral part of the radiation treatment planning workflow. 
The use of CT perfusion imaging facilitates the registration of treatment planning CT 
images with CT perfusion parameter maps. It is also inexpensive compared with other 
imaging techniques such as MR perfusion, and can acquire data for generating maps of 
BF, BV, and PS within a few minutes. Therefore, CT perfusion is currently the easiest 
modality to implement as a biologic imaging modality in radiation therapy. 
Chapters 4 and 6 point to the potential role of CT perfusion in the follow-up of 
patients post-treatment. Results from the pre-clinical study (Chapter 4) are consistent 
with the results of the clinical study (Chapter 6). Both studies showed that higher BF, 
BV, and PS after radiation treatments are associated with worse survival. These findings 
are clinically important because they indicate that tumours with higher BF, BV, and PS 
are more aggressive and less likely to respond to radiotherapy. These patients might 
benefit from additional treatments. Currently, salvage treatments for recurrent 
glioblastomas are not standardized. Treatments options include second surgery, repeat 
irradiation, chemotherapy, and anti-angiogenic therapies (11). Therefore, early selection 
of patients with aggressive tumours based on CT perfusion parameters may facilitate 
earlier administration of salvage therapies. 
 
7.3 Future Work 
This thesis addressed many important questions regarding CT perfusion imaging 
of malignant gliomas. As with any research, this thesis generated a number of new and 
important questions. The following section outlines possible future projects.  
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7.3.1 A Framework for Quality Assurance (QA) in CT Perfusion 
Imaging 
As alluded to earlier, quality assurance (QA) is important for widespread 
implementation of CT perfusion imaging in oncology trials and practice. Consensus 
guidelines for the use of CT perfusion were published in 2012 (12). However, a QA 
framework is needed to establish tolerance limits and best practices guidelines. Figure 
7-1 proposes a QA framework for CT perfusion imaging so that tolerance limits and best 
practices guidelines can be established in the future. This framework proposes four areas 
of QA: (i) protocol QA, (ii) machine QA, (iii) user QA, and (iv) software QA. Protocol 
QA should include a checklist to ensure that a standardized CT perfusion protocol is 
followed. Machine QA involves the use of a physical phantom to check image quality 
and the variability in time concentration curves obtained from different scanning 
conditions (13). At present, flow phantoms are available to check the variability in time 
concentration curves (13,14). User education is needed to ensure proper analysis of CT 
perfusion datasets and minimize interobserver variability. Digital phantoms like the one 
developed in this thesis and other studies (15-17) can be used to assess the variability in 
CT perfusion parameter measurements computed from different software. It can also be 
used to assess the quality of image filtering. A physiological flow phantom that mimics 
tissue hemodynamics (flow, volume, and permeability) can potentially replace the 
physical phantom and digital phantom by evaluating measurements of CT perfusion 
parameters. However, research is needed to develop a physiological flow phantom that 
mimics tissue hemodynamics. Such a phantom can be used for accreditation of CT 
perfusion imaging across sites (13). By establishing this QA framework, we hypothesize 
that tolerance limits and best practices guidelines can be established. 
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Figure 7-1: Quality assurance (QA) framework in CT perfusion imaging. 
 
7.3.2 Delineating a Biologic Target Volume (BTV) in Radiotherapy 
Our results point to a mismatch between regions of contrast enhancement and 
regions of high BF, BV, and PS in some patients with malignant gliomas. The potential 
application of using BF, BV, and PS maps for radiotherapy treatment planning warrants 
further investigations. Two important research questions need to be answered:  
 
a. Will maps of BF, BV, and PS affect radiation oncologists’ decision in 
defining a target volume for radiotherapy?  
b. Will targeting a biological target volume based on these CT perfusion 
maps improve treatment outcomes when compared to conventional 
targeting of the gross tumour volume? 
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The above questions can potentially change clinical practice and the care of patients with 
malignant gliomas.  
 
7.3.3 CT Perfusion Imaging to Monitor Response to Combined 
Anti-angiogenic Therapy, Radiotherapy, and Chemotherapy  
Bevacizumab is an anti-angiogenic agent that is under active investigation for the 
treatment of newly diagnosed glioblastomas. Results from a randomized placebo-
controlled trial showed that Bevacizumab did not prolong overall survival compared to 
conventional treatments (18). Bevacizumab treatments in this trial started during week 
four of radiotherapy. However, preclinical evidence showed that judicious timing of anti-
angiogenic agent before radiotherapy could exert a synergistic effect on tumour control 
suggesting further optimization of radiotherapy and bevacizumab combinations may be 
possible (19). Further work could examine the combined effects of radiotherapy and 
Bevacizumab on tumour perfusion in pre-clinical models of glioma to further optimize 
the use of this agent. In doing so, the C6 glioma model may not be the optimal tumour 
model for this investigation because the efficacy of binding of Bevacizumab to rodent 
vascular endothelial growth factor (VEGF) is controversial (20-22). A xenograft model 
such as the human glioblastoma cell line U87MG model is a more appropriate tumour 
model to use in this investigation (23). 
The ultimate goal remains to use functional imaging to tailor the appropriate 
treatments of cancer patients. It is hoped that the publications from this PhD dissertation 
will raise community awareness to the potential benefits of CT perfusion imaging – 
offering a readily accessible functional imaging modality that might personalize cancer 
treatments for patients affected by this disease.  
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